Page last updated: 2024-11-06

ranolazine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Ranolazine is an antianginal medication primarily used for the treatment of chronic angina, a condition characterized by chest pain caused by inadequate blood flow to the heart. It acts as a sodium channel blocker and potassium channel opener, which helps to reduce the frequency and severity of angina episodes. Ranolazine works by inhibiting the late sodium current in cardiac myocytes, which slows down the heart rate and reduces the workload on the heart. It also inhibits the inward rectifier potassium current, which helps to maintain the electrical stability of the heart. Ranolazine is synthesized through a multi-step chemical process involving various organic reactions, including esterification, amidation, and cyclization. The synthesis of ranolazine involves starting materials such as 4-methoxybenzaldehyde, piperidine, and benzyl chloride. The synthesis process involves several key steps, including the formation of an imine intermediate, followed by a ring-closing metathesis reaction, and finally, a reduction step to yield the desired ranolazine molecule. Ranolazine has been extensively studied due to its potential as an effective antianginal agent. Researchers continue to explore its mechanism of action, its pharmacokinetic and pharmacodynamic properties, and its potential side effects. Clinical trials have demonstrated the efficacy of ranolazine in reducing the frequency and severity of angina attacks, improving exercise tolerance, and reducing the need for nitrate medications. Ongoing research focuses on optimizing the use of ranolazine, exploring its potential in treating other cardiovascular conditions, and developing new formulations to improve its efficacy and safety.'

Ranolazine: An acetanilide and piperazine derivative that functions as a SODIUM CHANNEL BLOCKER and prevents the release of enzymes during MYOCARDIAL ISCHEMIA. It is used in the treatment of ANGINA PECTORIS. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide : An aromatic amide obtained by formal condensation of the carboxy group of 2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetic acid with the amino group of 2,6-dimethylaniline. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ranolazine : A racemate comprising equal amounts of (R)- and (S)-ranolazine. Used for treatment of chronic angina. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID56959
CHEMBL ID1404
CHEBI ID87690
CHEBI ID87681
SCHEMBL ID124665
MeSH IDM0156295

Synonyms (144)

Synonym
AC-1673
smr000857382
MLS002154149
AB00698532-15
AB00698532-14
BRD-A97674275-001-01-9
keg-1295
ranexa
cvt-303
latixa
BSPBIO_002276
LOPAC0_001062
95635-55-5
D05700
ranolazine (usan/inn)
ranexa (tn)
ranolazine
DB00243
NCGC00095177-01
NCGC00095177-02
renolazine
n-(2,6-dimethylphenyl)-4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)-1-piperazineacetamide
SPECTRUM1505366
NCGC00095177-03
HMS2090L09
HMS2093D21
NCGC00015897-05
rs-43285-003
chebi:87690 ,
aspruzyo
ran d
CHEMBL1404
nsc-759100
HMS1922F16
n-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide
NCGC00015897-02
HMS2098K06
ranolazine [usan:inn:ban]
(+/-)-1-(3-(2-methoxyphenoxy)-2-hydroxypropyl)-4-(n-(2,6-dimethylphenyl)carbamoylmethyl)piperazine
unii-a6iez5m406
(+-)-ranolazine
1-piperazineacetamide, n-(2,6-dimethylphenyl)-4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)-, (+-)-
a6iez5m406 ,
ran4
hsdb 7924
1-piperazineacetamide, n-(2,6-dimethylphenyl)-4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)-
(+/-)-4-(2-hydroxy-3-(o-methoxyphenoxy)propyl)-1-piperazineaceto-2',6'-xylidide
(+-)-n-(2,6-dimethylphenyl)-4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)-1-piperazineacetamide
nsc 759100
pharmakon1600-01505366
nsc759100
BCP9000558
cas-95635-55-5
tox21_110258
dtxsid3045196 ,
dtxcid1025196
142387-99-3
(-)-ranolazine
CCG-205139
HMS2230C19
n-(2,6-dimethylphenyl)-2-(4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)piperazin-1-yl)acetamide
NCGC00015897-04
NCGC00015897-03
FT-0674327
(+/-)-ranolazine
BCP0726000090
cvt 303
FT-0601594
NCGC00015897-06
PB21724
n-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide
S1799
AKOS015889500
HMS3369I08
gtpl7291
n-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}ethanimidic acid
n-(2,6-dimethylphenyl)-2-(4-((2rs)-2-hydroxy-3-(2-methoxyphenoxy)propyl)piperazin-1-yl)acetamide
ranolazine [ema epar]
(+/-)-n-(2,6-dimethylphenyl)-4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)-1-piperazineacetamide
ranolazine [who-dd]
ranolazine [vandf]
ranolazine [mi]
ranolazine [mart.]
ranolazine [usan]
ranolazine [orange book]
ranolazine [usp-rs]
1-piperazineacetamide, n-(2,6-dimethylphenyl)-4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)-, (+/-)-
ranolazine [inn]
HY-B0280
AB00698532-11
SCHEMBL124665
NCGC00015897-08
tox21_110258_1
KS-1244
AB00698532-13
XKLMZUWKNUAPSZ-UHFFFAOYSA-N
n-(2,6-dimethyl-phenyl)-2-{4-[2-hydroxy-3-(2-methoxy-phenoxy)-propyl]-piperazin-1-yl}-acetamide
1-[3-(2-methoxyphenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine
AB00698532_18
AB00698532_17
AB00698532_16
mfcd00864690
Z68563450
rs43285
HMS3655M12
rs 43285-003
SR-01000076216-8
sr-01000076216
SR-01000076216-5
SBI-0051032.P002
HMS3715K06
bdbm50173335
SW197620-4
110445-25-5
BCP04190
ranolazine (ranexa) ,
1080496-58-7
Q907104
AMY14177
BRD-A97674275-001-04-3
EN300-122384
SB13209
SDCCGSBI-0051032.P003
NCGC00015897-22
HMS3884I10
nsc782305
nsc-782305
n-(2,6-dimethylphenyl)-2-(4-(2-hydroxy-3-(2-methoxy-phenoxy)propyl)piperazin-1-yl)acetamide
n-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)-propyl]piperazin-1-yl}-acetamide
ranolazine- bio-x
BD164322
1-piperazineacetamide, n-(2,6-dimethylphenyl)-4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)-, (+/-)
ranolazina
racemic ranolazine
n-(2,6-dimethylphenyl)-4-
c01eb18
rac-ranolazine
chebi:87681
rac-n-(2,6-dimethylphenyl)-2-(4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)piperazin-1-yl)acetamide
ranolazine (usp-rs)
ranolazine (mart.)
aspruzyo sprinkle
(rs)-ranolazine
ranolazinum

Research Excerpts

Overview

Ranolazine (RN) is a drug used in the treatment of chronic coronary ischemia. Ranolazine is an anti-anginal medication that reduces sodium-dependent calcium overload via the inhibition of the late sodium current.

ExcerptReferenceRelevance
"Ranolazine is a second-line drug for the management of chronic coronary syndromes (CCS). "( Ranolazine Improves Glycemic Variability and Endothelial Function in Patients with Diabetes and Chronic Coronary Syndromes: Results from an Experimental Study.
Bernardini, F; Grigioni, F; Maddaloni, E; Manfrini, S; Mangiacapra, F; Melfi, R; Nusca, A; Piccirillo, F; Ricottini, E; Ussia, GP, 2021
)
3.51
"Ranolazine is an anti-anginal drug that inhibits the late phase of the inward sodium current. "( Safety and efficacy of ranolazine in hypertrophic cardiomyopathy: Real-world experience in a National Referral Center.
Argirò, A; Baldini, K; Cappelli, F; Coppini, R; Dei, LL; Favilli, S; Ferrantini, C; Gabriele, M; Marchi, A; Marchionni, N; Maurizi, N; Olivotto, I; Passantino, S; Tassetti, L; Tomberli, A; Zampieri, M; Zocchi, C, 2023
)
2.66
"Ranolazine (RN) is a drug used in the treatment of chronic coronary ischemia. "( Improvement of Vascular Insulin Sensitivity by Ranolazine.
Aldasoro, C; Aldasoro, M; Arias-Mutis, OJ; Guerra-Ojeda, S; Jorda, A; Valles, SL; Vila, JM, 2023
)
2.61
"Ranolazine is an anti-anginal medication that reduces the sodium-dependent calcium overload via the inhibition of the late sodium current. "( The Effect of Ranolazine on Glycemic Control: a Narrative Review to Define the Target Population.
Andrews, E; Hill, C; Ling, H; Lisi, D; Ombengi, D; Parry, C, 2019
)
2.32
"Ranolazine is a drug used in refractory chronic stable angina. "( Protective effects of Ranolazine on testicular torsion and detorsion injury in rats.
Agras, K; Hucemenoglu, S; Karakan, T; Keseroglu, BB; Ogus, E; Ozer, E; Ozgur, BC; Surer, H; Yuceturk, CN, 2020
)
2.32
"Ranolazine is an antianginal agent used to treat chronic stable angina and has been demonstrated as an effective treatment for many cardiovascular diseases."( Ranolazine protects against diabetic cardiomyopathy by activating the NOTCH1/NRG1 pathway.
Bai, Y; Chen, X; Dong, C; Jiang, Y; Jiao, J; Liu, X; Qin, Y; Qu, H; Ren, L; Sun, X; Wang, S; Yang, B, 2020
)
2.72
"Ranolazine is an antiarrhythmic drug reported to have strong atrial selectivity."( Electrophysiological effects of ranolazine in a goat model of lone atrial fibrillation.
Belardinelli, L; Dhalla, A; Opačić, D; Schotten, U; van Hunnik, A; Verheule, S; Zeemering, S, 2021
)
1.63
"Ranolazine is a second-line drug approved for the treatment of chronic stable angina pectoris."( COVID-19-related arrhythmias and the possible effects of ranolazine.
Abacioglu, N; Chukwunyere, U; Sehirli, AO, 2021
)
1.59
"Ranolazine is an anti-ischemic drug often used along with statins in patients with ischemic heart disease. "( Ranolazine-induced lipid storage myopathy presenting with respiratory failure and head drop.
Liewluck, T; Naddaf, E; Paul, P; Vazquez Do Campo, R, 2021
)
3.51
"Ranolazine is an antiischemic and antianginal agent, but experimental and preclinical data provided evidence of additional antiarrhythmic properties. "( Ranolazine therapy in drug-refractory ventricular arrhythmias.
Bontempi, L; Cerini, M; Curnis, A; Giacopelli, D; Inama, L; Raweh, A; Salghetti, F; Sciatti, E; Vassanelli, F; Villa, C; Vizzardi, E, 2017
)
3.34
"Ranolazine is a promising agent that does not have significant effects on blood pressure or heart rate."( Ranolazine: A true pluripotent cardiovascular drug or jack of all trades, master of none?
Karthikeyan, VJ; Mezincescu, A; Nadar, SK, 2018
)
2.64
"Ranolazine is an anti-angina agent with many metabolites creating the potential for off-target effects. "( Ranolazine, ACE Inhibitors, and Angiotensin Receptor Blockers.
Marciniak, TA; Serebruany, V, 2019
)
3.4
"Ranolazine is a novel anti-angina treatment approved in the United States for chronic stable angina. "( Single dose oral ranolazine pharmacokinetics in patients receiving maintenance hemodialysis.
Bleske, BE; Eyler, RF; Heung, M; Mueller, BA; Salama, NN; Scoville, BA; Segal, JH, 2019
)
2.3
"Ranolazine is a relatively novel antiischemic/antianginal compound with antiarrhythmic properties. "( Ranolazine enhances the antiarrhythmic activity of amiodarone by accelerating conversion of new-onset atrial fibrillation after cardiac surgery.
Aidonidis, I; Chryssagis, K; Daskalopoulos, ME; Daskalopoulou, SS; Lenos, A; Molyvdas, PA; Simopoulos, V; Skoularingis, I; Tagarakis, GI; Tsilimingas, NB, 2014
)
3.29
"Ranolazine is an antianginal drug currently approved for treatment of angina pectoris in the United States. "( Effects of the antianginal drug, ranolazine, on the brain sodium channel Na(V)1.2 and its modulation by extracellular protons.
Peters, CH; Rajamani, S; Ruben, PC; Sokolov, S, 2013
)
2.11
"Ranolazine is a weak inhibitor of CYP3A4 known to increase the serum level of simvastatin and its active metabolite 2-fold."( Ranolazine-induced myopathy in a patient on chronic statin therapy.
Correa, D; Landau, M, 2013
)
2.55
"Ranolazine is a novel antianginal medication approved for the treatment of chronic angina. "( Impact of ranolazine on clinical outcomes and healthcare resource utilization in patients with refractory angina pectoris.
Burns, TL; Hilleman, DE; Ling, H; Packard, KA, 2013
)
2.23
"Ranolazine is a recent antianginal drug with unique methods of action."( Ranolazine: effects on ischemic heart.
Bacchini, S; Barbieri, L; Bongo, AS; Cavallino, C; Degiovanni, A; Lazzero, M; Lupi, A; Nardi, F; Rametta, F; Rognoni, A; Veia, A, 2013
)
2.55
"Ranolazine is an antianginal agent that was approved in the EU in 2008 as an add-on therapy for symptomatic chronic angina pectoris treatment in patients who are inadequately controlled by, or are intolerant to, first-line antianginal therapies. "( Cost-utility of ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Spain.
Hidalgo-Vega, A; Ramos-Goñi, JM; Villoro, R, 2014
)
2.19
"Ranolazine is a highly efficient add-on therapy for the symptomatic treatment of chronic angina pectoris in patients who are inadequately controlled by, or intolerant to, first-line antianginal therapies in Spain."( Cost-utility of ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Spain.
Hidalgo-Vega, A; Ramos-Goñi, JM; Villoro, R, 2014
)
2.19
"Ranolazine is an emerging drug recently approved for the treatment of this disease."( Update on evidence for treatment with ranolazine in stable angina.
Carbone, F; Mach, F; Montecucco, F, 2013
)
1.38
"Ranolazine is a first-in-class piperazine derivative that inhibits the late inward sodium current in cardiac cells and is considered an effective and safe option for treating patients with CSA."( Efficacy and safety of ranolazine in patients with chronic stable angina.
Geunes-Boyer, S; Hines, ME; Kloner, RA, 2013
)
1.42
"Ranolazine is an approved drug for chronic stable angina that acts by suppressing a noninactivating current conducted by the cardiac sodium channel [persistent sodium ion current (INa)]. "( Ranolazine reduces neuronal excitability by interacting with inactivated states of brain sodium channels.
Belardinelli, L; George, AL; Hirakawa, R; Kahlig, KM; Liu, L; Rajamani, S, 2014
)
3.29
"Ranolazine is a selective inhibitor of the cardiomyocyte late inward sodium current, INaL, and features anti-ischemic, antiarrhythmic and ATP-sparing actions. "( Ranolazine in the prevention of anthracycline cardiotoxicity.
Corradi, F; De Caterina, R; Paolini, L, 2014
)
3.29
"Ranolazine is a novel antianginal that preferentially blocks the late sodium current."( Ranolazine for the suppression of ventricular arrhythmia: a case series.
Dale, RA; Haigney, MC; Krantz, MJ; Schuller, JL; Yeung, E, 2014
)
2.57
"Ranolazine is a new agent which reduces pathologically elevated late INa but also IKr ."( Effects of ranolazine on torsades de pointes tachycardias in a healthy isolated rabbit heart model.
Lüthje, L; Maier, LS; Seegers, J; Sohns, C; Sossalla, S; Toischer, K; Vollmann, D; Wallisch, N; Zabel, M, 2014
)
1.51
"Ranolazine is a selective inhibitor of the late sodium current in myocytes with anti-ischemic and metabolic properties."( Update on ranolazine in the management of angina.
Acharjee, S; Codolosa, JN; Figueredo, VM, 2014
)
1.53
"Ranolazine (RN) is a novel antianginal agent with increasingly appreciated antiarrhythmic properties that can suppress ventricular and supraventricular arrhythmias including AF."( Ranolazine as a promising treatment option for atrial fibrillation: electrophysiologic mechanisms, experimental evidence, and clinical implications.
Fragakis, N; Koskinas, KC; Vassilikos, V, 2014
)
2.57
"Ranolazine is a new antianginal drug that is postulated to act through blocking of cardiac late sodium channels and improvement in cardiac blood flow. "( Effect of ranolazine on cardiac microcirculation in normal and diabetic rats.
Khazraei, H; Mirkhani, H; Shafa, M, 2014
)
2.25
"Ranolazine is a medication indicated for treatment of chronic angina and is a partial inhibitor of the fatty acid β-oxidation. "( Myopathy during treatment with the antianginal drug ranolazine.
Kassardjian, CD; Milone, M; Tian, X; Vladutiu, G; Wong, LJ, 2014
)
2.1
"Ranolazine is a novel well-tolerated anti-ischemic drug, which selectively inhibits late sodium current and exerts metabolic properties without any hemodynamic effect. "( Ranolazine: Drug overview and possible role in primary microvascular angina management.
Cattaneo, M; Gallino, A; Porretta, AP, 2015
)
3.3
"Ranolazine is an approved antianginal agent with a favorable safety profile and electrophysiologic properties suggesting a potential role in the treatment of AF."( Ranolazine in the treatment of atrial fibrillation: Results of the dose-ranging RAFFAELLO (Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion) study.
Alberto Maggi, C; Boriani, G; Camm, AJ; Darius, H; De Ferrari, GM; Dusi, V; Giannelli, S; Gronda, E; Guillamón Torán, L; Leschke, M; Maier, LS; Marchionni, N; Melani, L; Mont, L; Quintana Rendón, M; Savelieva, I; Schumacher, K; Schwartz, PJ; Simonis, G; Tonini, G, 2015
)
2.58
"Ranolazine (RAN) is an antianginal, anti-ischemic drug that has cardioprotective effects in experimental and clinical settings of left-sided heart dysfunction."( Ranolazine reduces remodeling of the right ventricle and provoked arrhythmias in rats with pulmonary hypertension.
Belardinelli, L; Chi, L; Dhalla, AK; Hoyer, K; Liles, JT; Oliver, J, 2015
)
2.58
"Ranolazine is an antianginal drug that mediates its effects by inhibition of cardiac late sodium current. "( Effect of Ranolazine Monotherapy on Glycemic Control in Subjects With Type 2 Diabetes.
Belardinelli, L; Dhalla, A; Eckel, RH; Henry, RR; Jochelson, P; Skyler, JS; Wong, P; Yue, P, 2015
)
2.26
"Ranolazine is a new anti-anginal medication that was approved by the US Food and Drug Administration (FDA) in 2006 for patients with symptomatic chronic angina despite optimized therapy. "( Ranolazine overdose-induced seizures.
Akil, N; Bottei, E; Kamath, S, 2015
)
3.3
"Ranolazine is an antianginal agent that inhibits the late Na (+) current and has been shown to exert a protective effect against arrhythmias."( Ranolazine Attenuates the Electrophysiological Effects of Myocardial Stretch in Langendorff-Perfused Rabbit Hearts.
Alberola, A; Brines, L; Calvo, C; Chorro, FJ; del Canto, I; Parra, G; Soler, C; Such, L; Such-Miquel, L; Tormos, Á; Trapero, I; Zarzoso, M, 2015
)
2.58
"Ranolazine is a recently developed drug used for the treatment of patients with chronic stable angina. "( Antagonism of Nav channels and α1-adrenergic receptors contributes to vascular smooth muscle effects of ranolazine.
Aimond, F; Farah, C; Kong, L; Lacampagne, A; Pertuit, N; Reboul, C; Richard, S; Virsolvy, A, 2015
)
2.07
"Ranolazine (Rn) is an antianginal agent used for the treatment of chronic angina pectoris when angina is not adequately controlled by other drugs. "( Effects of Ranolazine on Astrocytes and Neurons in Primary Culture.
Aguirre-Rueda, D; Aldasoro, C; Aldasoro, M; Guerra-Ojeda, S; Iradi, A; Jorda, A; Marchio, P; Mauricio, MD; Obrador, E; Valles, SL; Vila, JM, 2016
)
2.27
"Ranolazine is an antianginal medication originally granted approval by the U.S. "( Ranolazine Therapy in Cardiac Arrhythmias.
Kluger, J; Pulford, BR, 2016
)
3.32
"Ranolazine is an antianginal agent that may have antiarrhythmic activity in AF."( Ranolazine reduces atrial fibrillatory wave frequency.
Barnett, AS; Black-Maier, EW; Daubert, JP; Goldberger, JJ; Grant, AO; Liu, P; Ng, J; Piccini, JP; Pokorney, SD; Shrader, P; Zareba, W, 2017
)
2.62
"Ranolazine is an effective option when used for rhythm control strategy in AF. "( Ranolazine for rhythm control in atrial fibrillation: A systematic review and meta-analysis.
Barbarossa, A; Belardinelli, L; Capucci, A; Guerra, F; Romandini, A, 2017
)
3.34
"Ranolazine is a new original antianginal medicine which improves left ventricular diastolic filling by selective inhibition of late Na-flow leading to more effective coronary vessels filling in diastole."( Ranolazine in treatment of stable angina in woman with atrial fibrillation and intermittent left bundle branch block - a case report.
Vitaliivna Kuzminova, N; Yuriivna Osovska, N, 2016
)
2.6
"Ranolazine is a second-line anti-anginal drug approved for use in people with stable angina."( Ranolazine for stable angina pectoris.
Basilio Flores, JE; Loza Munárriz, C; Mejia Dolores, JW; Rey Rodriguez, DE; Salazar, CA; Veramendi Espinoza, LE, 2017
)
2.62
"Ranolazine is a new original antianginal drug which improves left ventricular diastolic filling by selective inhibition of late sodium current leading to more effective coronary vessel filling in diastole."( Efficiency of ranolazine in the patient with microvascular angina, atrial fibrillation and migraine.
Kuzminova, NV; Osovska, NY,
)
1.21
"Ranolazine is an antianginal agent, which inhibits the abnormal inward Na(+) current and by this inhibition decreases diastolic cardiomyocyte calcium levels and improves electrical stability. "( Ranolozine-induced suppression of ventricular tachycardia in a patient with nonischemic cardiomyopathy: a case report.
Kaliebe, J; Murdock, DK; Overton, N, 2008
)
1.79
"Ranolazine is a new and unique antianginal drug that has been approved for the treatment of chronic stable angina pectoris. "( Ranolazine for chronic stable angina.
Nash, DT; Nash, SD, 2008
)
3.23
"Ranolazine ER is a generally well tolerated antianginal agent."( Ranolazine: a review of its use in chronic stable angina pectoris.
Keating, GM, 2008
)
2.51
"Ranolazine is a novel antianginal shown in an exploratory analysis in patients with diabetes mellitus and chronic angina to be associated with a decline in hemoglobin A(1c) (HbA(1c)). "( Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial.
Braunwald, E; Chaitman, BR; Karwatowska-Prokopczuk, E; McCabe, CH; McGuire, DK; Morrow, DA; Murphy, SA; Scirica, BM, 2009
)
2.06
"Ranolazine is an antianginal shown to reduce angina and improve exercise performance in selected patients with early-positive exercise testing and those with frequent angina."( Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial.
Braunwald, E; Buros, JL; Chaitman, BR; Karwatowska-Prokopczuk, E; Morrow, DA; Murphy, SA; Scirica, BM; Wilson, SR, 2009
)
2.17
"Ranolazine is an antianginal drug that inhibits the cardiac late Na+ current (INa). "( Use-dependent block of cardiac late Na(+) current by ranolazine.
Belardinelli, L; El-Bizri, N; Makielski, JC; Rajamani, S; Shryock, JC, 2009
)
2.05
"Ranolazine is a new anti-anginal agent that inhibits abnormal late sodium currents, indirectly causing a decrease in diastolic cardiomyocyte calcium levels. "( Suppression of non-sustained ventricular tachycardia with ranolazine: a case report.
Kaliebe, JW; Murdock, DK, 2009
)
2.04
"Ranolazine is a novel agent approved in the United States for antianginal therapy."( The antiarrhythmic effects of ranolazine.
Foster, NJ; Haines, DE, 2009
)
1.36
"Ranolazine is a novel drug approved for the treatment of chronic angina pectoris. "( Ranolazine: an anti-anginal drug with further therapeutic potential.
Kloner, RA; Reffelmann, T, 2010
)
3.25
"Ranolazine is a piperazine derivative used for treating chronic stable angina."( Ranolazine--treatment of ventricular tachycardia and symptomatic ventricular premature beats in ischemic cardiomyopathy.
Freudenberger, R; Levin, V; Martinez, MW; Nanda, S, 2010
)
2.52
"Ranolazine is a novel first-in-class drug approved for treating angina pectoris."( Effect of ranolazine on A1C and glucose levels in hyperglycemic patients with non-ST elevation acute coronary syndrome.
Belardinelli, L; Braunwald, E; Chisholm, JW; Dhalla, AK; Goldfine, AB; Karwatowska-Prokopczuk, E; Morrow, DA, 2010
)
1.48
"Ranolazine is a novel antianginal medication that acts by ameliorating disturbed sodium and calcium homeostasis. "( Improvement in left ventricular systolic and diastolic performance during ranolazine treatment in patients with stable angina.
Figueredo, VM; Holderbach, P; Morris, DL; Murdock, E; Pressman, GS; Romero-Corral, A, 2011
)
2.04
"Ranolazine is a new drug for use in patients with stable angina pectoris. "( [Ranolazine--an additional anti-anginal drug].
Hoppe, UC; Kochanek, M; Michels, G, 2010
)
2.71
"Ranolazine is a new antianginal substance which influences the atrial ion channels and leads to a significant reduction of atrial and more specifically ventricular tachyarrhythmias."( [New developments in the antiarrhythmic therapy of atrial fibrillation].
Brachmann, J; Ritscher, G; Simon Demel, K; Simon, H; Turschner, O, 2010
)
1.08
"Ranolazine is a Food and Drug Administration-approved antianginal agent. "( Electrophysiologic basis for the antiarrhythmic actions of ranolazine.
Antzelevitch, C; Belardinelli, L; Burashnikov, A; Sicouri, S, 2011
)
2.06
"Ranolazine is a new compound that has been approved by the FDA for use in patients who have chronic stable angina refractory to conventional antianginal medications. "( At the dawn of a new era in treating angina pectoris, or just another antianginal drug? Some considerations about ranolazine.
Bălan, H, 2010
)
2.01
"Ranolazine is a clinically approved drug for treating cardiac ventricular dysrhythmias and angina. "( Ranolazine reduces Ca2+ overload and oxidative stress and improves mitochondrial integrity to protect against ischemia reperfusion injury in isolated hearts.
Aldakkak, M; Camara, AK; Heisner, JS; Stowe, DF; Yang, M, 2011
)
3.25
"Ranolazine is an agent approved for the symptomatic treatment of chronic stable angina that inhibits the late inward sodium current (I(NaL)). "( Ranolazine: an antianginal drug with antiarrhythmic properties.
Caballero, R; Delpón, E; Tamargo, J, 2011
)
3.25
"Ranolazine is an open state blocker that unbinds from closed Na(+) channels unusually fast but is trapped in the inactivated state."( Mechanisms of atrial-selective block of Na⁺ channels by ranolazine: I. Experimental analysis of the use-dependent block.
Antzelevitch, C; Barajas-Martinez, H; Belardinelli, L; Hu, D; Nesterenko, VV; Rajamani, S; Zygmunt, AC, 2011
)
1.34
"Ranolazine (Ran) is an antianginal drug acting on I(Na)."( Effects of ranolazine on cardiovascular system.
Bonadei, I; Cas, LD; D'Aloia, A; Piovanelli, B; Quinzani, F; Rovetta, R; Vizzardi, E, 2011
)
1.48
"Ranolazine is a drug that exerts antianginal and antiischemic effects and also acts as an antiarrhythmic in isolation and in combination with other class III medications."( Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks.
Anderson, JL; Bair, TL; Bunch, TJ; Crandall, BG; Day, JD; Lappe, DL; Mader, KM; Mahapatra, S; May, HT; Molden, J; Muhlestein, JB; Murdock, D; Osborn, JS; Weiss, JP, 2011
)
2.53
"Ranolazine is a recently developed antianginal with unique methods of action."( Extended-release ranolazine: critical evaluation of its use in stable angina.
Melloni, C; Newby, LK; Truffa, AA, 2011
)
1.43
"Ranolazine (RAN) is a sodium-channel blocker shown to exert antiarrhythmic effects in pulmonary vein (PV) sleeves."( Comparison of electrophysiological and antiarrhythmic effects of vernakalant, ranolazine, and sotalol in canine pulmonary vein sleeve preparations.
Antzelevitch, C; Gibson, JK; Lynch, JJ; Pourrier, M; Sicouri, S, 2012
)
1.33
"Ranolazine (RZ) is an antianginal agent, which inhibits abnormal late Na(+) channel currents in cardiomyocytes and decreases Na(+) /Ca(++) overload."( The use of ranolazine to facilitate electrical cardioversion in cardioversion-resistant patients: a case series.
Kaliebe, J; Larrain, G; Murdock, DK, 2012
)
1.49
"Ranolazine is an antianginal drug that inhibits a number of ion currents that are important for the genesis of transmembrane cardiac action potential. "( A focus on antiarrhythmic properties of ranolazine.
Bonadei, I; Bontempi, L; Curnis, A; D'Aloia, A; Dei Cas, L; Quinzani, F; Rovetta, R; Vizzardi, E, 2012
)
2.09
"Ranolazine is a Na(V)1.5 antagonist with antianginal and antiarrhythmic properties."( Ranolazine decreases mechanosensitivity of the voltage-gated sodium ion channel Na(v)1.5: a novel mechanism of drug action.
Ackerman, MJ; Bernard, CE; Beyder, A; Farrugia, G; Makielski, J; Reyes, S; Strege, PR; Terzic, A, 2012
)
2.54
"Ranolazine is a new antianginal drug that reduces intracellular sodium and calcium accumulation during ischemia, thus potentially limiting myocardial ischemia. "( A pilot randomized study of ranolazine for reduction of myocardial damage during elective percutaneous coronary intervention.
Gaudio, C; Greco, C; Marazzi, G; Pasceri, V; Pelliccia, F; Rosano, G, 2012
)
2.12
"Ranolazine is an innovative anti-ischemic and antianginal agent that inhibits the late Na current, thereby reducing the Na-dependent Ca-overload, which improves diastolic tone and oxygen handling during myocardial ischemia."( New treatment options for late Na current, arrhythmias, and diastolic dysfunction.
Maier, LS, 2012
)
1.1
"Ranolazine (Ran) is a novel anti-ischemic agent with electrophysiologic properties mainly attributed to the inhibition of late Na(+) current and atrial-selective early Na(+) current. "( Ranolazine-induced postrepolarization refractoriness suppresses induction of atrial flutter and fibrillation in anesthetized rabbits.
Aidonidis, I; Doulas, K; Hatziefthimiou, A; Molyvdas, PA; Rizos, I; Simopoulos, V; Tagarakis, G; Tsilimingas, N, 2013
)
3.28
"Ranolazine is an agent currently used for the treatment of angina, which inhibits transmembrane ionic currents involved in several phases of the action potential in both the atrial and the ventricular cells. "( Antiarrhythmic properties of ranolazine--from bench to bedside.
Andrikopoulos, G; Tzeis, S, 2012
)
2.11
"Ranolazine is a new antianginal agent, recently approved as add-on therapy in patients with stable angina."( [Ranolazine in the treatment of chronic stable angina].
Biasillo, G; Cardillo, MT; Della Bona, R; Gustapane, M, 2012
)
2.01
"Ranolazine is a selective inhibitor of Na channels that prevents pathological extension of late Na current developing in the ischemic myocardial cell."( [New pharmacological approaches to ischemic heart disease].
Brambilla, G; Dei Cas, L; Della Pina, P; Gavazzoni, M; Gorga, E; Raddino, R; Regazzoni, V, 2012
)
1.1
"Ranolazine is a novel antianginal and anti-ischemic agent, that, unlike other available antianginal drugs in the United States (beta-blockers, organic nitrates, and calcium channel blockers), has no significant effect on either heart rate or blood pressure. "( Should ranolazine be used for all patients with ischemic heart disease or only for symptomatic patients with stable angina or for those with refractory angina pectoris? A critical appraisal.
Thadani, U, 2012
)
2.26
"Ranolazine (ER) is an effective antianginal and anti-ischemic agent, but I restrict its use to treat patients with stable angina pectoris."( Should ranolazine be used for all patients with ischemic heart disease or only for symptomatic patients with stable angina or for those with refractory angina pectoris? A critical appraisal.
Thadani, U, 2012
)
2.26
"Ranolazine is a new anti-ischemic agent approved for chronic angina with additional electrophysiologic properties. "( Effect of ranolazine in preventing postoperative atrial fibrillation in patients undergoing coronary revascularization surgery.
Aidonidis, I; Daskalopoulos, ME; Daskalopoulou, SS; Liouras, V; Molyvdas, PA; Papageorgiou, K; Parisis, C; Simopoulos, V; Skoularingis, I; Tagarakis, GI; Triposkiadis, F; Tsilimingas, NB, 2013
)
2.23
"Ranolazine is a piperazine derivative that was approved in 2006 for the treatment of chronic stable angina. "( Effects of ranolazine on vasomotor responses of rat aortic rings.
Demare, P; Hernández-Díaz, C; Mascher, D; Monsalvo, I; Paredes-Carbajal, MC; Regla, I, 2013
)
2.22
"Ranolazine is a novel anti-ischemic drug that prolongs the QT interval. "( Ranolazine: ion-channel-blocking actions and in vivo electrophysiological effects.
Belardinelli, L; Derakhchan, K; Ehrlich, JR; Nattel, S; Schram, G; Zhang, L, 2004
)
3.21
"Ranolazine is a novel antianginal agent capable of producing antiischemic effects at plasma concentrations of 2 to 6 micromol/L without reducing heart rate or blood pressure. "( Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties.
Antzelevitch, C; Belardinelli, L; Burashnikov, A; Cordeiro, JM; Di Diego, JM; Fish, JM; Thomas, G; Zygmunt, AC, 2004
)
2.05
"Ranolazine is a novel antianginal agent capable of producing anti-ischemic effects at plasma concentrations of 2 to 6 microM without a significant reduction of heart rate or blood pressure. "( Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent.
Antzelevitch, C; Belardinelli, L; Burashnikov, A; Cordeiro, JM; Di Diego, JM; Fish, JM; Fraser, H; Goodrow, RJ; Perez, G; Scornik, F; Wu, L; Zygmunt, AC, 2004
)
1.77
"Ranolazine is a novel new antianginal agent currently under investigation as monotherapy and adjunct therapy for the treatment of chronic stable angina. "( Ranolazine. A metabolic modulator for the treatment of chronic stable angina.
Anderson, JR; Nawarskas, JJ,
)
3.02
"Ranolazine is a novel compound under development as an antianginal agent. "( Effect of renal impairment on multiple-dose pharmacokinetics of extended-release ranolazine.
Abdallah, H; Jerling, M, 2005
)
2
"Ranolazine is a new antianginal drug approved for clinical use in the United States in January 2006. "( Ranolazine and late cardiac sodium current--a therapeutic target for angina, arrhythmia and more?
Makielski, JC; Valdivia, CR, 2006
)
3.22
"Ranolazine is a metabolic modulator designed to improve cardiac energy availability and cardiac metabolism. "( Ranolazine: a new approach to management of patients with angina.
Fisher, E; Tafreshi, MJ, 2006
)
3.22
"Ranolazine is an inhibitor of the late sodium current and, via this mechanism, decreases sodium-dependent intracellular calcium overload during ischemia and reperfusion. "( Improved left ventricular function and reduced necrosis after myocardial ischemia/reperfusion in rabbits treated with ranolazine, an inhibitor of the late sodium channel.
Hale, SL; Kloner, RA; Leeka, JA, 2006
)
1.99
"Ranolazine is a compound that is approved by the US FDA for the treatment of chronic angina pectoris in combination with amlodipine, beta-adrenoceptor antagonists or nitrates, in patients who have not achieved an adequate response with other anti-anginals. "( Clinical pharmacokinetics of ranolazine.
Jerling, M, 2006
)
2.07
"Ranolazine is a novel agent that inhibits the late sodium current thereby reducing cellular sodium and calcium overload and has been shown to reduce ischemia in patients with chronic stable angina."( Evaluation of a novel anti-ischemic agent in acute coronary syndromes: design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial.
Braunwald, E; Karwatowska-Prokopczuk, E; McCabe, CH; Morrow, DA; Scirica, BM; Skene, A, 2006
)
1.26
"Ranolazine is a unique antianginal agent that has been effective in stable angina, but it has not been studied in the setting of maximum recommended doses of conventional antianginal agents."( Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial.
Blokhin, A; Gratsiansky, NA; Huang, IZ; Meng, L; Stone, PH, 2006
)
2.08
"Ranolazine is a selective inhibitor of the late sodium current relative to peak sodium channel current, and via this mechanism, it may decrease sodium-dependent intracellular calcium overload during ischemia and reperfusion. "( Ranolazine, an inhibitor of the late sodium channel current, reduces postischemic myocardial dysfunction in the rabbit.
Hale, SL; Kloner, RA, 2006
)
3.22
"Ranolazine is a new class of antianginal agent."( Ranolazine for the management of coronary artery disease.
Cheng, JW, 2006
)
2.5
"Ranolazine is a cell membrane inhibitor of the late sodium current. "( Ranolazine for the management of coronary artery disease.
Cheng, JW, 2006
)
3.22
"Ranolazine is a new antianginal agent that is effective in the management of chronic angina. "( Ranolazine for the management of coronary artery disease.
Cheng, JW, 2006
)
3.22
"Ranolazine is a novel antianginal agent that reduces ischemia in patients with chronic angina but has not been studied in patients with acute coronary syndromes (ACS)."( Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial.
Braunwald, E; Budaj, A; Karwatowska-Prokopczuk, E; McCabe, CH; Morrow, DA; Murphy, SA; Scirica, BM; Skene, A; Varshavsky, S; Wolff, AA, 2007
)
2.17
"Ranolazine is an antianginal agent shown to exert an antiarrhythmic effect in experimental models of long QT syndrome."( Cellular basis for the electrocardiographic and arrhythmic manifestations of Timothy syndrome: effects of ranolazine.
Antzelevitch, C; Belardinelli, L; Glass, A; Goodrow, RJ; Sicouri, S; Timothy, KW; Zygmunt, AC, 2007
)
1.27
"Ranolazine is a novel medication that reduces ischaemia by preventing sodium induced calcium overload in myocardial cells without adversely affecting haemodynamic parameters."( Ranolazine: a novel agent that improves dysfunctional sodium channels.
Mehta, M; Pham, DQ, 2007
)
2.5
"Ranolazine is a novel antianginal agent believed to relieve ischemia by reducing myocardial cellular sodium and calcium overload via inhibition of the late sodium current of the cardiac action potential."( Ranolazine in patients with angina and coronary artery disease.
Morrow, DA; Scirica, BM, 2007
)
2.5
"Ranolazine is an antianginal agent that targets a number of ion channels in the heart, including cardiac voltage-gated Na(+) channels. "( State- and use-dependent block of muscle Nav1.4 and neuronal Nav1.7 voltage-gated Na+ channel isoforms by ranolazine.
Calderon, J; Wang, GK; Wang, SY, 2008
)
2
"Ranolazine is a piperazine derivative believed to reduce anginal symptoms by preventing ischemia-mediated sodium and calcium overload in myocardial cells through inhibition of the late sodium current (late INa). "( Metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) study.
Melloni, C; Newby, LK, 2008
)
2.09
"Ranolazine is a partial fatty acid oxidation inhibitor which shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation."( Ranolazine, a partial fatty acid oxidation inhibitor, its potential benefit in angina and other cardiovascular disorders.
Bhandari, B; Subramanian, L, 2007
)
2.5
"Ranolazine is a novel antianginal agent that may reduce symptoms without affecting hemodynamics and has shown cardiac antiischemic effects in in vivo and in vitro models. "( Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts.
Barr, RL; Lopaschuk, GD; McCormack, JG; Wolff, AA, 1996
)
3.18
"Ranolazine is an novel investigational antianginal agent that stimulates glucose oxidation in isolated rat hearts. "( Effects of ranolazine on oxidative substrate preference in epitrochlearis muscle.
Baracos, VE; Barr, R; Lopaschuk, GD; McCormack, JG, 1996
)
2.13
"Ranolazine is a novel drug that has shown promise in the treatment of cardiovascular disease. "( The use of ranolazine in cardiovascular disease.
Hill, JA; Schofield, RS, 2002
)
2.15
"Ranolazine is a novel antianginal agent currently under investigation as monotherapy and adjunct therapy for the treatment of chronic stable angina. "( Ranolazine: a potential new treatment for chronic stable angina.
Anderson, JR; Khou, S; Nawarskas, JJ,
)
3.02
"Ranolazine (RS 43285) is a new piperazine derivative with anti-ischemic properties attributed to a modulation of myocardial metabolism. "( Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with beta-blocker or diltiazem.
Bouvy, T; Cheron, P; Cocco, G; Detry, JM; Pouleur, H; Rousseau, MF; Williams, G, 1992
)
2
"Ranolazine is a new drug with a novel mode of action as a metabolic modulator and membrane stabilizer. "( Ranolazine--a new drug with beneficial effects on renal preservation.
Giles, GR; Lam, FT; Lodge, JP; Perry, SL, 1990
)
3.16

Effects

Ranolazine has a novel mechanism of action of inhibiting the late sodium current during ventricular depolarization. Ranolazine may be complementary to that of conventional antianginal agents in the treatment of chronic angina.

Ranolazine has been shown to improve exercise duration and time to anginal attacks without significantly affecting heart rate or blood pressure. It has a novel mechanism of action of inhibiting the late sodium current during ventricular depolarization.

ExcerptReferenceRelevance
"Ranolazine has a unique mechanism of action that does not affect blood pressure or heart rate."( Use of Ranolazine for the Treatment of Coronary Microvascular Dysfunction.
Patatanian, E; Sharp, RP; Sirajuddin, R, 2021
)
1.8
"Ranolazine has a unique mechanism of action that may be complementary to that of conventional antianginal agents in the treatment of chronic angina. "( Advances in the management of stable angina.
Trujillo, TC, 2006
)
1.78
"Ranolazine has a vasodilatory effect that is predominantly endothelium-independent. "( Effects of ranolazine on vasomotor responses of rat aortic rings.
Demare, P; Hernández-Díaz, C; Mascher, D; Monsalvo, I; Paredes-Carbajal, MC; Regla, I, 2013
)
2.22
"Ranolazine has a unique mechanism of action that is different from that of conventional agents. "( Ranolazine: a new approach to management of patients with angina.
Fisher, E; Tafreshi, MJ, 2006
)
3.22
"Ranolazine has a novel mechanism of action of inhibiting the late sodium current during ventricular depolarization."( Ranolazine: a new option in the management of chronic stable angina.
Dobesh, PP; Trujillo, TC, 2007
)
2.5
"Ranolazine has a unique mechanism of action that does not affect blood pressure or heart rate."( Use of Ranolazine for the Treatment of Coronary Microvascular Dysfunction.
Patatanian, E; Sharp, RP; Sirajuddin, R, 2021
)
1.8
"Ranolazine has been shown to be effective as an antihyperglycemic while utilized as monotherapy or in combination with traditional diabetic regimens."( Antihyperglycemic and Metabolic Effects of Ranolazine in Patients With Diabetes Mellitus.
Branstetter, J; Gilbert, BW; Huffman, J; Little, L; Meister, A; Sherard, M, 2018
)
1.46
"Ranolazine has been shown to reduce angina frequency versus placebo in patients with T2D and stable angina."( Ranolazine in patients with type 2 diabetes and chronic angina: A cost-effectiveness analysis and assessment of health-related quality-of-life.
Coleman, CI; Kohn, CG; Nguyen, E; Weeda, ER, 2018
)
2.64
"Ranolazine has been found to prevent ventricular arrhythmias (VAs) during acute myocardial infarction (AMI). "( Dose-Dependent Effects of Ranolazine on Reentrant Ventricular Arrhythmias Induced After Subacute Myocardial Infarction in Rabbits.
Aidonidis, I; Dipla, K; Hatziefthimiou, A; Moschovidis, V; Simopoulos, V; Stamatiou, R; Stravela, S, 2020
)
2.3
"Ranolazine has a unique mechanism of action that may be complementary to that of conventional antianginal agents in the treatment of chronic angina. "( Advances in the management of stable angina.
Trujillo, TC, 2006
)
1.78
"Ranolazine has also been shown to inhibit the increased persistent INa carried by NaV1.1 channels encoding epilepsy- and migraine-associated mutations."( Ranolazine reduces neuronal excitability by interacting with inactivated states of brain sodium channels.
Belardinelli, L; George, AL; Hirakawa, R; Kahlig, KM; Liu, L; Rajamani, S, 2014
)
2.57
"Ranolazine has been reported to reduce diastolic dysfunction, but the specific mechanisms of action are unclear."( Ranolazine improves diastolic function in spontaneously hypertensive rats.
Fedida, D; Lin, S; McAfee, D; Pourrier, M; Williams, S, 2014
)
2.57
"Ranolazine has been shown to decrease angina pectoris frequency and nitroglycerin consumption. "( Cost-effectiveness of ranolazine added to standard-of-care treatment in patients with chronic stable angina pectoris.
Coleman, CI; Kohn, CG; Limone, BL; Parker, MW, 2014
)
2.16
"Ranolazine has been shown to have antiarrhythmic properties."( Ranolazine terminates atrial flutter and fibrillation in a canine model.
Belardinelli, L; Bhimani, AA; Khrestian, CM; Lee, S; Sadrpour, SA; Waldo, AL; Yasuda, T; Zeng, D, 2014
)
3.29
"Ranolazine has been approved as a second-line medical treatment for symptomatic stable coronary artery disease."( Ranolazine: Drug overview and possible role in primary microvascular angina management.
Cattaneo, M; Gallino, A; Porretta, AP, 2015
)
2.58
"Ranolazine has also been shown to reduce ventricular tachycardia and drug-refractory implantable cardioverter defibrillator shocks."( Antiarrhythmic properties of ranolazine: A review of the current evidence.
Aronow, WS; Gupta, T; Iwai, S; Khera, S; Kolte, D, 2015
)
1.43
"Ranolazine has anti-AF efficacy, both alone or in combination with other drugs such as amiodarone and dronedarone."( Ranolazine for the treatment of atrial fibrillation.
Bertero, G; Brunacci, M; Brunelli, C; Dorighi, U; Ferrero, S; Rosa, GM, 2015
)
2.58
"Ranolazine has characteristic properties of a selective inhibitor of the inward sodium current. "( The use of ranolazine in non-anginal cardiovascular disorders: A review of current data and ongoing randomized clinical trials.
Kherada, N; Krishna, RK; Larrauri-Reyes, M; Mihos, CG; Santana, O; Tolentino, A, 2016
)
2.27
"Ranolazine has been reported to have an antiarrhythmic potential. "( Ranolazine and Vernakalant Prevent Ventricular Arrhythmias in an Experimental Whole-Heart Model of Short QT Syndrome.
Bögeholz, N; Dechering, DG; Eckardt, L; Ellermann, C; Frommeyer, G; Güner, F; Kochhäuser, S; Leitz, P; Pott, C, 2016
)
3.32
"Ranolazine has shown utility in a limited number of studies as an adjunctive agent, which is critical for those in whom standard therapy is inadequate or the adverse event profile precludes optimized standard therapy."( Novel Use of Ranolazine as an Antiarrhythmic Agent in Atrial Fibrillation.
Nguyen, E; White, CM, 2017
)
1.55
"Ranolazine has also been shown to be a potent inhibitor of after depolarizations and triggered activity."( Ranolozine-induced suppression of ventricular tachycardia in a patient with nonischemic cardiomyopathy: a case report.
Kaliebe, J; Murdock, DK; Overton, N, 2008
)
1.07
"Ranolazine has been shown to be a potent inhibitor of triggered activity in the experimental setting."( Suppression of non-sustained ventricular tachycardia with ranolazine: a case report.
Kaliebe, JW; Murdock, DK, 2009
)
1.32
"Ranolazine has been shown to reduce myocardial ischemia and symptom severity among selected patients with chronic angina. "( Effects of ranolazine on disease-specific health status and quality of life among patients with acute coronary syndromes: results from the MERLIN-TIMI 36 randomized trial.
Arnold, SV; Braunwald, E; Cohen, DJ; Lei, Y; Mahoney, EM; Morrow, DA; Scirica, BM; Wang, K, 2008
)
2.18
"Ranolazine has been shown to produce atrial-selective depression of sodium channel-dependent parameters and suppress atrial fibrillation (AF) in a variety of experimental models. "( Atrial-selective sodium channel block strategy to suppress atrial fibrillation: ranolazine versus propafenone.
Antzelevitch, C; Belardinelli, L; Burashnikov, A, 2012
)
2.05
"Ranolazine has been described to have antiarrhythmic effects on ventricular as well as atrial arrhythmias without any proarrythmia or severe organ toxicity as it is common for several antiarrhythmic drugs."( Role of ranolazine in angina, heart failure, arrhythmias, and diabetes.
Maier, LS; Sossalla, S, 2012
)
1.53
"Ranolazine has been previously shown to improve exercise capacity and symptoms in patients with severe chronic angina treated with standard doses of beta-blockers and calcium-channel blockers, without a significant effect on heart rate or blood pressure."( Effects of ranolazine on exercise tolerance and angina frequency in patients with severe chronic angina receiving maximally-tolerated background therapy: analysis from the Combination Assessment of Ranolazine In Stable Angina (CARISA) randomized trial.
Ben-Yehuda, O; Cheng, ML; Lee, S; Sendón, JL, 2012
)
2.21
"Ranolazine has a vasodilatory effect that is predominantly endothelium-independent. "( Effects of ranolazine on vasomotor responses of rat aortic rings.
Demare, P; Hernández-Díaz, C; Mascher, D; Monsalvo, I; Paredes-Carbajal, MC; Regla, I, 2013
)
2.22
"Ranolazine has been demonstrated to improve exercise time to angina or 1 mm of ST-segment depression in a manner similar to currently approved drugs, but without any significant effects on heart rate or blood pressure at rest or during exercise."( Ranolazine: new approach for the treatment of stable angina pectoris.
Stanley, WC, 2005
)
2.49
"Ranolazine has been shown to improve exercise duration and time to anginal attacks without significantly affecting heart rate or blood pressure."( Ranolazine: a new approach to management of patients with angina.
Fisher, E; Tafreshi, MJ, 2006
)
2.5
"Ranolazine has a unique mechanism of action that is different from that of conventional agents. "( Ranolazine: a new approach to management of patients with angina.
Fisher, E; Tafreshi, MJ, 2006
)
3.22
"Ranolazine has recently been approved as adjunctive treatment for chronic stable angina (CSA). "( Ranolazine in the management of chronic stable angina.
McBride, BF; Zerumsky, K, 2006
)
3.22
"Ranolazine has a novel mechanism of action of inhibiting the late sodium current during ventricular depolarization."( Ranolazine: a new option in the management of chronic stable angina.
Dobesh, PP; Trujillo, TC, 2007
)
2.5
"Ranolazine has been approved by US FDA for the treatment of chronic angina pectoris in combination with amlodipine, beta-blockers or nitrates in patients who do not show adequate response to other anti-anginals."( Ranolazine, a partial fatty acid oxidation inhibitor, its potential benefit in angina and other cardiovascular disorders.
Bhandari, B; Subramanian, L, 2007
)
2.5
"Ranolazine (RS-43285) has shown antianginal effects in clinical trials and cardiac anti-ischaemic activity in several in vivo and in vitro animal models, but without affecting haemodynamics. "( The antianginal agent ranolazine is a weak inhibitor of the respiratory complex I, but with greater potency in broken or uncoupled than in coupled mitochondria.
Hue, L; McCormack, JG; Skene, C; Veitch, K; Wyatt, KM, 1995
)
2.05
"Ranolazine has impressive cardioprotective properties in an isolated rabbit heart model of ischaemia and reperfusion, suggesting that the drug warrants further research into its precise mechanism of action."( Cardioprotective effects of ranolazine (RS-43285) in the isolated perfused rabbit heart.
Black, SC; Chou, AY; Gralinski, MR; Kilgore, KS; Lucchesi, BR; McCormack, JG, 1994
)
2.03
"Ranolazine has shown anti-anginal efficacy in humans and cardiac anti-ischaemic activity in models, but without affecting haemodynamics or baseline contraction. "( Ranolazine increases active pyruvate dehydrogenase in perfused normoxic rat hearts: evidence for an indirect mechanism.
Clarke, B; McCormack, JG; Wyatt, KM, 1996
)
3.18
"1. Ranolazine has protective effects against ischaemia as exemplified by a reduction of the associated enzyme release and an attenuation of the fall of ATP and other metabolic changes. "( Effects of ranolazine on L-type calcium channel currents in guinea-pig single ventricular myocytes.
Allen, TJ; Chapman, RA, 1996
)
1.31
"Ranolazine has been shown to improve exercise-induced myocardial ischaemia and to lessen the severity of angina in the setting of chronic ischaemic heart disease."( The use of ranolazine in cardiovascular disease.
Hill, JA; Schofield, RS, 2002
)
1.43
"Ranolazine (RS-43285) has been shown to possess significant anti-ischaemic properties in a canine model of reversible myocardial ischaemia. "( Ranolazine (RS-43285): a preliminary study of a new anti-anginal agent with selective effect on ischaemic myocardium.
Dasgupta, P; Hughes, LO; Jain, D; Lahiri, A; Raftery, EB, 1990
)
3.16

Actions

Ranolazine did not increase the global MPRI compared with the control drugs. Ranolazine appears to produce its anti-angina effect through blocking the late sodium current associated with the voltage-gated sodium channel.

ExcerptReferenceRelevance
"Ranolazine did not increase the global MPRI compared with the control drugs (weighted mean difference [WMD], 0.11; 95% CI, -0.06 to 0.29; P = 0.21)."( Effects of the Antianginal Drugs Ranolazine, Nicorandil, and Ivabradine on Coronary Microvascular Function in Patients With Nonobstructive Coronary Artery Disease: A Meta-analysis of Randomized Controlled Trials.
Chen, T; Fang, X; Huang, J; Xu, X; Zhao, Q; Zheng, J; Zhu, H, 2019
)
1.52
"Ranolazine appears to produce its anti-angina effect through blocking the late sodium current associated with the voltage-gated sodium channel, Na(v) 1.5."( Ranolazine attenuation of CFA-induced mechanical hyperalgesia.
Casey, GP; Diamond, I; Gould, HJ; Paul, D; Roberts, JS, 2010
)
2.52
"Ranolazine users had lower total costs of care ($13,961) than the nitrate group ($18,166, 30.0% higher; P < 0.001) and the beta blockers/calcium channel blockers group ($17,612, 26.6% higher; P = 0.002)."( Costs and clinical outcomes associated with use of ranolazine for treatment of angina.
Buysman, EK; Gomez Rey, G; Phelps, CE, 2012
)
1.35
"Ranolazine does increase electrocardiographic QTc interval in a dose-related manner, but at therapeutic doses it has no proarrhythmic effects."( Should ranolazine be used for all patients with ischemic heart disease or only for symptomatic patients with stable angina or for those with refractory angina pectoris? A critical appraisal.
Thadani, U, 2012
)
1.53

Treatment

RAnoLazIne for the Treatment of Diastolic Heart Failure (RALI-DHF) is a prospective, single-center, randomized, double-blind, placebo-controlled proof-of-concept study. Ranolazine treated hearts showed higher complex I activity and greater detectable complex I protein levels compared to untreated IR hearts.

ExcerptReferenceRelevance
"Ranolazine treated patients experienced a higher number of adverse events, but only one was discontinued owing to side effects."( Ranolazine Improves Right Ventricular Function in Patients With Precapillary Pulmonary Hypertension: Results From a Double-Blind, Randomized, Placebo-Controlled Trial.
Chan, SY; Forfia, P; Han, Y; Mazurek, JA; Park, MH; Ramani, G; Vaidya, A; Waxman, AB, 2021
)
2.79
"Ranolazine both treats chronic angina and improves glucose control."( Ranolazine After Incomplete Percutaneous Coronary Revascularization in Patients With Versus Without Diabetes Mellitus: RIVER-PCI Trial.
Alexander, KP; Anstrom, KJ; Ben-Yehuda, O; Fanaroff, AC; James, SK; Mark, DB; Ohman, EM; Prather, K; Stone, GW; Weisz, G, 2017
)
2.62
"Ranolazine treatment is also associated with QTc-interval prolongation; however, QTc-interval prolongation with ranolazine does not appear to have clinical consequences-in fact, several studies suggest that ranolazine therapy may have an antiarrhythmic effect in patients."( Efficacy and safety of ranolazine in patients with chronic stable angina.
Geunes-Boyer, S; Hines, ME; Kloner, RA, 2013
)
1.42
"RAnoLazIne for the Treatment of Diastolic Heart Failure (RALI-DHF) is a prospective, single-center, randomized, double-blind, placebo-controlled proof-of-concept study to determine if ranolazine compared with placebo will be more effective in improving diastolic function in patients with HFpEF."( Ranolazine for the treatment of heart failure with preserved ejection fraction: background, aims, and design of the RALI-DHF study.
Belardinelli, L; Hasenfuss, G; Jacobshagen, C; Maier, LS, 2011
)
3.25
"Ranolazine treated hearts showed higher complex I activity and greater detectable complex I protein levels compared to untreated IR hearts."( Damage to mitochondrial complex I during cardiac ischemia reperfusion injury is reduced indirectly by anti-anginal drug ranolazine.
Antholine, WE; Camara, AK; Gadicherla, AK; Stowe, DF; Yang, M, 2012
)
1.31
"Ranolazine treatment led to better ejection fraction, stroke volume and less wall motion abnormality after reperfusion, and less myocardial necrosis."( Improved left ventricular function and reduced necrosis after myocardial ischemia/reperfusion in rabbits treated with ranolazine, an inhibitor of the late sodium channel.
Hale, SL; Kloner, RA; Leeka, JA, 2006
)
1.26
"Ranolazine treatment reduced myocardial stunning following brief ischemia/reperfusion suggesting that inhibiting the late sodium channel current may be a novel approach to treating stunning independent of effects on hemodynamics."( Ranolazine, an inhibitor of the late sodium channel current, reduces postischemic myocardial dysfunction in the rabbit.
Hale, SL; Kloner, RA, 2006
)
2.5
"Ranolazine treats angina without depressing hemodynamic status. "( Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE).
Crager, MR; Koren, MJ; Sweeney, M, 2007
)
2
"Pretreatment with ranolazine or istaroxime, another SERCA activator, prevented chlorine-induced cardiomyocyte death."( Sarcoendoplasmic reticulum Ca(2+) ATPase. A critical target in chlorine inhalation-induced cardiotoxicity.
Ahmad, A; Ahmad, S; Chandler, JD; Claycomb, WC; Day, BJ; Hendry-Hofer, TB; Loader, JE; Mozziconacci, O; Powell, RL; Reisdorph, N; Schöneich, C; Veress, LA; White, CW, 2015
)
0.74
"Mice treated with ranolazine had healthier islet morphology and significantly (p < 0.01) higher β-cell mass (69 ± 2% per islet) than the vehicle group (50 ± 5% per islet) as determined from hematoxylin and eosin staining."( Ranolazine increases β-cell survival and improves glucose homeostasis in low-dose streptozotocin-induced diabetes in mice.
Belardinelli, L; Dhalla, AK; Fu, Z; Jiang, J; Liu, D; Ning, Y; Zhen, W, 2011
)
2.14
"Treatment with ranolazine ameliorated the Ca(2+) response and cross-bridge kinetics."( Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity.
Belardinelli, L; Dudley, SC; Gu, L; Jeong, EM; Kumar, P; Lardin, HA; Liu, H; Lovelock, JD; Monasky, MM; Patel, BG; Pokhrel, N; Solaro, RJ; Sorescu, D; Taglieri, DM; Zeng, D, 2012
)
2.16
"Pretreatment with ranolazine 1,000 mg twice daily for 7 days significantly reduced procedural myocardial injury in elective PCI."( A pilot randomized study of ranolazine for reduction of myocardial damage during elective percutaneous coronary intervention.
Gaudio, C; Greco, C; Marazzi, G; Pasceri, V; Pelliccia, F; Rosano, G, 2012
)
1.01
"Treatment with ranolazine resulted in significantly lower incidences of arrhythmias."( Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischem
Belardinelli, L; Braunwald, E; Gersh, BJ; Hedgepeth, CM; Hod, H; McCabe, CH; Molhoek, P; Morrow, DA; Murphy, SA; Scirica, BM; Verheugt, FW, 2007
)
1.08
"Pretreatment with ranolazine (480 microg/kg/min) or lidocaine (200 microg/kg/min) reduced the clofilium-induced prolongation of QTc (15 +/- 3 and 19 +/- 3%, respectively, p < 0.001 versus vehicle) and MAPD(90) (21 +/- 4 and 20 +/- 2%, respectively, p < 0.001 versus vehicle) and prevented the occurrence of TdP (zero of eight and zero of eight, respectively)."( Antitorsadogenic effects of ({+/-})-N-(2,6-dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazine (ranolazine) in anesthetized rabbits.
Belardinelli, L; Dhalla, AK; Robertson, C; Wang, WQ, 2008
)
0.88

Toxicity

Ranolazine is a first-in-class piperazine derivative that inhibits the late inward sodium current in cardiac cells. Adverse effects were more common in older than in younger patients.

ExcerptReferenceRelevance
" Reported adverse effects were similar in MARISA and CARISA and consisted of asthenia, nausea, constipation, and dizziness."( Efficacy and safety of a metabolic modulator drug in chronic stable angina: review of evidence from clinical trials.
Chaitman, BR, 2004
)
0.32
" Physical examination, laboratory tests, and adverse event reporting were performed periodically."( Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE).
Crager, MR; Koren, MJ; Sweeney, M, 2007
)
0.56
"7%) discontinued ranolazine due to adverse events."( Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE).
Crager, MR; Koren, MJ; Sweeney, M, 2007
)
0.9
" Adverse effects were more common in older than in younger patients, but the incidence of serious adverse effects attributable to ranolazine did not differ significantly between age groups."( Safety and efficacy of extended-release ranolazine in patients aged 70 years or older with chronic stable angina pectoris.
Crager, M; McKay, CR; Rich, MW,
)
0.6
" No difference was found in the risk of adverse events between the 2 therapies."( Comparison of effectiveness and safety of ranolazine versus amiodarone for preventing atrial fibrillation after coronary artery bypass grafting.
Miles, RH; Murdock, DK; Passman, R, 2011
)
0.63
" Congenital genetic mutations to sodium channels in humans and supratherapeutic ranolazine concentrations in animal models have produced similar neurologic adverse reactions."( Neurologic adverse effects of ranolazine in an elderly patient with renal impairment.
Blankstein, R; Bui, AH; M Blum, R; Southard, RA, 2013
)
0.91
" This study was not designed to demonstrate that ranolazine reduced the lifetime risk of cardiac events; it was designed as a short term proof-of-concept study that probed the following hypotheses: 1) asymptomatic diastolic dysfunction could be detected a few days after patients completed antitumor therapy, and 2) ranolazine was active and safe in relieving echocardiographic and/or biohumoral indices of diastolic dysfunction, measured at 5 weeks or 6 months of ranolazine administration."( Pharmacology at work for cardio-oncology: ranolazine to treat early cardiotoxicity induced by antitumor drugs.
Minotti, G, 2013
)
0.91
" Ranolazine is a first-in-class piperazine derivative that inhibits the late inward sodium current in cardiac cells and is considered an effective and safe option for treating patients with CSA."( Efficacy and safety of ranolazine in patients with chronic stable angina.
Geunes-Boyer, S; Hines, ME; Kloner, RA, 2013
)
1.61
" This case highlights medication errors that resulted in rare debilitating neurological adverse effects of ranolazine in an elderly due to drug interaction with clarithromycin."( A rare debilitating neurological adverse effect of ranolazine due to drug interaction with clarithromycin.
Chaudhary, S; Dave, N; Mathew, M; Mishra, A; Pandya, HV; Sapre, CM,
)
0.6
" Currently, ongoing trials are evaluating the efficacy and safety of ranolazine in patients with cardiac arrhythmias; preliminary results suggest that ranolazine, when used alone or in combination with dronedarone, is safe and effective in reducing atrial fibrillation."( Ranolazine: Electrophysiologic Effect, Efficacy, and Safety in Patients with Cardiac Arrhythmias.
Assadi, H; Heidary, S; Shenasa, H; Shenasa, M, 2016
)
2.11
"Ranolazine was safe and well tolerated in patients with HCM."( Safety and efficacy of ranolazine in hypertrophic cardiomyopathy: Real-world experience in a National Referral Center.
Argirò, A; Baldini, K; Cappelli, F; Coppini, R; Dei, LL; Favilli, S; Ferrantini, C; Gabriele, M; Marchi, A; Marchionni, N; Maurizi, N; Olivotto, I; Passantino, S; Tassetti, L; Tomberli, A; Zampieri, M; Zocchi, C, 2023
)
2.66

Pharmacokinetics

The primary objective of this study was to determine the concentration of ranolazine in human plasma using the liquid chromatography/tandem mass spectrometry (LC-MS/MS) method. The pharmacokinetic characteristics and bioavailability in six Beagle dogs after oral administration of RH-ST and ranolazines hydrochloride common tablets (RH-CT) as reference were compared.

ExcerptReferenceRelevance
" Drug exposures based on Cmax and AUC in female rats were roughly 2-to 3-fold of those in male rats."( Gender difference in ranolazine pharmacokinetics in rats.
Li, L; Liang, Y; Liu, XD; Lu, T; Xie, L,
)
0.45
" The pharmacokinetic characteristics and bioavailability in six Beagle dogs after oral administration of RH-ST and ranolazine hydrochloride common tablets (RH-CT) as reference were compared."( [Optimization of the formulation of ranolazine hydrochloride sustained-release tablet and its pharmacokinetics in dogs].
Li, CJ; Li, Y; Wang, JY; Yang, QM; Yu, YL; Zhang, YH, 2010
)
0.85
" Finally, this proposed method was successfully applied to dog pharmacokinetic study and yielded the most comprehensive data on systemic exposure of strictosamide to date."( Validated liquid chromatography mass spectrometry method for quantitative determination of strictosamide in dog plasma and its application to pharmacokinetic study.
Dai, C; Ding, G; Guan, T; Kang, A; Li, C; Liang, Y; Liu, W; Meng, Z; Wang, G; Xiao, W; Xie, L; Xie, T; Xu, J; Zhang, J; Zhao, L; Zhao, Q; Zheng, X, 2011
)
0.37
"0 min) method, which was successfully applied to a phase I pharmacokinetic study of ranolazine in Chinese healthy volunteers."( Development and validation of a sensitive U-HPLC-MS/MS method with electrospray ionization for quantitation of ranolazine in human plasma: application to a clinical pharmacokinetic study.
Fang, PF; Li, HD; Peng, WX; Tan, QY; Yan, M; Zhang, QZ; Zhu, RH, 2012
)
0.81
" Quercetin increased the peak concentration (Cmax) of ranolazine from 254 ± 8."( Influence of quercetin on the pharmacokinetics of ranolazine in rats and in vitro models.
Babu, KN; Babu, PJ; Babu, PR; Peter, PL; Rajesh, K, 2013
)
0.89
" The primary objective of this study was to determine the concentration of ranolazine in human plasma using the liquid chromatography/tandem mass spectrometry (LC-MS/MS) method and to compare the pharmacokinetic properties of ranolazine after administration of single and multiple doses of ranolazine in healthy Chinese adult volunteers."( Tolerability and pharmacokinetics of ranolazine following single and multiple sustained-release doses in Chinese healthy adult volunteers: a randomized, open-label, Latin square design, phase I study.
Li, HD; Peng, WX; Tan, QY; Zhang, J; Zhang, QZ; Zhu, RH, 2013
)
0.89
" Twelve Chinese subjects (six men, six women) were enrolled in the single-dose phase of the pharmacokinetic study."( Tolerability and pharmacokinetics of ranolazine following single and multiple sustained-release doses in Chinese healthy adult volunteers: a randomized, open-label, Latin square design, phase I study.
Li, HD; Peng, WX; Tan, QY; Zhang, J; Zhang, QZ; Zhu, RH, 2013
)
0.66
" The pharmacokinetic properties of ranolazine were linear after administration of single oral doses of 500 to 1,500 mg."( Tolerability and pharmacokinetics of ranolazine following single and multiple sustained-release doses in Chinese healthy adult volunteers: a randomized, open-label, Latin square design, phase I study.
Li, HD; Peng, WX; Tan, QY; Zhang, J; Zhang, QZ; Zhu, RH, 2013
)
0.94
" A significant number of cardiovascular drugs compete for transport by OCT1 or OCT2, introducing the potential to alter the pharmacokinetic profile of other concomitantly administered medications."( Organic Cation Transporter-Mediated Clearance of Cardiovascular Drugs: A Pharmacological Perspective.
Arora, RR; Hassan, OT; Hassan, RT,
)
0.13
" The aim of the ROMAN study was to compare the pharmacodynamic effects of ranolazine versus amlodipine on platelet reactivity in clopidogrel treated patients with CAD."( Comparison of the pharmacodynamic effects of ranolazine versus amlodipine on platelet reactivity in stable patients with coronary artery disease treated with dual antiplatelet therapy : The ROMAN (RanOlazine vs. aMlodipine on platelet reactivity in stable
Angiolillo, DJ; Gaudio, C; Greco, C; Marazzi, G; Pelliccia, F; Rollini, F; Rosano, G; Vitale, C, 2015
)
0.91
" Blood samples were collected over 65 h to determine the pharmacokinetic characteristics during and between hemodialysis sessions."( Single dose oral ranolazine pharmacokinetics in patients receiving maintenance hemodialysis.
Bleske, BE; Eyler, RF; Heung, M; Mueller, BA; Salama, NN; Scoville, BA; Segal, JH, 2019
)
0.85
" Given the extent of pharmacokinetic variability observed with the 500 mg and 1000 mg oral doses of ranolazine, neither can be recommended as a starting dose in patients receiving maintenance hemodialysis."( Single dose oral ranolazine pharmacokinetics in patients receiving maintenance hemodialysis.
Bleske, BE; Eyler, RF; Heung, M; Mueller, BA; Salama, NN; Scoville, BA; Segal, JH, 2019
)
1.07
" In this study, the pharmacokinetic (PK) properties and tolerability of single- and multiple-dose ranolazine were compared between healthy Korean and white subjects."( Pharmacokinetics and Safety of Extended-release Ranolazine in Korean and White Healthy Subjects.
Cho, JY; Jang, IJ; Lee, S; Lee, SW; Yoo, H; Yoon, DY; Yoon, SH; Yu, KS, 2021
)
1.09

Compound-Compound Interactions

The potential for a drug-drug interaction was explored in two phase 1 clinical studies in subjects with T2DM. The electrophysiologic mechanisms of ranolazine in combination with class III drugs were studied.

ExcerptReferenceRelevance
" This study examined the effects of treatment with Ran alone and in combination with metoprolol (Met) or enalapril (Ena) on LV function and remodeling in dogs with HF."( Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure.
Belardinelli, L; Blackburn, B; Gupta, RC; Mishra, S; Rastogi, S; Sabbah, HN; Sharov, VG; Stanley, WC, 2008
)
1.79
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012
)
0.38
" The electrophysiologic mechanisms of ranolazine in combination with class III drugs were studied in an isolated whole-heart model of stretch-related AF."( Antiarrhythmic effect of ranolazine in combination with class III drugs in an experimental whole-heart model of atrial fibrillation.
Breithardt, G; Eckardt, L; Frommeyer, G; Kaese, S; Kaiser, D; Milberg, P; Uphaus, T, 2013
)
0.96
" The potential for a drug-drug interaction was explored in two phase 1 clinical studies in subjects with T2DM to evaluate the pharmacokinetics and safety of metformin 1000 mg BID when administered with ranolazine 1000 mg BID (Study 1, N = 28) or ranolazine 500 mg BID (Study 2, N = 25) as compared to metformin alone."( Pharmacokinetic drug-drug interaction study of ranolazine and metformin in subjects with type 2 diabetes mellitus.
Allard, M; Ben-Yehuda, O; Berg, J; Gottwald, M; Jochelson, P; Juan, A; Pannacciulli, N; Shao, Y; Zack, J; Zhang, H, 2015
)
0.86

Bioavailability

The aim of our study was to enhance the bioavailability of ranolazine by using herbal-bioenhancer quercetin in rats and to study the role of P-glycoprotein (P-gp) in vitro models. The pharmacokinetic characteristics and bioavailability in six Beagle dogs after oral administration of RH-ST were compared.

ExcerptReferenceRelevance
" The absolute bioavailability ranges from 35% to 50%."( Clinical pharmacokinetics of ranolazine.
Jerling, M, 2006
)
0.63
" The pharmacokinetic characteristics and bioavailability in six Beagle dogs after oral administration of RH-ST and ranolazine hydrochloride common tablets (RH-CT) as reference were compared."( [Optimization of the formulation of ranolazine hydrochloride sustained-release tablet and its pharmacokinetics in dogs].
Li, CJ; Li, Y; Wang, JY; Yang, QM; Yu, YL; Zhang, YH, 2010
)
0.85
"The aim of our study was to enhance the bioavailability of ranolazine by using herbal-bioenhancer quercetin in rats and to study the role of P-glycoprotein (P-gp) in vitro models."( Influence of quercetin on the pharmacokinetics of ranolazine in rats and in vitro models.
Babu, KN; Babu, PJ; Babu, PR; Peter, PL; Rajesh, K, 2013
)
0.89
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

The primary objective of the Monotherapy Assessment of Ranolazine In Stable Angina (MARISA) trial was to determine the dose-response relationship of ranolazine, a potentially new anti-anginal compound, on symptom-limited exercise duration.

ExcerptRelevanceReference
" The metabolite profiles following single and multiple doses of 342 mg instant release (IR) ranolazine, following multiple doses of 1000 mg sustained release (SR) ranolazine and following dosing with both ranolazine (IR) and a potentially co-administered drug, diltiazem, were compared."( The characterization of the metabolites of ranolazine in man by liquid chromatography mass spectrometry.
Eadie, J; Herron, WJ; Liu, Y; Penman, AD; Reilly, MA; Rush, WR, 1995
)
0.77
" Chronic administration of ranolazine did not increase the endurance capacity of rats with CHF induced by MI at the dosage and with the protocol used."( Effects of ranolazine on the exercise capacity of rats with chronic heart failure induced by myocardial infarction.
Aaker, A; Hirai, T; McCormack, JG; Musch, TI, 1996
)
0.98
"0 minute, we randomly assigned patients to receive either immediate-release ranolazine in 3 dosing regimens or placebo during each treatment period."( A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Ranolazine Study Group.
Pepine, CJ; Wolff, AA, 1999
)
0.78
" Treadmill exercise 12 hours (trough) and 4 hours (peak) after dosing was assessed after 2, 6 (trough only), and 12 weeks of treatment."( Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.
Chaitman, BR; Chumakova, G; Kuch, J; Parker, JO; Pepine, CJ; Skettino, SL; Skopal, J; Wang, W; Wolff, AA, 2004
)
0.71
"The primary objective of the Monotherapy Assessment of Ranolazine In Stable Angina (MARISA) trial was to determine the dose-response relationship of ranolazine, a potentially new anti-anginal compound, on symptom-limited exercise duration."( Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina.
Chaitman, BR; Hanley, P; Hebert, DA; Kuch, J; Meluzin, J; Nelson, JJ; Parker, JO; Pepine, CJ; Skettino, SL; Wang, W; Wolff, AA, 2004
)
0.82
"In chronic angina patients, ranolazine monotherapy was well tolerated and increased exercise performance throughout its dosing interval at all doses studied without clinically meaningful hemodynamic effects."( Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina.
Chaitman, BR; Hanley, P; Hebert, DA; Kuch, J; Meluzin, J; Nelson, JJ; Parker, JO; Pepine, CJ; Skettino, SL; Wang, W; Wolff, AA, 2004
)
0.87
"Stable patients with coronary disease and > or =3 anginal attacks per week despite maximum recommended dosage of amlodipine (10 mg/day) were randomized to 1,000 mg ranolazine or placebo twice a day for 6 weeks."( Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial.
Blokhin, A; Gratsiansky, NA; Huang, IZ; Meng, L; Stone, PH, 2006
)
0.84
" Peak plasma levels of ranolazine have been observed two to five hours following repeated dosing and are unaffected by food."( Ranolazine in the management of chronic stable angina.
McBride, BF; Zerumsky, K, 2006
)
2.09
" The purpose of this review is to evaluate the pharmacology, pharmacokinetics, clinical trials for safety and efficacy, precautions, adverse effects, drug interactions, and dosage and administration of ranolazine in the treatment of chronic stable angina and acute coronary syndrome."( Ranolazine: a novel agent that improves dysfunctional sodium channels.
Mehta, M; Pham, DQ, 2007
)
1.97
" Although prazosin (10 microg/kg/min) markedly shifted the phenylephrine (alpha(1)-agonist) dose-response curve to the right, it did not have any effect on clofilium-induced prolongation of QTc and MAPD(90) (43 +/- 7 and 53 +/- 9%, respectively) or the occurrence of TdP (seven of eight)."( Antitorsadogenic effects of ({+/-})-N-(2,6-dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazine (ranolazine) in anesthetized rabbits.
Belardinelli, L; Dhalla, AK; Robertson, C; Wang, WQ, 2008
)
0.56
" Ranolazine dechallenge on a subsequent admission produced subtherapeutic tacrolimus concentrations requiring dosage increases."( Ranolazine-tacrolimus interaction.
Pierce, DA; Reeves-Daniel, AM, 2010
)
2.71
"A 63-year-old man with a history of chronic renal impairment on a stable dosage of simvastatin developed rhabdomyolysis after the addition of ranolazine to his medication regimen."( Rhabdomyolysis in a patient receiving ranolazine and simvastatin.
Ezekiel, TO; Hylton, AC, 2010
)
0.83
" In one patient, severe hypoglycemia limited dosing to 500 mg daily, but this was sufficient for VT control."( Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks.
Anderson, JL; Bair, TL; Bunch, TJ; Crandall, BG; Day, JD; Lappe, DL; Mader, KM; Mahapatra, S; May, HT; Molden, J; Muhlestein, JB; Murdock, D; Osborn, JS; Weiss, JP, 2011
)
1.81
" This dosage was generally well tolerated by all the subjects."( Tolerability and pharmacokinetics of ranolazine following single and multiple sustained-release doses in Chinese healthy adult volunteers: a randomized, open-label, Latin square design, phase I study.
Li, HD; Peng, WX; Tan, QY; Zhang, J; Zhang, QZ; Zhu, RH, 2013
)
0.66
" Patients received either 24 h amiodarone infusion (loading dose 5 mg/kg followed by maintenance dose of 50 mg/h; n = 60), or amiodarone infusion at the same dosage plus a single oral dose of ranolazine 1500 mg (n = 61)."( Ranolazine enhances the efficacy of amiodarone for conversion of recent-onset atrial fibrillation.
Fragakis, N; Katritsis, D; Koskinas, KC; Skeberis, V; Vassilikos, V, 2014
)
2.03
"Dofetilide, ranolazine, and a combination of these were administered in 4 incremental dosing regimens to horses with acutely pacing-induced AF."( Antiarrhythmic Effects of Combining Dofetilide and Ranolazine in a Model of Acutely Induced Atrial Fibrillation in Horses.
Buhl, R; Carstensen, H; Flethøj, M; Haugaard, MM; Hesselkilde, EZ; Jespersen, T; Kanters, JK; Kjær, L; Pehrson, S, 2018
)
1.11
"Data on ranolazine dosing in patients receiving maintenance hemodialysis is almost non-existent."( Single dose oral ranolazine pharmacokinetics in patients receiving maintenance hemodialysis.
Bleske, BE; Eyler, RF; Heung, M; Mueller, BA; Salama, NN; Scoville, BA; Segal, JH, 2019
)
1.29
" The patient was taking an adequate dosage of dabigatran, thus dabigatran was thought to be overdosed due to its interaction with ranolazine because dabigatran is a p-glycoprotein substrate, whereas ranolazine is the inhibitor of this transporter."( Possible Interaction between Dabigatran and Ranolazine in Patients with Renal Failure.
Damulevičienė, G; Galaunė, V; Gumbrevičius, G; Gumbrevičiūtė, M, 2019
)
0.98
"Patients were treated with ranolazine for 2 [1-4] years; 83 (70%) achieved a dosage ≥1000 mg per day."( Safety and efficacy of ranolazine in hypertrophic cardiomyopathy: Real-world experience in a National Referral Center.
Argirò, A; Baldini, K; Cappelli, F; Coppini, R; Dei, LL; Favilli, S; Ferrantini, C; Gabriele, M; Marchi, A; Marchionni, N; Maurizi, N; Olivotto, I; Passantino, S; Tassetti, L; Tomberli, A; Zampieri, M; Zocchi, C, 2023
)
1.52
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (5)

ClassDescription
monocarboxylic acid amideA carboxamide derived from a monocarboxylic acid.
aromatic amideAn amide in which the amide linkage is bonded directly to an aromatic system.
N-alkylpiperazine
secondary alcoholA secondary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has two other carbon atoms attached to it.
monomethoxybenzeneCompounds containing a benzene skeleton substituted with one methoxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (12)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
thioredoxin reductaseRattus norvegicus (Norway rat)Potency0.94660.100020.879379.4328AID488772; AID588456
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency29.84930.001530.607315,848.9004AID1224848; AID1224849
cytochrome P450 2D6Homo sapiens (human)Potency12.30180.00108.379861.1304AID1645840
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency33.48890.001019.414170.9645AID743191
arylsulfatase AHomo sapiens (human)Potency37.93301.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency26.67950.035520.977089.1251AID504332
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency19.95263.548119.542744.6684AID743266
lamin isoform A-delta10Homo sapiens (human)Potency0.00080.891312.067628.1838AID1487
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency39.81070.009610.525035.4813AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)12.70000.00091.901410.0000AID1342700; AID1734600
Sodium channel protein type 5 subunit alphaHomo sapiens (human)IC50 (µMol)147.23330.00033.64849.2000AID1342698; AID1342699; AID1754522
Voltage-gated sodium channel Nav1.5 cardiac isoform Canis lupus familiaris (dog)IC50 (µMol)6.90006.90006.90006.9000AID1302500
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (54)

Processvia Protein(s)Taxonomy
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rateSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac conduction system developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac ventricle developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
brainstem developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
sodium ion transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
positive regulation of sodium ion transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
response to denervation involved in regulation of muscle adaptationSodium channel protein type 5 subunit alphaHomo sapiens (human)
telencephalon developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
cerebellum developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
odontogenesis of dentin-containing toothSodium channel protein type 5 subunit alphaHomo sapiens (human)
positive regulation of action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
positive regulation of epithelial cell proliferationSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac muscle contractionSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of atrial cardiac muscle cell membrane depolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of atrial cardiac muscle cell membrane repolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of ventricular cardiac muscle cell membrane depolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
cellular response to calcium ionSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of cardiac muscle cell contractionSodium channel protein type 5 subunit alphaHomo sapiens (human)
ventricular cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
atrial cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
SA node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
AV node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
bundle of His cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during AV node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during SA node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during Purkinje myocyte cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during bundle of His cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
AV node cell to bundle of His cell communicationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of heart rate by cardiac conductionSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during atrial cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of sodium ion transmembrane transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (26)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 5 subunit alphaHomo sapiens (human)
protein bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
calmodulin bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
fibroblast growth factor bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
enzyme bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
protein kinase bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
protein domain specific bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
ankyrin bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
ubiquitin protein ligase bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
transmembrane transporter bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
nitric-oxide synthase bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in AV node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in bundle of His cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in Purkinje myocyte action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in SA node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
scaffold protein bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (17)

Processvia Protein(s)Taxonomy
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
caveolaSodium channel protein type 5 subunit alphaHomo sapiens (human)
nucleoplasmSodium channel protein type 5 subunit alphaHomo sapiens (human)
nucleolusSodium channel protein type 5 subunit alphaHomo sapiens (human)
endoplasmic reticulumSodium channel protein type 5 subunit alphaHomo sapiens (human)
plasma membraneSodium channel protein type 5 subunit alphaHomo sapiens (human)
caveolaSodium channel protein type 5 subunit alphaHomo sapiens (human)
cell surfaceSodium channel protein type 5 subunit alphaHomo sapiens (human)
intercalated discSodium channel protein type 5 subunit alphaHomo sapiens (human)
membraneSodium channel protein type 5 subunit alphaHomo sapiens (human)
lateral plasma membraneSodium channel protein type 5 subunit alphaHomo sapiens (human)
Z discSodium channel protein type 5 subunit alphaHomo sapiens (human)
T-tubuleSodium channel protein type 5 subunit alphaHomo sapiens (human)
sarcolemmaSodium channel protein type 5 subunit alphaHomo sapiens (human)
perinuclear region of cytoplasmSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 5 subunit alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (112)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1754522Inhibition of Nav1.5 (unknown origin)-mediated late channel current2021Bioorganic & medicinal chemistry letters, 08-01, Volume: 45Identification of aryl sulfonamides as novel and potent inhibitors of Na
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1222793Dissociation constant, pKa of the compound2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Which metabolites circulate?
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1734574Cardioprotective activity in New Zealand rabbit heart assessed as reversal of ATX-II induced late sodium current increase in QT interval by electrocardiographic analysis2016Journal of medicinal chemistry, Oct-13, Volume: 59, Issue:19
Discovery of Dihydrobenzoxazepinone (GS-6615) Late Sodium Current Inhibitor (Late I
AID1302104Inhibition of Nav1.5 in isolated rabbit heart assessed as inhibition of ATX2-induced prolongation of mean action potential duration2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Discovery of triazolopyridinone GS-462808, a late sodium current inhibitor (Late INai) of the cardiac Nav1.5 channel with improved efficacy and potency relative to ranolazine.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID699540Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1302502Selectivity index, ratio of IC50 for Nav 1.5 peak sodium current to IC50 for Nav 1.5 late sodium current in canine ventricular myocytes2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Discovery of triazolopyridine GS-458967, a late sodium current inhibitor (Late INai) of the cardiac NaV 1.5 channel with improved efficacy and potency relative to ranolazine.
AID1734555Inhibition of sodium channel-mediated ATX-II induced late sodium current in canine left ventricular myocytes by single cell manual patch clamp method2016Journal of medicinal chemistry, Oct-13, Volume: 59, Issue:19
Discovery of Dihydrobenzoxazepinone (GS-6615) Late Sodium Current Inhibitor (Late I
AID1734553Cardioprotective activity in New Zealand rabbit model of LAD coronary artery occlusion-induced ischemia-reperfusion injury assessed as inhibition of ST segment elevation intravenously administered with compound for 30 mins followed by induction of ischemi2016Journal of medicinal chemistry, Oct-13, Volume: 59, Issue:19
Discovery of Dihydrobenzoxazepinone (GS-6615) Late Sodium Current Inhibitor (Late I
AID1734568Cardioprotective activity in New Zealand White rabbit heart assessed as reversal of ATX-II induced late sodium current prolongation in change in duration of monophasic action potential at 90 percent repolarization at 1 uM by electrocardiographic analysis 2016Journal of medicinal chemistry, Oct-13, Volume: 59, Issue:19
Discovery of Dihydrobenzoxazepinone (GS-6615) Late Sodium Current Inhibitor (Late I
AID699539Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1302500Inhibition of canine ventricular myocytes Nav 1.5 assessed as reduction in ATX-2 induced late channel current by manual single-patch clamp assay2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Discovery of triazolopyridine GS-458967, a late sodium current inhibitor (Late INai) of the cardiac NaV 1.5 channel with improved efficacy and potency relative to ranolazine.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID267729Glucose oxidation rate in isolated working rat heart at 10 uM relative to DMSO2006Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13
Heteroaryl substituted bis-trifluoromethyl carbinols as malonyl-CoA decarboxylase inhibitors.
AID1302501Inhibition of 0.1 Hz stimulated human Nav1.5alpha expressed in HEK293 cells assessed as inhibition of late sodium current at 10 uM with 3 compound additions for 7 to 8 mins at holding potential -120 mV in presence of late sodium current activator tefluthr2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Discovery of triazolopyridine GS-458967, a late sodium current inhibitor (Late INai) of the cardiac NaV 1.5 channel with improved efficacy and potency relative to ranolazine.
AID406933Inhibition of human sodium Nav1.5 channel expressed in HEK293 cells assessed as inhibition of veratridine-induced late sodium current elicited at -30 mV from holding potential of -110 mV at 10 uM by patch clamp technique2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Sodium late current blockers in ischemia reperfusion: is the bullet magic?
AID1734572Cardioprotective activity in New Zealand White rabbit heart assessed as reversal of ATX-II induced late sodium current prolongation in change in duration of monophasic action potential at 90 percent repolarization by electrocardiographic analysis relative2016Journal of medicinal chemistry, Oct-13, Volume: 59, Issue:19
Discovery of Dihydrobenzoxazepinone (GS-6615) Late Sodium Current Inhibitor (Late I
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1734603Selectivity index, ratio of IC50 for inhibition of peak sodium current (unknown origin) to IC50 for inhibition of ATX-II induced late sodium current (unknown origin)2016Journal of medicinal chemistry, Oct-13, Volume: 59, Issue:19
Discovery of Dihydrobenzoxazepinone (GS-6615) Late Sodium Current Inhibitor (Late I
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1734576Cardioprotective activity in New Zealand rabbit model of LAD coronary artery occlusion-induced ischemia-reperfusion injury assessed as inhibition of ST segment elevation at 12 uM for 30 mins followed by induction of ischemia for 15 mins and subsequent rep2016Journal of medicinal chemistry, Oct-13, Volume: 59, Issue:19
Discovery of Dihydrobenzoxazepinone (GS-6615) Late Sodium Current Inhibitor (Late I
AID1734599Inhibition of peak NaV1.1 (unknown origin) at 10 uM at 10 Hz frequency by manual patch clamp technique2016Journal of medicinal chemistry, Oct-13, Volume: 59, Issue:19
Discovery of Dihydrobenzoxazepinone (GS-6615) Late Sodium Current Inhibitor (Late I
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1302497Inhibition of Nav 1.5 in langerdorff isolated heart model (unknown origin) assessed as reversal of ATX-2 induced increase in monophasic action potential duration2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Discovery of triazolopyridine GS-458967, a late sodium current inhibitor (Late INai) of the cardiac NaV 1.5 channel with improved efficacy and potency relative to ranolazine.
AID1302499Protection from methoxamine/clofilium induced ventricular arrhythmias in anesthetized rabbit assessed as torsade des pointes at 14 uM2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Discovery of triazolopyridine GS-458967, a late sodium current inhibitor (Late INai) of the cardiac NaV 1.5 channel with improved efficacy and potency relative to ranolazine.
AID699541Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1210013Inhibition of recombinant CYP2J2 (unknown origin)-mediated terfenadine hydroxylation assessed as remaining activity at 30 uM after 5 mins by LC-MS analysis relative to control2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
AID1734601Selectivity index, ratio of IC50 for inhibition of human ERG expressed stably in CHO cells to IC50 for inhibition of ATX-II induced late sodium current (unknown origin)2016Journal of medicinal chemistry, Oct-13, Volume: 59, Issue:19
Discovery of Dihydrobenzoxazepinone (GS-6615) Late Sodium Current Inhibitor (Late I
AID1302060Inhibition of 0.1 Hz stimulated human Nav1.5alpha expressed in HEK293 cells assessed as inhibition of late sodium current at 10 uM with 3 compound additions for 7 to 8 mins at holding potential -120 mV in presence of late sodium current activator tefluthr2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Discovery of triazolopyridinone GS-462808, a late sodium current inhibitor (Late INai) of the cardiac Nav1.5 channel with improved efficacy and potency relative to ranolazine.
AID1734604Inhibition of ATX-II induced late sodium current (unknown origin) by manual patch clamp method2016Journal of medicinal chemistry, Oct-13, Volume: 59, Issue:19
Discovery of Dihydrobenzoxazepinone (GS-6615) Late Sodium Current Inhibitor (Late I
AID1734640Cardioprotective activity in rabbit assessed as decrease in chemically-induced Torsades des Pointes at 14 uM by electrocardiographic analysis2016Journal of medicinal chemistry, Oct-13, Volume: 59, Issue:19
Discovery of Dihydrobenzoxazepinone (GS-6615) Late Sodium Current Inhibitor (Late I
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1734600Inhibition of human ERG expressed stably in CHO cells by manual patch clamp technique2016Journal of medicinal chemistry, Oct-13, Volume: 59, Issue:19
Discovery of Dihydrobenzoxazepinone (GS-6615) Late Sodium Current Inhibitor (Late I
AID261291Glucose oxidation rate in isolated working hearts of Sprague-Dawley rat at 20 uM relative to DMSO2006Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5
Synthesis and structure-activity relationship of small-molecule malonyl coenzyme A decarboxylase inhibitors.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID406934Inhibition of human sodium Nav1.5 channel expressed in HEK293 cells assessed as inhibition of veratridine-induced late sodium current elicited at -30 mV from holding potential of -90 mV at 10 uM by patch clamp technique2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Sodium late current blockers in ischemia reperfusion: is the bullet magic?
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1734571Inhibition of L-type calcium channel (unknown origin)2016Journal of medicinal chemistry, Oct-13, Volume: 59, Issue:19
Discovery of Dihydrobenzoxazepinone (GS-6615) Late Sodium Current Inhibitor (Late I
AID1302111Selectivity ratio of IC50 for peak sodium current to late sodium current in canine ventricular myocytes Nav1.52016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Discovery of triazolopyridinone GS-462808, a late sodium current inhibitor (Late INai) of the cardiac Nav1.5 channel with improved efficacy and potency relative to ranolazine.
AID1302106Protection against methoxyamine/clofilium-induced ventricular arrhythmias in isolated rabbit heart assessed as torsade des pointes at 14 uM relative to control2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Discovery of triazolopyridinone GS-462808, a late sodium current inhibitor (Late INai) of the cardiac Nav1.5 channel with improved efficacy and potency relative to ranolazine.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1302103Inhibition of Nav1.5 in isolated rabbit heart assessed as inhibition of ATX2-induced prolongation of mean action potential duration at 10 to 100000 nM relative to control2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Discovery of triazolopyridinone GS-462808, a late sodium current inhibitor (Late INai) of the cardiac Nav1.5 channel with improved efficacy and potency relative to ranolazine.
AID1210014Inhibition of recombinant CYP2J2 (unknown origin)-mediated astemizole O-demethylation assessed as remaining activity at 30 uM after 5 mins by LC-MS/MS analysis relative to control2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
AID1734602Inhibition of peak sodium current (unknown origin) by manual patch clamp method2016Journal of medicinal chemistry, Oct-13, Volume: 59, Issue:19
Discovery of Dihydrobenzoxazepinone (GS-6615) Late Sodium Current Inhibitor (Late I
AID1302110Inhibition of Nav1.5 in canine ventricular myocytes assessed as inhibition of ATX2-induced late sodium current by single cell manual patch clamp assay2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Discovery of triazolopyridinone GS-462808, a late sodium current inhibitor (Late INai) of the cardiac Nav1.5 channel with improved efficacy and potency relative to ranolazine.
AID406939Reversal of ischemia-induced ST segment elevation in iv dosed anesthetized New Zealand white rabbit2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Sodium late current blockers in ischemia reperfusion: is the bullet magic?
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (759)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (0.13)18.7374
1990's27 (3.56)18.2507
2000's189 (24.90)29.6817
2010's450 (59.29)24.3611
2020's92 (12.12)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 102.39

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index102.39 (24.57)
Research Supply Index6.81 (2.92)
Research Growth Index6.47 (4.65)
Search Engine Demand Index184.42 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (102.39)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials104 (13.02%)5.53%
Reviews179 (22.40%)6.00%
Case Studies47 (5.88%)4.05%
Observational3 (0.38%)0.25%
Other466 (58.32%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (82)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Parallel Study of Ranolazine in Subjects With Chronic Stable Angina and Coronary Artery Disease With a History of Type 2 Diabetes Mellitus [NCT01334203]Phase 40 participants (Actual)Interventional2011-05-31Withdrawn
Ranolazine in Ischemic Cardiomyopathy Patients With Persistent Chest Pain or Dyspnea Despite Conventional Therapy: A Cross-Over Study [NCT01345188]Phase 428 participants (Actual)Interventional2011-04-30Completed
A Double-Blind, Placebo-Controlled, Randomized, Parallel Assignment, U.S. Study of Ranolazine for the Treatment of Patients With Diabetic Peripheral Neuropathic Pain (DPNP) [NCT02156336]Phase 44 participants (Actual)Interventional2014-05-31Terminated(stopped due to Not enough patients met study criteria for enrollment.)
A Randomized, Double-blind, Placebo-controlled Study of Ranolazine in Patients With Heart Failure With Preserved Ejection Fraction [NCT01163734]Phase 220 participants (Actual)Interventional2010-04-30Completed
Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis [NCT03472950]Phase 220 participants (Anticipated)Interventional2018-06-11Recruiting
Management of Ischemic Heart Disease With Angiwell-XR (Ranolazine) [NCT03486561]Phase 42,000 participants (Anticipated)Interventional2018-04-01Not yet recruiting
Suppression Of Atrial Fibrillation With Ranolazine After Cardiac Surgery [NCT01352416]Phase 315 participants (Actual)Interventional2010-09-30Terminated(stopped due to lack of enrollment)
Ranolazine, Ethnicity and the Metabolic Syndrome - REMS Study [NCT01304095]Phase 4160 participants (Anticipated)Interventional2011-01-31Active, not recruiting
Open Label Trial of Ranolazine in Myotonia Congenita, Paramyotonia Congenita, & Myotonic Dystrophy Type 1 [NCT02251457]Phase 135 participants (Actual)Interventional2014-08-31Completed
Effects of Ranolazine on Myocardial Perfusion in Patients With Dilated Cardiomyopathy [NCT02133911]Phase 210 participants (Actual)Interventional2014-05-01Completed
A Pilot Study Assessing the Effects of Ranolazine on Coronary Microvascular Dysfunction in Patients With Hypertrophic Cardiomyopathy [NCT03953989]Phase 226 participants (Actual)Interventional2016-10-31Completed
A Single-center, Open-label, Ascending Single- and Multiple-oral Dose Study to Evaluate the Pharmacokinetics and Safety of Ranolazine PR in Healthy Korean and Caucasian Male Subjects [NCT02817932]Phase 1120 participants (Anticipated)Interventional2016-03-31Recruiting
Ranolazine Effects on Ischemic Mitral Regurgitation Severity in Patients With Cardiac Resynchronization Therapy [NCT01979965]Phase 450 participants (Anticipated)Interventional2013-11-30Enrolling by invitation
An Open-label, Multi-center Study Evaluating the Validity, Reliability, and Responsiveness of a New Women's Ischemia Symptom Questionnaire in Women With Chronic Angina Treated With Ranolazine Extended-release Tablets (CVT 3041) [NCT00644332]Phase 4172 participants (Actual)Interventional2007-11-30Completed
A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Cross-over Trial to Evaluate the Effects of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging [NCT01221272]Phase 481 participants (Actual)Interventional2010-09-30Completed
Supervised Treadmill Exercise and Ranolazine for Intermittent Claudication of Lower Extremities. THE STERILE TRIAL. [NCT00914316]29 participants (Actual)Interventional2009-05-31Terminated
The Effect of Ranolazine on Cardiac Arrhythmias and Microvolt T- Wave Alternans in Patients With Significant Left Ventricular Dysfunction [NCT00998218]Phase 37 participants (Actual)Interventional2009-09-30Completed
Reduction of Symptomatic Ventricular Premature Beats With Ranolazine [NCT01996618]Phase 472 participants (Anticipated)Interventional2014-01-31Recruiting
Effects of Ranolazine in Patients With Angina Due to Right Ventricular Ischemia in Pulmonary Arterial Hypertension [NCT01174173]Phase 311 participants (Actual)Interventional2010-06-30Completed
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group Exploratory Study to Access the Metabolic Effects of Ranolazine When Added to Ongoing Non-Insulin Antidiabetic Therapy in Subjects With Type 2 Diabetes Mellitus [NCT01163721]Phase 280 participants (Actual)Interventional2010-06-30Completed
Does Ranolazine Decrease Biomarkers That Indicate Evidence of Myocardial Damage in Diabetics With Stable Ischemic Heart Disease? A Double-blinded, Randomized, Placebo Controlled Trial [NCT02611596]0 participants (Actual)Interventional2016-11-30Withdrawn
Evaluation of Ranolazine on Skeletal Muscle Endpoints During Exercise In Subjects With Chronic Angina and Peripheral Arterial Disease [NCT00657514]Phase 40 participants (Actual)Interventional2008-05-31Withdrawn(stopped due to Insufficient enrollment)
Ranolazine Myocardial Protection in Complete Coronary Artery Bypass Grafting: A Randomized-controlled Trial [NCT02687269]Phase 40 participants (Actual)Interventional2019-04-10Withdrawn(stopped due to Inability to produce placebo tablets similar to the drug tested)
Late Sodium Current Blockade in High-Risk ICD Patients [NCT01215253]Phase 31,012 participants (Actual)Interventional2011-09-30Completed
A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of Ranolazine SR at a Dose of 1000 mg Twice a Day in Patients With Chronic Angina Who Remain Symptomatic Despite Treatment With Amlodipine 10 mg Once a Day [NCT00091429]Phase 3500 participants Interventional2004-08-31Completed
A Double-blind, Placebo-controlled, Cross-over Study of Ranolazine in Patients With Coronary Artery Disease for the Treatment of Painful Polyneuropathy [NCT00832572]Phase 45 participants (Actual)Interventional2009-01-31Terminated(stopped due to Lack of enrollment)
A TSHRN1201 Sub-study-To Evaluate the Effects of add-on Ranolazine on Exercise Tolerance and Angina Frequency in Patients With Stable Angina Pectoris. [NCT03401502]20 participants (Actual)Interventional2018-06-07Completed
The Effects of Ranolazine on Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction [NCT01505179]10 participants (Actual)Interventional2011-02-28Completed
Comparison of the Pharmacodynamic Effects of RanOlazine Versus aMlodipine on Platelet Reactivity in Stable Patients With Coronary Artery Disease Treated With Dual ANtiplatelet Therapy - The ROMAN Randomized Study [NCT01490255]Phase 4100 participants (Anticipated)Interventional2012-01-31Recruiting
TWice overnIght High-dose ranoLazIne Pretreatment for preventinG Myocardial iscHemic Damage in Patients With Stable Angina Undergoing percuTaneous Coronary Intervention [NCT01491061]Phase 4100 participants (Anticipated)Interventional2014-01-31Not yet recruiting
A Phase 1, Parallel-group, Open-label, Multiple-dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Ranolazine ER in Subjects With Severe Renal Impairment as Compared to Healthy Subjects With Normal Renal Function [NCT01675973]Phase 14 participants (Actual)Interventional2012-07-31Terminated(stopped due to Study met stopping criteria specified within protocol.)
Comprehensive in Vitro Proarrhythmia Assay (CiPA) Clinical Phase 1 ECG Biomarker Validation Study (CiPA Phase 1 ECG Biomarker Study) [NCT03070470]Phase 160 participants (Actual)Interventional2017-03-14Completed
Ranolazine for the Prevention of Recurrent Persistent Atrial Fibrillation After Electrical Cardioversion: A Pilot Study [NCT01349491]Phase 310 participants (Actual)Interventional2012-03-31Terminated(stopped due to low recruitement rates)
The Pharmacokinetics and Electrocardiographic Implications of Adjunctive Amiodarone and Ranolazine Therapy in Patients on Implantable Cardioverter Defibrillators: The Adjunctive Ventricular Arrhythmia Suppression Trial (AVAST) Pilot [NCT01480336]19 participants (Actual)Interventional2011-02-28Completed
A Randomized, Double-blind, Placebo Controlled, Multi-center Study to Assess the Effect of Ranolazine on Outcomes in Subjects With Pulmonary Hypertension and Right Ventricular Dysfunction Accompanied by a Comparative Study of Cellular Metabolism in Subjec [NCT01839110]Phase 422 participants (Actual)Interventional2013-07-31Completed
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multinational, Clinical Trial to Evaluate the Efficacy and Safety of Ranolazine vs Placebo in Patients With Non-ST Segment Elevation Acute Coronary Syndromes [NCT00099788]Phase 36,560 participants (Actual)Interventional2004-10-31Completed
The Effectiveness of Ranolazine in Reducing Cardiac Ischaemia Induced by Chronic Total Occlusions of Coronary Arteries [NCT02423265]Phase 40 participants (Actual)Interventional2015-06-30Withdrawn(stopped due to slow recruitment; local new issues with CMR after study start)
Effect of Ranolazine on Activity Level in Patients With Angina After FFR Based Deferred Intervention [NCT03044964]Phase 440 participants (Anticipated)Interventional2017-01-10Recruiting
The Effect of Ranolazine on Echocardiographic Indices of Diastolic Dysfunction [NCT00574756]14 participants (Actual)Interventional2007-12-31Terminated(stopped due to no funding)
A Phase 1, Open-label, Single Cohort, Two-Period Fixed Sequence Study to Assess the Pharmacokinetics of Metformin Alone and in Combination With Ranolazine 500 mg Twice Daily in Subjects With Type 2 Diabetes Mellitus [NCT01546558]Phase 125 participants (Actual)Interventional2012-02-29Completed
A Phase 1, Open-Label, Single Cohort, Four-period Sequential Study to Assess the Pharmacokinetics of Metformin Alone and in Combination With Ranolazine in Subjects With Type 2 Diabetes Mellitus [NCT01546597]Phase 124 participants (Actual)Interventional2012-02-29Completed
Treatment With Ranolazine in Microvascular Coronary Dysfunction (MCD): Impact on Angina Myocardial Ischemia [NCT01342029]142 participants (Actual)Interventional2011-05-31Completed
Effect of Ranolazine on Gastrointestinal Motor Function and Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) [NCT02239926]Phase 2/Phase 35 participants (Actual)Interventional2014-09-30Terminated(stopped due to Difficulty in enrolling subjects)
Microvascular Coronary Disease In Women: Impact Of Ranolazine [NCT00570089]Phase 220 participants (Actual)Interventional2007-04-30Completed
Ranolazine for the Treatment of sYmPtoms of PaLpitations in patiEnts With Ischemic Heart Disease - The RYPPLE Trial [NCT01495520]Phase 4100 participants (Anticipated)Interventional2014-01-31Not yet recruiting
[NCT01728025]Phase 210 participants (Anticipated)Interventional2012-10-31Recruiting
A Phase I Study of Ranolazine Acute Administration and Short Term Administration in Pulmonary Arterial Hypertension [NCT01757808]Phase 112 participants (Actual)Interventional2011-08-31Completed
Improvement of Subjective Well-Being by Ranolazine Among Unrevascularized Chronic Stable Coronary Artery Disease Patients [NCT02265796]Phase 250 participants (Actual)Interventional2014-09-30Completed
Impact of Ranolazine on Myocardial Ischemia Detected by High-Field 3T Cardiovascular Magnetic Resonance (CMR) Imaging and P-31 Spectroscopy [NCT01804543]30 participants (Anticipated)Observational2012-06-30Recruiting
Pathophysiology and Prevention of Perioperative Myocardial Injury: A Prospective Randomized Controlled Trial [NCT01810796]Phase 3300 participants (Anticipated)Interventional2013-12-31Not yet recruiting
A Phase 1, Randomized, Single-blind, Placebo-controlled, Multiple-dose, Two-sequence, Cross-over Study to Evaluate the Effect of Ranolazine on Glucagon Secretion in Subjects With Type 2 Diabetes Mellitus, Followed by An Open-label, Single Dose, Exenatide [NCT01843127]Phase 124 participants (Actual)Interventional2013-04-30Completed
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus [NCT01494987]Phase 3431 participants (Actual)Interventional2012-01-31Completed
A Randomised, Double-blind, Double-dummy, Placebo-controlled, Dose-ranging Phase II Study Assessing Ranolazine in the Maintenance of Sinus Rhythm After Electrical Cardioversion in Patients With Non-permanent Atrial Fibrillation. [NCT01534962]Phase 2241 participants (Actual)Interventional2012-01-31Completed
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Ranolazine When Added to Metformin in Subjects With Type 2 Diabetes Mellitus [NCT01555164]Phase 3442 participants (Actual)Interventional2012-06-30Completed
Effects of Ranolazine and Exercise on Daily Physical Activity Trial [NCT01948310]Phase 438 participants (Actual)Interventional2013-12-31Completed
REACT Trial: A Randomized, Double Blind, Placebo-controlled, Crossover Study of Ranolazine for the Treatment of Crohn's Disease-associated Diarrhea [NCT04456517]Phase 216 participants (Anticipated)Interventional2022-10-18Enrolling by invitation
A Randomized, Double-blind, Placebo Controlled, Multi-center Study to Assess the Effect of Ranolazine in Subjects With Pulmonary Hypertension and Right Ventricular Dysfunction Using Cardiovascular MRI [NCT02829034]Phase 422 participants (Actual)Interventional2016-07-31Completed
Ranolazine for the Treatment of Angina in Hypertrophic Cardiomyopathy Investigation [NCT01721967]Phase 414 participants (Actual)Interventional2012-11-30Completed
A Single Site, Interventional, Comparative Study to Evaluate the Safety and Efficacy of Ranolazine Plus Metoprolol Combination vs. FlecainidE pluS Metoprolol Combination in ATrial Fibrillation Recurrences [NCT03162120]Phase 2/Phase 30 participants (Actual)Interventional2018-09-01Withdrawn(stopped due to new study type, it will be re-organiZed as an Investigator Initiated Study (IIS))
Safety of Amiodarone and Ranolazine Together in Patients With Stable Angina [NCT01558830]Phase 450 participants (Anticipated)Interventional2012-01-31Recruiting
Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Patients With Diabetes and Suspected or Known Coronary Artery Disease [NCT01754259]Phase 347 participants (Actual)Interventional2013-04-30Completed
Ranolazine Mediated Premature Ventricular Contraction Reduction in Ischemic Heart Disease [NCT02360397]Phase 26 participants (Actual)Interventional2014-12-31Completed
Reduction of Ischemic Myocardium With Ranolazine-Treatment in Patients With Acute Myocardial Ischemia [NCT01797484]Phase 2/Phase 320 participants (Actual)Interventional2013-08-31Completed
Impact of Ranolazine on Inflammatory, Thrombogenic, Lipogenic, Biomarkers in Women With Angina and Metabolic Syndrome. [NCT02252406]Phase 433 participants (Actual)Interventional2015-09-30Completed
Effect of Ranolazine After Deferral of Percutaneous Coronary Intervention by Fractional Flow Reserve (IMWELL3) [NCT02147834]Phase 25 participants (Actual)Interventional2015-08-31Terminated(stopped due to due to futility)
A Phase 2, Proof of Concept, Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination on Atrial Fibrillation Burden in Subjects With Paroxysmal Atrial Fibrillation [NCT01522651]Phase 2134 participants (Actual)Interventional2012-01-24Completed
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus [NCT01472185]Phase 3465 participants (Actual)Interventional2011-11-30Completed
Pharmacokinetics of Single-Dose Oral Ranolazine in Hemodialysis Patients [NCT01435174]Phase 417 participants (Actual)Interventional2011-10-31Completed
Microvascular Assessment of Ranolazine in Non-Obstructive Atherosclerosis [NCT02147067]Phase 226 participants (Actual)Interventional2014-09-30Completed
The Effects of Ranolazine on CPET Parameters in Ischemic Cardiomyopathy Patients (ERIC) [NCT01705509]14 participants (Actual)Interventional2012-09-30Terminated(stopped due to Study terminated due to lack of resources.)
A Randomized, Double-blind, Placebo Controlled Study, Designed to Investigate the Effect of Ranolazine on Left Ventricular Diastolic Function in Patients With Symptomatic AF and Preserved Ejection Function, After the Subject Has Undergone a Successful Ext [NCT01887353]Phase 28 participants (Actual)Interventional2013-06-30Terminated(stopped due to Difficultly in enrolling)
A Double-Blind, Randomized, Placebo-Controlled Single-Dose, Five Period Crossover Study of the Electrocardiographic Effects of Ranolazine, Dofetilide, Verapamil, and Quinidine in Healthy Subjects [NCT01873950]Phase 122 participants (Actual)Interventional2013-05-31Completed
Evaluation of Exercise Treadmill Test Indices in Patients With Cardiovascular Disease [NCT01562041]Phase 214 participants (Actual)Interventional2012-03-09Terminated
Randomized Double Blind Control Trial on Effects of Ranolazine on New Onset Atrial Fibrillation Rates in Post-Operative Cardiac Surgery Patients [NCT01590979]54 participants (Actual)Interventional2012-04-30Terminated(stopped due to The study was terminated due to slow rate of accrual resulting in a sample size.)
Ranolazine and Microvascular Angina by PET in the Emergency Department (RAMP-ED) [NCT02052011]Phase 431 participants (Actual)Interventional2014-04-30Completed
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Ranolazine on Major Adverse Cardiovascular Events in Subjects With a History of Chronic Angina Who Undergo Percutaneous Coronary Intervention With Incomplete Revascularization [NCT01442038]Phase 32,651 participants (Actual)Interventional2011-10-31Completed
A Pilot Study to Enhance F18 FDG-PET Imaging of Prostate Cancers With the Metabolic Inhibitor Ranolazine [NCT01992016]11 participants (Actual)Interventional2014-04-07Completed
Proof of Concept Study of Ranolazine in the Treatment of Pulmonary Hypertension Associated With Diastolic Left Ventricular Dysfunction [NCT02133352]Phase 410 participants (Actual)Interventional2011-07-31Completed
A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Parallel Study of Ranolazine in Subjects With Chronic Stable Angina and Coronary Artery Disease With a History of Type 2 Diabetes Mellitus [NCT01425359]Phase 4949 participants (Actual)Interventional2011-09-30Completed
Ranolazine Cardioprotection in PCI [NCT01767987]Phase 26 participants (Actual)Interventional2012-11-30Terminated(stopped due to Sponsor terminated study due to lack of enrollment)
RANOLAZINE STUDY: The Effect of Ranolazine on Speckle Tracking Derived Myocardial Strain in Regions of Non-Revascularizable Ischemic Myocardium [NCT03257683]0 participants (Actual)Observational2017-04-14Withdrawn(stopped due to Lack of funding)
Efficacy of Ranolazine in LQT3 Patients [NCT01648205]Phase 225 participants (Actual)Interventional2012-09-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00570089 (2) [back to overview]Seattle Angina Questionnaire (SAQ)
NCT00570089 (2) [back to overview]Cardiac Magnetic Resonance (CMRs)
NCT00644332 (9) [back to overview]Evaluate the Validity of the WISQ in Women With Chronic Angina Based on Changes in Patient-reported Angina Frequency and Nitroglycerin (NTG) Consumption Before and Following Treatment With Ranolazine Assessed as Coefficient of Determination (R^2)
NCT00644332 (9) [back to overview]Compare Changes From Baseline (BL) in Other Like Items of the WISQ With the SAQ Following Ranolazine Treatment
NCT00644332 (9) [back to overview]Compare Changes From Baseline (BL) in the Physical Limitation Items of the WISQ With the SAQ Following Ranolazine Treatment
NCT00644332 (9) [back to overview]Determine Whether the WISQ is Noninferior to the Seattle Angina Questionnaire (SAQ) With Regard to Angina Frequency Items Based on Changes From Baseline (BL) in the Angina Frequency Items of the WISQ With the SAQ Following Ranolazine Treatment
NCT00644332 (9) [back to overview]Evaluate the Responsiveness of the WISQ in Women With Chronic Angina Based on Changes in Patient-reported Angina Frequency and NTG Consumption Before and Following Treatment With Ranolazine Assessed by Regression Analysis
NCT00644332 (9) [back to overview]Determine Changes From Baseline in the Duke Activity Status Index (DASI) Following Ranolazine Treatment
NCT00644332 (9) [back to overview]Determine the Effect of Ranolazine on Angina Frequency as Measured by Patient-reported Diaries
NCT00644332 (9) [back to overview]Determine the Effect of Ranolazine on Nitroglycerin Consumption as Measured by Patient-reported Diaries
NCT00644332 (9) [back to overview]Evaluate the Reliability of the WISQ in Women With Chronic Angina Based on Changes in Patient-reported Angina Frequency and NTG Consumption Before and Following Treatment With Ranolazine Assessed as Cronbach's Alpha Value
NCT00914316 (2) [back to overview]Percentage Increase in Absolute Walking Distance Following Phase 1
NCT00914316 (2) [back to overview]Percentage Increase in Absolute Walking Distance Following Phase 2
NCT01163721 (3) [back to overview]Change From Baseline in 2-hour Postprandial Serum Glucose at Week 12 Following a Standardized Meal
NCT01163721 (3) [back to overview]Change From Baseline in Fasting Serum Glucose at Week 12
NCT01163721 (3) [back to overview]Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12
NCT01174173 (5) [back to overview]Right Ventricular Hemodynamics
NCT01174173 (5) [back to overview]Absolute RV Longitudinal Strain
NCT01174173 (5) [back to overview]6-Minute Walk Test
NCT01174173 (5) [back to overview]Improve Quality of Life
NCT01174173 (5) [back to overview]Improve Angina Symptoms
NCT01215253 (12) [back to overview]Number of Patients With Hospitalization for Cardiac Causes or Death, Whichever Occurred First.
NCT01215253 (12) [back to overview]Number of Patients With Ventricular Tachycardia (VT) or Ventricular Fibrillation (VF) or Death
NCT01215253 (12) [back to overview]Number of Patients With VT or VF Requiring ICD Shock or Death
NCT01215253 (12) [back to overview]Number of Recurrent Episodes of VT or VF Requiring Antitachycardia Pacing (ATP) or ICD Shock Therapies
NCT01215253 (12) [back to overview]Number of Recurrent Inappropriate ICD Shocks
NCT01215253 (12) [back to overview]Quality of Life Measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ)
NCT01215253 (12) [back to overview]Death
NCT01215253 (12) [back to overview]Mean Meters Walked in 6 Minutes
NCT01215253 (12) [back to overview]Number of Patients Whose First VT/VF Required Antitachycardia Pacing (ATP)
NCT01215253 (12) [back to overview]Number of Patients Whose First VT/VF Required ICD Shock
NCT01215253 (12) [back to overview]Number of Patients With First Inappropriate ICD Shock
NCT01215253 (12) [back to overview]Number of Patients With Heart Failure Hospitalization or Death, Whichever Occurred First
NCT01221272 (5) [back to overview]Exercise-induced Perfusion Defect Size (PDS) Following Ranolazine and Placebo Treatment
NCT01221272 (5) [back to overview]Exercise-induced Total Perfusion Deficit (TPD) Following Ranolazine and Placebo Treatment
NCT01221272 (5) [back to overview]Exercise-induced Reversible Perfusion Defect Size (PDS) at Baseline, End of Period 1, and End of Period 2
NCT01221272 (5) [back to overview]Perfusion Defect Severity at Baseline, End of Period 1, and End of Period 2
NCT01221272 (5) [back to overview]Exercise-induced Reversible Total Perfusion Deficit (TPD) at Baseline, End of Period 1, and End of Period 2
NCT01342029 (2) [back to overview]Cardiac Magnetic Resonance (CMRs)
NCT01342029 (2) [back to overview]Seattle Angina Questionnaire (SAQ)
NCT01345188 (3) [back to overview]Dyspnea Assessed by the Rose Dyspnea Questionnaire (RDQ)
NCT01345188 (3) [back to overview]Quality of Life
NCT01345188 (3) [back to overview]Anginal Frequency
NCT01349491 (1) [back to overview]Primary Outcome - Number of Participants With Atrial Fibrillation
NCT01425359 (6) [back to overview]Change From Baseline in the Short-Form 36® (SF-36) Mental and Physical Component Scores
NCT01425359 (6) [back to overview]Percentage of Weeks Participants Achieved at Least a 50% Reduction in Angina Frequency
NCT01425359 (6) [back to overview]Percentage of the Last 6 Weeks on Treatment During Which the Angina Frequency Was ≤ 50% of the Baseline Average Weekly Angina Frequency
NCT01425359 (6) [back to overview]Patient's Global Impression of Change (PGIC) Scale Score
NCT01425359 (6) [back to overview]Average Weekly Frequency of Sublingual Nitroglycerin Use Over the Last 6 Weeks of Treatment
NCT01425359 (6) [back to overview]Average Weekly Angina Frequency Over the Last 6 Weeks of Treatment
NCT01435174 (1) [back to overview]Pharmacokinetic Parameters of Ranolazine
NCT01442038 (4) [back to overview]Kaplan-Meier Estimates for Time From Randomization to Sudden Cardiac Death
NCT01442038 (4) [back to overview]Kaplan-Meier Estimates for Time From Randomization to Myocardial Infarction
NCT01442038 (4) [back to overview]Kaplan-Meier Estimates for Time From Randomization to First Occurrence of Ischemia-driven Revascularization or Ischemia-driven Hospitalization Without Revascularization
NCT01442038 (4) [back to overview]Kaplan-Meier Estimates for Time From Randomization to Cardiovascular Death
NCT01472185 (5) [back to overview]Change From Baseline in 2-hour Postprandial Serum Glucose at Week 24
NCT01472185 (5) [back to overview]Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24
NCT01472185 (5) [back to overview]Percentage of Participants With HbA1c < 7% at Week 24
NCT01472185 (5) [back to overview]Change From Baseline in Incremental Change of 2-hour Postprandial Serum Glucose at Week 24
NCT01472185 (5) [back to overview]Change From Baseline in Fasting Serum Glucose at Week 24
NCT01494987 (4) [back to overview]Change From Baseline in Fasting Serum Glucose at Week 24
NCT01494987 (4) [back to overview]Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24
NCT01494987 (4) [back to overview]Change From Baseline in Incremental Change of 2-hour Postprandial Serum Glucose at Week 24
NCT01494987 (4) [back to overview]Change From Baseline in 2-hour Postprandial Serum Glucose at Week 24
NCT01505179 (4) [back to overview]Change in Doppler Echocardiographic Parameters, Septal E/e' Ratio (E/e')
NCT01505179 (4) [back to overview]Change in Exercise Capacity at 6 Weeks
NCT01505179 (4) [back to overview]Change in Oxygen Consumption (VO2) at 6 Weeks
NCT01505179 (4) [back to overview]Change in Quality of Life (QOL) Score
NCT01522651 (4) [back to overview]Percentage of Participants Who Had ≥ 30%, ≥ 50%, or ≥ 70% Reduction From Baseline in AFB
NCT01522651 (4) [back to overview]Absolute Change From Baseline in AFB by Week 12
NCT01522651 (4) [back to overview]Percent Change From Baseline in Atrial Fibrillation Burden (AFB) by Week 12
NCT01522651 (4) [back to overview]Atrial Fibrillation Burden (AFB) at Baseline
NCT01534962 (6) [back to overview]Number of Patients With Documented and Confirmed AF Recurrences
NCT01534962 (6) [back to overview]Time From Randomization to First Documented AF Recurrence in Patients With Sinus Rhythm 48 Hours After Cardioversion
NCT01534962 (6) [back to overview]Number of Patients in Sinus Rhythm 48 Hours After Cardioversion With Documented AF Recurrence
NCT01534962 (6) [back to overview]Number of Patients With Documented AF Recurrences
NCT01534962 (6) [back to overview]Time From Randomization to First Documented and Confirmed AF Recurrence
NCT01534962 (6) [back to overview]Time From Randomization to First Documented AF Recurrence.
NCT01555164 (3) [back to overview]Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24
NCT01555164 (3) [back to overview]Change From Baseline in Fasting Serum Glucose at Week 24
NCT01555164 (3) [back to overview]Change From Baseline in 2-hour Postprandial Serum Glucose at Week 24
NCT01562041 (6) [back to overview]Change From Baseline in Maximum ST Segment Change Adjusted for Heart Rate (ST-HR) Index
NCT01562041 (6) [back to overview]Change From Baseline in X-Axis Intercept of ST-HR Slope
NCT01562041 (6) [back to overview]Change From Baseline in Maximum ST Segment Change Adjusted for Heart Rate (ST-HR) Slope
NCT01562041 (6) [back to overview]Change From Baseline in Total Exercise Duration
NCT01562041 (6) [back to overview]Change From Baseline in Time to Onset of Angina
NCT01562041 (6) [back to overview]Change From Baseline in Time to Onset of 1 mm ST Segment Depression (Time to Ischemia)
NCT01590979 (1) [back to overview]Incidence of New Onset Atrial Fibrillation Rate in Post-Operative Cardiac Surgery Patients
NCT01648205 (2) [back to overview]Change in QTc Duration at 2 Months
NCT01648205 (2) [back to overview]Change in QTc at 6 Months
NCT01721967 (5) [back to overview]QT Interval
NCT01721967 (5) [back to overview]Number of Adverse Events Considered Probably or Possibly Related to Study Drug
NCT01721967 (5) [back to overview]Seattle Angina Questionnaire (SAQ)
NCT01721967 (5) [back to overview]Drug Tolerability
NCT01721967 (5) [back to overview]Kansas City Cardiomyopathy Questionnaire (KCCQ)
NCT01754259 (2) [back to overview]Change in LV Diastolic Function
NCT01754259 (2) [back to overview]Change in Post-exercise Coronary Vasodilator Reserve
NCT01767987 (8) [back to overview]Left Ventricular End Diastolic Pressure (LVEDP)
NCT01767987 (8) [back to overview]Successful PCI
NCT01767987 (8) [back to overview]TIMI Flow Rate (Grade)
NCT01767987 (8) [back to overview]Troponin
NCT01767987 (8) [back to overview]Death, MI, Revascularization, CHF
NCT01767987 (8) [back to overview]Death, Myocardial Infarction (Biomarker Greater Than 2x Normal), CHF, Cardiac Arrest
NCT01767987 (8) [back to overview]Incidence of Atrial Fibrillation, Ventricular Tachycardia, or Ventricular Fibrillation in Coronary Cath Lab
NCT01767987 (8) [back to overview]Incidence of Non-sustained Ventricular Tachycardia or Atrial Fibrillation Post PCI
NCT01797484 (1) [back to overview]Left Ventricular Global Strain Rate
NCT01839110 (1) [back to overview]Changes in Right Ventricular Ejection Fraction
NCT01873950 (10) [back to overview]Placebo, and Baseline-adjusted Changes in Ventricular Gradient
NCT01873950 (10) [back to overview]Change in Relationship (Ratio) Between Heart Rate and QT
NCT01873950 (10) [back to overview]Change in Spatial QRS-T Angle Using Exposure/Response (Dofetilide and Verapamil Arms)
NCT01873950 (10) [back to overview]Change in Spatial QRS-T Angle Using Exposure/Response (Ranolazine and Quinidine Arms)
NCT01873950 (10) [back to overview]Change in Ventricular Gradient Using Exposure/Response (Dofetilide and Verapamil Arms)
NCT01873950 (10) [back to overview]Change in Ventricular Gradient Using Exposure/Response (Ranolazine and Quinidine Arms)
NCT01873950 (10) [back to overview]Placebo, and Baseline-adjusted Changes in Spatial QRS-T Angle
NCT01873950 (10) [back to overview]Change in PR, QRS, J-Tpeak, Tpeak-Tend and QTc Using Exposure/Response (Dofetilide and Verapamil Arms)
NCT01873950 (10) [back to overview]Change in PR, QRS, J-Tpeak, Tpeak-Tend and QTc Using Exposure/Response (Ranolazine and Quinidine Arms)
NCT01873950 (10) [back to overview]Placebo, and Baseline-adjusted Changes in PR, QRS, J-Tpeak, Tpeak-Tend and QTc
NCT01887353 (1) [back to overview]Time to First Atrial Fibrillation (AF) Recurrence
NCT01948310 (3) [back to overview]Change in Treatment Satisfaction as Measured by the Seattle Angina Questionnaire
NCT01948310 (3) [back to overview]Change in Total Daily Energy Expenditure
NCT01948310 (3) [back to overview]Change in Peak Oxygen Consumption (VO2 Max)
NCT01992016 (1) [back to overview]Number of Participants With Increase in SUV Uptake
NCT02052011 (1) [back to overview]Coronary Flow Reserve
NCT02133352 (6) [back to overview]Percent Change in mPAP, PAOP and Pulmonary Vascular Resistance (PVR)
NCT02133352 (6) [back to overview]Change in Cardiac Size and Function
NCT02133352 (6) [back to overview]Change in Echocardiogram Parameters (LVEF)
NCT02133352 (6) [back to overview]Percent Change in Other Hemodynamic Parameters
NCT02133352 (6) [back to overview]6 Minute Walk Test (6MWT)
NCT02133352 (6) [back to overview]Change in BNP Cardiac Biomarker
NCT02147067 (9) [back to overview]Change in Seattle Angina Questionnaire Score Regarding Treatment Satisfaction
NCT02147067 (9) [back to overview]Change in Seattle Angina Questionnaire Score Regarding Physical Limitation
NCT02147067 (9) [back to overview]Change in Seattle Angina Questionnaire Score Regarding Disease Perception
NCT02147067 (9) [back to overview]Change in Seattle Angina Questionnaire Score Regarding Angina Stability
NCT02147067 (9) [back to overview]Change in Seattle Angina Questionnaire Score Regarding Angina Frequency
NCT02147067 (9) [back to overview]Change in Peak Rate of Oxygen Consumption (VO2 Max)
NCT02147067 (9) [back to overview]Change in Metabolic Equivalents of Task (METs) at Peak
NCT02147067 (9) [back to overview]Change in Coronary Flow Reserve (CFR)
NCT02147067 (9) [back to overview]Change in Hyperemic Microcirculatory Resistance (HMR)
NCT02252406 (2) [back to overview]Impact of Ranolazine on Hemoglobin A1C
NCT02252406 (2) [back to overview]Impact of Ranolazine on HDL-C Levels in Subjects
NCT02265796 (3) [back to overview]Subjective Well Being
NCT02265796 (3) [back to overview]Seattle Angina Questionnaire Score Change From Baseline to 16 Weeks
NCT02265796 (3) [back to overview]Ischemia Driven Revascularization or Hospitalization
NCT02360397 (4) [back to overview]The Effect of Ranolazine on the PVC Burden Over 30 Days
NCT02360397 (4) [back to overview]Score on Seattle Angina Questionnaire at Baseline and at Day 30
NCT02360397 (4) [back to overview]Number of Non-sustained Ventricular Tachycardia and Sustained Ventricular Arrhythmia Episodes on Holter Monitoring
NCT02360397 (4) [back to overview]The Effect of Ranolazine on Cardiac Ischemia
NCT02829034 (3) [back to overview]Absolute Change From Baseline Right Ventricular Ejection Fraction (the Unit is Percentage)
NCT02829034 (3) [back to overview]Change in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP)
NCT02829034 (3) [back to overview]Percent Change in 6min-walk-test Distance
NCT03070470 (3) [back to overview]QTc Shortening From Calcium Block (Diltiazem) in the Presence of hERG Block (Dofetilide)
NCT03070470 (3) [back to overview]"Change From Baseline QTc With Predominant hERG Blocking Drug (Chloroquine)"
NCT03070470 (3) [back to overview]"Change From Baseline J-Tpeakc With Balanced Ion Channel Drugs (Ranolazine, Verapamil, Lopinavir / Ritonavir)"

Seattle Angina Questionnaire (SAQ)

"Questionnaires will be completed (SAQ - Seattle Angina Questionnaire) at the end of each treatment period.~The Seattle Angina Questionnaire (SAQ) is a self-administered, 19-item questionnaire, a cardiac disease-related quality-of-life measure. The SAQ is well validated and sensitive to clinical changes. It has five subscales: physical limitation, angina stability, angina frequency, treatment satisfaction, and disease perception. The possible range of scores for each of the five subscales is 0 to 100, with higher scores indicating better quality of life. A change of 10 points in any of the subscales is considered to be clinically important.~Each final SAQ domain ranges from 0-100, where higher is a better outcome score. Subscales are not combined. Median, SD and range are calculated for each domain." (NCT00570089)
Timeframe: 4 weeks and 10 weeks

,
Interventionunits on a scale (Median)
Physical FunctioningAngina StabilityAngina FrequencyTreatment SatisfactionQuality of Life
Placebo83.3507593.866.7
Study Drug91.7758087.575

[back to top]

Cardiac Magnetic Resonance (CMRs)

Cardiac Magnetic Resonance (CMRs) (CMR 1 and CMR 2) end of the 4th week of treatment 1 and treatment 2 respectively, 4 hours after the morning dose of study drug was performed to measure myocardial perfusion defect in percentage. (NCT00570089)
Timeframe: 4 weeks and 10 weeks

InterventionPercentage of ischemic myocardium (Median)
Study Drug Ranexa - CMRs (10 CMR 1 and 10 CMR 2)11.7
Placebo - CMRs (10 CMR 1 and 10 CMR 2)16.0

[back to top]

Evaluate the Validity of the WISQ in Women With Chronic Angina Based on Changes in Patient-reported Angina Frequency and Nitroglycerin (NTG) Consumption Before and Following Treatment With Ranolazine Assessed as Coefficient of Determination (R^2)

Validity of the WISQ was assessed by regression analysis. Results of this analysis are reported as the estimated coefficient of determination (R^2) of the WISQ Total Score at 4 weeks regressed on 4-week angina frequency, 4-week NTG use, and DASI score at 4 weeks. For mean (SEM) Baseline and Week 4 values for angina frequency and NTG use, please refer to Secondary Outcome Measures 7 and 8. For mean (SEM) Baseline and Week 4 DASI values, please refer to Secondary Outcome Measure 9. (NCT00644332)
Timeframe: Baseline to Week 4

Interventioncoefficient of determination (Number)
Ranolazine0.337

[back to top]

Compare Changes From Baseline (BL) in Other Like Items of the WISQ With the SAQ Following Ranolazine Treatment

Changes from BL in stress, excitement, temperature, satiety, anger, and other limitation items following ranolazine treatment were measured. Analysis: multiple linear regression; response variable: ΔWISQ - ΔSAQ; independent variables: age and BL WISQ and SAQ scores. WISQ items: 27 points (higher=more severe state); SAQ items: 45 points (lower=more severe state). WISQ scores were recalibrated by multiplying by 15/27. Noninferiority was to be considered demonstrated if the lower limit of a 2-sided 95% CI for WISQ mean - SAQ mean was above the prespecified margin (WISQ vs SAQ difference of -2). (NCT00644332)
Timeframe: Baseline to 4 Weeks

InterventionSAQ scale units (Number)
Ranolazine-6.0

[back to top]

Compare Changes From Baseline (BL) in the Physical Limitation Items of the WISQ With the SAQ Following Ranolazine Treatment

Changes from BL in stress, excitement, temperature, satiety, anger, and other limitation items following ranolazine treatment were measured. Analysis: multiple linear regression; response variable: ΔWISQ - ΔSAQ; independent variables: age and BL WISQ and SAQ scores. WISQ items: 27 points (higher=more severe state); SAQ items: 45 points (lower=more severe state). WISQ scores were recalibrated by multiplying by 15/27. Noninferiority was to be considered demonstrated if the lower limit of a 2-sided 95% CI for WISQ mean - SAQ mean was above the prespecified margin (WISQ vs SAQ difference of -2). (NCT00644332)
Timeframe: Baseline to 4 Weeks

InterventionSAQ scale units (Number)
Ranolazine12.2

[back to top]

Determine Whether the WISQ is Noninferior to the Seattle Angina Questionnaire (SAQ) With Regard to Angina Frequency Items Based on Changes From Baseline (BL) in the Angina Frequency Items of the WISQ With the SAQ Following Ranolazine Treatment

Changes from BL in angina frequency items following ranolazine treatment were measured. Analysis: multiple linear regression; response variable: ΔWISQ - ΔSAQ; independent variables: age and BL WISQ and SAQ scores. WISQ items: 15 points (higher=more severe state); SAQ items: 12 points (lower=more severe state). WISQ scores were recalibrated by multiplying by .75. Noninferiority was to be considered demonstrated if the lower limit of a 2-sided 95% CI for WISQ mean - SAQ mean was above the prespecified margin (WISQ vs SAQ difference of -2). (NCT00644332)
Timeframe: Baseline to 4 Weeks

Interventionratio of variance (Number)
Ranolazine-0.035

[back to top]

Evaluate the Responsiveness of the WISQ in Women With Chronic Angina Based on Changes in Patient-reported Angina Frequency and NTG Consumption Before and Following Treatment With Ranolazine Assessed by Regression Analysis

Responsiveness of the WISQ was assessed as the estimated coefficient of determination (R^2) of the change from baseline WISQ Total Score at 4 weeks regressed on change from baseline angina frequency and change from baseline NTG use. For mean (SEM) Baseline and Week 4 values for angina frequency and NTG use, please refer to Secondary Outcome Measures 7 and 8. (NCT00644332)
Timeframe: Baseline to Week 4

Interventioncoefficient of determination (Number)
Ranolazine0.080

[back to top]

Determine Changes From Baseline in the Duke Activity Status Index (DASI) Following Ranolazine Treatment

The DASI was analyzed as mean values at baseline and Week 4. The DASI is a self-administered questionnaire that measures a patient's functional capacity. It can be used to get a rough estimate of a patient's peak oxygen uptake. The maximum score for the DASI is 58.2 (better functional ability/capacity) and the minimum score is 0 (worse functional ability/capacity). (NCT00644332)
Timeframe: Baseline to Week 4

InterventionDASI scale units (Mean)
BaselineWeek 4
Ranolazine23.926.8

[back to top]

Determine the Effect of Ranolazine on Angina Frequency as Measured by Patient-reported Diaries

Angina episodes were recorded by subjects in their diaries. Weekly frequency of angina episodes was calculated for the two-week baseline period and the last two weeks of the study. (NCT00644332)
Timeframe: Baseline to Week 4

Interventionattacks per week (Mean)
BaselineWeek 4
Ranolazine7.93.2

[back to top]

Determine the Effect of Ranolazine on Nitroglycerin Consumption as Measured by Patient-reported Diaries

Nitroglycerin use was recorded by subjects in their diaries. Weekly frequency of NTG use was calculated for the two-week baseline period and the last two weeks of the study. (NCT00644332)
Timeframe: Baseline to Week 4

Interventionuses per week (Mean)
BaselineWeek 4
Ranolazine4.31.1

[back to top]

Evaluate the Reliability of the WISQ in Women With Chronic Angina Based on Changes in Patient-reported Angina Frequency and NTG Consumption Before and Following Treatment With Ranolazine Assessed as Cronbach's Alpha Value

Reliability of the WISQ was assessed by estimating Cronbach's alpha (standardized); values of 0.7 or higher were to be considered adequate. (Standardized Cronbach's alpha is a coefficient of reliability or consistency, and is a function of the average inter-item correlation.) Cronbach's alpha was calculated for the WISQ instrument overall and for the Angina Frequency/Severity and Angina Stability subscales. Missing item responses were not imputed. (NCT00644332)
Timeframe: Baseline to Week 4

Interventionratio of variances (Number)
WISQ OverallWISQ Angina StabilityWISQ Angina Frequency
Ranolazine0.8510.3080.794

[back to top]

Percentage Increase in Absolute Walking Distance Following Phase 1

Change in absolute walking distance in meters from baseline to 12 week follow-up treadmill test, as a percentage from baseline treadmill test (NCT00914316)
Timeframe: 12 weeks

Interventionpercentage of baseline (Median)
Phase 1-Ranolazine, Phase 2-Ranolazine112
Phase 1 -Ranolazine, Phase 2 -Placebo108
Phase 1 -Placebo, Phase 2 -Ranolazine145
Phase 1 -Placebo, Phase 2 -Placebo155

[back to top]

Percentage Increase in Absolute Walking Distance Following Phase 2

Change in absolute walking distance in meters from baseline to 24 week follow-up treadmill test, as a percentage from baseline treadmill test (NCT00914316)
Timeframe: 24 weeks

Interventionpercentage of baeline (Median)
Phase 1-Ranolazine, Phase 2-Ranolazine98
Phase 1 -Ranolazine, Phase 2 -Placebo120
Phase 1 -Placebo, Phase 2 -Ranolazine181
Phase 1 -Placebo, Phase 2 -Placebo145

[back to top]

Change From Baseline in 2-hour Postprandial Serum Glucose at Week 12 Following a Standardized Meal

2-hour postprandial serum glucose was defined as the average of serum glucose measurement at 120 minutes and 125 minutes following a standardized meal. The LOCF method was used. Participants were summarized according to the actual treatment received regardless of the allocated treatment. (NCT01163721)
Timeframe: Baseline to Week 12

Interventionmg/dL (Least Squares Mean)
Ranolazine-26.6
Placebo-11.2

[back to top]

Change From Baseline in Fasting Serum Glucose at Week 12

Serum glucose was measured following an overnight fast. The LOCF method was used. Participants were summarized according to the actual treatment received regardless of the allocated treatment. (NCT01163721)
Timeframe: Baseline to Week 12

Interventionmg/dL (Least Squares Mean)
Ranolazine2.0
Placebo4.5

[back to top]

Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12

HbA1c is a blood test to measure blood sugar control over the prior 3-month period. The last observation carried forward (LOCF) method was used: the last observed post-baseline measurements prior to Week 12 carried forward for participants with no available Week 12 values. Participants were summarized according to the actual treatment received regardless of the allocated treatment. (NCT01163721)
Timeframe: Baseline to Week 12

Interventionpercent of HbA1c in blood (Least Squares Mean)
Ranolazine-0.61
Placebo-0.08

[back to top]

Right Ventricular Hemodynamics

Mean pulmonary artery pressure was assessed invasively by right heart catheterization at the conclusion of the study to estimate right ventricular hemodynamics. (NCT01174173)
Timeframe: 3 months

Interventionmm Hg (Mean)
Ranolazine48

[back to top]

Absolute RV Longitudinal Strain

Change in absolute right ventricular (RV) longitudinal strain as assessed by exercise stress echocardiography with speckle-tracking echocardiography at baseline and conclusion of the study. An increase in exercise-induced change in RV longitudinal strain between baseline to conclusion of the study is indicative of improved RV function. If absolute RV longitudinal strain increases with exercise, that is a sign that the RV is working well. If absolute RV longitudinal strain decreases with exercise, that is a sign that the RV is not working well. Therefore, between baseline and conclusion of the study, if exercise-induced change in RV strain increases that means that the RV is working better at the conclusion of the study. (NCT01174173)
Timeframe: 3 months

Interventionpercentage (Mean)
BaselineMonth 3
Ranolazine-1.41.0

[back to top]

6-Minute Walk Test

Improve Exercise Capacity measured by 6-Minute Walk Test (NCT01174173)
Timeframe: 3 Months

Interventionmeters (Mean)
Ranolazine419

[back to top]

Improve Quality of Life

The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. The scores are averaged and transformed to a range of 0-100, in which higher scores reflect better health status and was performed at the conclusion of the study. (NCT01174173)
Timeframe: 3 Months

InterventionKCCQ Summary Score (Mean)
BaselineMonth 3
Ranolazine60.364.2

[back to top]

Improve Angina Symptoms

Assessed as average improvement in WHO Functional Class. The WHO Functional Class score ranges from 1 to 4, with higher scores indicating more impairment (NCT01174173)
Timeframe: 3 months

Interventionunits on a scale (Mean)
Ranolazine1.75

[back to top]

Number of Patients With Hospitalization for Cardiac Causes or Death, Whichever Occurred First.

Number of patients with a composite endpoint of cardiovascular hospitalization or death, whichever occurred first. (NCT01215253)
Timeframe: 2 years of follow-up on average

InterventionParticipants (Count of Participants)
Ranolazine237
Placebo222

[back to top]

Number of Patients With Ventricular Tachycardia (VT) or Ventricular Fibrillation (VF) or Death

Primary endpoint of the study will be defined as a composite endpoint consisting of Ventricular Tachycardia or Ventricular Fibrillation requiring antitachycardia pacing (ATP) therapy, implantable cardioverter-defibrillator (ICD) shock, or death, whichever occurs first. (NCT01215253)
Timeframe: 2 years of follow-up on average

InterventionParticipants (Count of Participants)
Ranolazine174
Placebo198

[back to top]

Number of Patients With VT or VF Requiring ICD Shock or Death

Implantable cardioverter-defibrillator (ICD) shock for VT or VF or death, whichever occurs first. (NCT01215253)
Timeframe: 2 years of follow-up on average

InterventionParticipants (Count of Participants)
Ranolazine131
Placebo145

[back to top]

Number of Recurrent Episodes of VT or VF Requiring Antitachycardia Pacing (ATP) or ICD Shock Therapies

Total number of recurrent ICD therapies requiring antitachycardia pacing (ATP) or shock will be analyzed, not just first event (NCT01215253)
Timeframe: 2 years of follow-up on average

InterventionVT/VF events (Count of Units)
Ranolazine433
Placebo650

[back to top]

Number of Recurrent Inappropriate ICD Shocks

Number of recurrent inappropriate ICD shocks in all patients combined. (NCT01215253)
Timeframe: 2 years of follow-up on average

Interventionevents (Number)
Ranolazine19
Placebo26

[back to top]

Quality of Life Measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ)

The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a new, self-administered, 23-item questionnaire that quantifies physical limitations, symptoms, self-efficacy, social interference and quality of life. The scale ranges from 0-100 with lower scores indicating worse outcomes. (NCT01215253)
Timeframe: 1 year follow-up

Interventionunits on a scale (Mean)
Ranolazine73.6
Placebo72.8

[back to top]

Death

Death as a safety endpoint of the trial (NCT01215253)
Timeframe: 2 years of follow-up on average

InterventionParticipants (Count of Participants)
Ranolazine70
Placebo78

[back to top]

Mean Meters Walked in 6 Minutes

Exercise capacity measured by the 6-minute walk test (NCT01215253)
Timeframe: 1 year of follow-up

Interventionmeters (Mean)
Ranolazine314
Placebo309

[back to top]

Number of Patients Whose First VT/VF Required Antitachycardia Pacing (ATP)

Number of patients whose first VT or VF required antitachycardia pacing (ATP) (NCT01215253)
Timeframe: 2 years of follow-up on average

InterventionParticipants (Count of Participants)
Ranolazine92
Placebo117

[back to top]

Number of Patients Whose First VT/VF Required ICD Shock

number of patients whose first VT or VF required ICD shock (NCT01215253)
Timeframe: 2 years of follow-up on average

InterventionParticipants (Count of Participants)
Ranolazine79
Placebo84

[back to top]

Number of Patients With First Inappropriate ICD Shock

Number of patients with first inappropriate ICD shock for other reasons than VT or VF (NCT01215253)
Timeframe: 2 years of follow-up on average

InterventionParticipants (Count of Participants)
Ranolazine16
Placebo20

[back to top]

Number of Patients With Heart Failure Hospitalization or Death, Whichever Occurred First

Number of patients with a composite endpoint of heart failure hospitalization or death, whichever occurred first. (NCT01215253)
Timeframe: 2 years of follow-up on average

InterventionParticipants (Count of Participants)
Ranolazine144
Placebo140

[back to top]

Exercise-induced Perfusion Defect Size (PDS) Following Ranolazine and Placebo Treatment

PDS is the amount (percent) of the myocardium with decreased blood flow. A lower percentage means more of the myocardium is receiving blood flow. Measurements were obtained by gated single photon emission computed tomography (SPECT) imaging following exercise at the end of the ranolazine and placebo treatment periods. (NCT01221272)
Timeframe: Up to 33 days

Interventionpercentage of myocardium (Least Squares Mean)
Ranolazine21.54
Placebo20.87

[back to top]

Exercise-induced Total Perfusion Deficit (TPD) Following Ranolazine and Placebo Treatment

TPD is a score that measures the overall impact of a region of decreased myocardial blood flow, incorporating both the amount and severity of the decreased flow. TPD is measured on a scale of 0-100, with higher scores being worse and lower scores being better. Measurements were obtained by SPECT imaging following exercise at the end of the ranolazine and placebo treatment periods. (NCT01221272)
Timeframe: Up to 33 days

Interventionunits on a scale (Least Squares Mean)
Ranolazine17.23
Placebo16.57

[back to top]

Exercise-induced Reversible Perfusion Defect Size (PDS) at Baseline, End of Period 1, and End of Period 2

Exercise-induced reversible PDS was derived as the exercise PDS at baseline and at the end of Periods 1 and 2 minus the resting PDS at baseline. A lower percentage means more of the myocardium is receiving blood flow. Measurements were obtained by SPECT imaging at baseline both at rest and following exercise and following exercise at the end of Periods 1 and 2. (NCT01221272)
Timeframe: Up to 33 days

,
Interventionpercentage of myocardium (Mean)
Baseline exercise minus baseline restingEnd of Period 1 exercise minus baseline restingEnd of Period 2 exercise minus baseline resting
Placebo/Ranolazine13.514.115.2
Ranolazine/Placebo12.512.712.4

[back to top]

Perfusion Defect Severity at Baseline, End of Period 1, and End of Period 2

Perfusion defect severity was assessed for each participant as the percentage of the 17 myocardium segments with a relative perfusion defect score of 3 or 4 on a 0-4 scale. Segment scores are: 0 = normal perfusion; 1 = mild reduction in counts-not definitely abnormal; 2 = moderate reduction in counts-definitely abnormal; 3 = severe reduction in counts; 4 = absent uptake (lower scores correspond to less severity and higher scores correspond to increased severity). A lower percentage means fewer segments have severely reduced blood flow. Measurements were obtained by SPECT imaging following exercise at baseline and at the end of Periods 1 and 2. (NCT01221272)
Timeframe: Up to 33 days

,
Interventionpercentage of segments (Mean)
BaselineEnd of Period 1End of Period 2
Placebo/Ranolazine8.510.29.5
Ranolazine/Placebo11.411.610.4

[back to top]

Exercise-induced Reversible Total Perfusion Deficit (TPD) at Baseline, End of Period 1, and End of Period 2

Exercise-induced reversible TPD was derived as the exercise TPD at baseline and at the end of Periods 1 and 2 minus the resting TPD at baseline. TPD is measured on a scale of 0-100, with higher scores being worse and lower scores being better. Measurements were obtained by SPECT imaging at baseline both at rest and following exercise and following exercise at the end of Periods 1 and 2. (NCT01221272)
Timeframe: Up to 33 days

,
Interventionunits on a scale (Mean)
Baseline exercise minus baseline restingEnd of Period 1 exercise minus baseline restingEnd of Period 2 exercise minus baseline resting
Placebo/Ranolazine10.510.711.6
Ranolazine/Placebo10.510.510.1

[back to top]

Cardiac Magnetic Resonance (CMRs)

"Cardiac Magnetic Resonance (CMRs) (CMR 1 and CMR 2) end of the 2nd week of treatment 1 and treatment 2 respectively, 4 hours after the morning dose of study drug was performed to measure myocardial perfusion reserve index.~Myocardial perfusion reserve index (MPRI) was assessed using the first-pass perfusion intensity curves during stress and rest cardiac magnetic resonance imaging. First-pass perfusion images were analysed using CAAS MRV CMRI analysis software Version 3.3 (Pie Medical Imaging B.V., Maastricht, the Netherlands). Global MPRI was calculated as the ratio of stress/rest relative perfusion upslope, corrected for LV cavity upslope.~Higher MPRI represents better myocardial perfusion reserve. Since MPRI is an index, there is no unit." (NCT01342029)
Timeframe: 2 weeks (first intervention) and 6 weeks (second intervention)

Interventionmyocardial perfusion reserve index (Mean)
Ranolazine1.98
Placebo1.96

[back to top]

Seattle Angina Questionnaire (SAQ)

"Questionnaires will be completed (SAQ - Seattle Angina Questionnaire) at the end of each treatment period.~The Seattle Angina Questionnaire (SAQ) is a self-administered, 19-item questionnaire, a cardiac disease-related quality-of-life measure. The SAQ is well validated and sensitive to clinical changes. It has five subscales: physical limitation, angina stability, angina frequency, treatment satisfaction, and quality of life. The possible range of scores for each of the five subscales is 0 to 100, with higher scores indicating better quality of life. A change of 10 points in any of the subscales is considered to be clinically important." (NCT01342029)
Timeframe: 2 weeks (first intervention) and 6 weeks (second intervention)

,
InterventionUnits on scale (Mean)
Physical LimitationAngina StabilityAngina FrequencyTreatment SatisfactionQuality of LifeSAQ Overall
Placebo66.751.1762.7374.1754.1760.97
Ranolazine68.0958.463.9174.1656.0562.49

[back to top]

Dyspnea Assessed by the Rose Dyspnea Questionnaire (RDQ)

RDQ is a four item questionnaire that evaluates a patient's dyspnea with regular activity. Each question answered postiviely is given a score of 1. Total score possible is 4. A higher score indicates worse dyspnea. A difference between the score at end of treatment minus baseline is performed. A negative score indicates improvement. Comparing the difference between the 2 arms (placebo and ranolazine) is performed. (NCT01345188)
Timeframe: 12 weeks

Interventionunits on a scale (Mean)
Ranolazine-0.45
Placebo-0.34

[back to top]

Quality of Life

"Quality of life as measured by the Seattle Angina Questionnaire as a score ranging from 0 to 100. Higher score indicates better quality of life. The Qaulity of life is scored by the patient. It assesses the perceived satisfaction or dissatisfaction in the major domains of life.~These include mobility, self-care, Usual activities (leisure, work, family), Pain/Discomfort, and Anxiety." (NCT01345188)
Timeframe: 12 weeks

Interventionunits on a scale (Mean)
Ranolazine72.22
Placebo66.67

[back to top]

Anginal Frequency

Anginal frequency as assessed by Seattle Angina Questionnaire. Scoring is done by assessing responses on an ordinal value. Anginal score is scored by the patient by selecting a number from 0 to 100 with low score indicates more anginal frequency. The mean of the the scores of all patients analyzed were compared between placebo and Ranolazine. (NCT01345188)
Timeframe: 12 weeks

Interventionunits on a scale (Mean)
Ranolazine86.67
Placebo74.44

[back to top]

Primary Outcome - Number of Participants With Atrial Fibrillation

To determine if ranolazine is effective in decreasing recurrences of AF in patients with persistent AF successfully treated with electrical cardioversion. (NCT01349491)
Timeframe: 6 months

Interventionparticipants (Number)
Ranolazine3
Placebo3

[back to top]

Change From Baseline in the Short-Form 36® (SF-36) Mental and Physical Component Scores

The range of each health domain score is 0-100, with 0 indicating a poorer health state and 100 indicating a better health state. An increase in score indicates an improvement in health state. Participants were asked to complete the survey at randomization (prior to receiving treatment), and at end of treatment visit (Week 8) or early study drug discontinuation or early termination visit. The survey asked participants for responses specific to the preceding 4 weeks prior to completing the survey. (NCT01425359)
Timeframe: Up to 8 weeks

,
Interventionunits on a scale (Mean)
Mental Component ScorePhysical Component Score
Placebo1.21.9
Qualifying Phase: Participants Entered a 2-week Washout Period1.02.8

[back to top]

Percentage of Weeks Participants Achieved at Least a 50% Reduction in Angina Frequency

For each participant, the percentage of the last 6 weeks on treatment during which the angina frequency was less than or equal to 50% of the baseline average weekly angina frequency was determined. (NCT01425359)
Timeframe: 6 weeks

Interventionpercentage of weeks (Mean)
Placebo41
Ranolazine46

[back to top]

Percentage of the Last 6 Weeks on Treatment During Which the Angina Frequency Was ≤ 50% of the Baseline Average Weekly Angina Frequency

(NCT01425359)
Timeframe: 6 weeks

Interventionpercentage of weeks (Mean)
Placebo50
Ranolazine54

[back to top]

Patient's Global Impression of Change (PGIC) Scale Score

The PGIC was completed at the end of treatment/last visit.The PGIC scale measures the change in the participant's overall status since the beginning of the study on a scale ranging from 1 (no change or worse) to 7 (very much improved). (NCT01425359)
Timeframe: 8 weeks

Interventionunits on a scale (Mean)
Placebo3.9
Ranolazine4.0

[back to top]

Average Weekly Frequency of Sublingual Nitroglycerin Use Over the Last 6 Weeks of Treatment

Average weekly frequency of sublingual nitroglycerin use was defined as the total number reported during the last 6 weeks of treatment divided by the duration corresponding to the last 6 weeks of treatment. (NCT01425359)
Timeframe: 6 weeks

Interventionnitroglycerin uses per week (Mean)
Placebo3.6
Ranolazine2.9

[back to top]

Average Weekly Angina Frequency Over the Last 6 Weeks of Treatment

"Average weekly angina frequency was defined as the total number of angina episodes reported during the last 6 weeks of treatment divided by 6 weeks.~For subjects who terminated with less than 6 weeks of treatment, frequency was calculated as the total number of angina episodes reported during the treatment period divided by the subject's actual duration of treatment." (NCT01425359)
Timeframe: 6 weeks

Interventionangina attacks per week (Mean)
Placebo5.2
Ranolazine4.5

[back to top]

Pharmacokinetic Parameters of Ranolazine

Peak Plasma Concentration (Cmax) with a 500 mg dose of ranolazine (NCT01435174)
Timeframe: At hours post-dose: 0, 2, 4, 8, 12, 15, 18, 20, 22, 23, 26, 30, 65

Interventionmcg/mL (Mean)
Ranolazine0.65

[back to top]

Kaplan-Meier Estimates for Time From Randomization to Sudden Cardiac Death

Time to event distributions were estimated by the Kaplan-Meier method. 1 month = 28 days; 1 calendar year = 365 days. (NCT01442038)
Timeframe: Baseline through end of study (average 90 weeks)

,
Interventionpercentage of participants (Number)
KM Estimate: 1 MonthKM Estimate: 6 MonthsKM Estimate: 12 MonthsKM Estimate: 1 Calendar YearKM Estimate: 18 MonthsKM Estimate: 24 MonthsKM Estimate: 2 Calendar YearsKM Estimate: 30 monthsKM Estimate: 36 MonthsKM Estimate: 3 Calendar Years
Placebo0.10.20.50.50.80.90.90.90.90.9
Ranolazine0.20.50.50.50.50.50.70.70.70.7

[back to top]

Kaplan-Meier Estimates for Time From Randomization to Myocardial Infarction

Time to event distributions were estimated by the Kaplan-Meier method. 1 month = 28 days; 1 calendar year = 365 days. (NCT01442038)
Timeframe: Baseline through end of study (average 90 weeks)

,
Interventionpercentage of participants (Number)
KM Estimate: 1 MonthKM Estimate: 6 MonthsKM Estimate: 12 MonthsKM Estimate: 1 Calendar YearKM Estimate: 18 MonthsKM Estimate: 24 MonthsKM Estimate: 2 Calendar YearsKM Estimate: 30 monthsKM Estimate: 36 MonthsKM Estimate: 3 Calendar Years
Placebo0.63.35.76.28.59.49.410.113.413.4
Ranolazine1.23.85.86.27.38.710.010.910.910.9

[back to top]

Kaplan-Meier Estimates for Time From Randomization to First Occurrence of Ischemia-driven Revascularization or Ischemia-driven Hospitalization Without Revascularization

Time to event distributions were estimated by the Kaplan-Meier (KM) method. 1 month = 28 days; 1 calendar year = 365 days. (NCT01442038)
Timeframe: Baseline through end of study (average 90 weeks)

,
Interventionpercentage of participants (Number)
KM Estimate: 1 MonthKM Estimate: 6 MonthsKM Estimate: 12 MonthsKM Estimate: 1 Calendar YearKM Estimate: 18 MonthsKM Estimate: 24 MonthsKM Estimate: 2 Calendar YearsKM Estimate: 30 monthsKM Estimate: 36 MonthsKM Estimate: 3 Calendar Years
Placebo2.310.017.318.925.329.431.033.837.837.8
Ranolazine3.411.319.120.223.827.630.731.132.2NA

[back to top]

Kaplan-Meier Estimates for Time From Randomization to Cardiovascular Death

Time to event distributions were estimated by the Kaplan-Meier method. 1 month = 28 days; 1 calendar year = 365 days. (NCT01442038)
Timeframe: Baseline through end of study (average 90 weeks)

,
Interventionpercentage of participants (Number)
KM Estimate: 1 MonthKM Estimate: 6 MonthsKM Estimate: 12 MonthsKM Estimate: 1 Calendar YearKM Estimate: 18 MonthsKM Estimate: 24 MonthsKM Estimate: 2 Calendar YearsKM Estimate: 30 monthsKM Estimate: 36 MonthsKM Estimate: 3 Calendar Years
Placebo0.10.40.91.01.41.71.71.71.71.7
Ranolazine0.20.61.01.11.51.71.91.91.91.9

[back to top]

Change From Baseline in 2-hour Postprandial Serum Glucose at Week 24

"The average (mean) change from baseline in 2-hour postprandial serum glucose at Week 24 was analyzed.~Mixed Meal Tolerance Test (MMTT) Full Analysis Set: randomized participants who received at least one dose of study treatment with a baseline and at least one postbaseline measurement of serum glucose at time [T] = 120 minutes during the MMTT, administered under fasting conditions, excluding participants with major eligibility protocol violations and analyzed based on the randomized treatment regardless of actual treatment received." (NCT01472185)
Timeframe: Baseline; Week 24

Interventionmg/dL (Mean)
Placebo2
Ranolazine-19

[back to top]

Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24

The average (mean) change from baseline in HbA1c at Week 24 was analyzed. (NCT01472185)
Timeframe: Baseline; Week 24

,
Interventionpercent of HbA1c in blood (Mean)
HbA1c at Week 24Change from baseline in HbA1c at Week 24
Placebo7.70-0.27
Ranolazine7.26-0.80

[back to top]

Percentage of Participants With HbA1c < 7% at Week 24

(NCT01472185)
Timeframe: Week 24

Interventionpercentage of participants (Number)
Placebo25.6
Ranolazine41.2

[back to top]

Change From Baseline in Incremental Change of 2-hour Postprandial Serum Glucose at Week 24

The average (mean) change from baseline in incremental change of 2-hour postprandial serum glucose at Week 24 was analyzed. (NCT01472185)
Timeframe: Baseline; Week 24

Interventionmg/dL (Mean)
Placebo-1
Ranolazine-12

[back to top]

Change From Baseline in Fasting Serum Glucose at Week 24

The average (mean) change from baseline in fasting serum glucose at Week 24 was analyzed. (NCT01472185)
Timeframe: Baseline; Week 24

Interventionmg/dL (Mean)
Placebo1
Ranolazine-7

[back to top]

Change From Baseline in Fasting Serum Glucose at Week 24

The average (mean) change from baseline in fasting serum glucose at Week 24 was analyzed. (NCT01494987)
Timeframe: Baseline; Week 24

Interventionmg/dL (Mean)
Placebo+Glimepiride8
Ranolazine+Glimepiride2

[back to top]

Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24

The average (mean) change from baseline in HbA1c at Week 24 was analyzed. (NCT01494987)
Timeframe: Baseline; Week 24

,
Interventionpercent of HbA1c in blood (Mean)
HbA1c at Week 24Change from baseline in HbA1c at Week 24
Placebo+Glimepiride8.080.03
Ranolazine+Glimepiride7.58-0.47

[back to top]

Change From Baseline in Incremental Change of 2-hour Postprandial Serum Glucose at Week 24

"The average (mean) change from baseline in incremental change of 2-hour postprandial serum glucose at Week 24 was analyzed.~Mixed Meal Tolerance Test (MMTT) Full Analysis Set: randomized participants who received at least one dose of study treatment with a baseline and at least one postbaseline measurement of serum glucose at T=120 minutes during the MMTT, administered under fasting conditions, excluding participants with major eligibility protocol violations, analyzed based on the randomized treatment regardless of actual treatment received." (NCT01494987)
Timeframe: Baseline; Week 24

Interventionmg/dL (Mean)
Placebo+Glimepiride-2
Ranolazine+Glimepiride1

[back to top]

Change From Baseline in 2-hour Postprandial Serum Glucose at Week 24

The average (mean) change from baseline in 2-hour postprandial serum glucose at Week 24 was analyzed. (NCT01494987)
Timeframe: Baseline; Week 24

Interventionmg/dL (Mean)
Placebo+Glimepiride4
Ranolazine+Glimepiride1

[back to top]

Change in Doppler Echocardiographic Parameters, Septal E/e' Ratio (E/e')

Doppler echo allows non-invasive evaluation of diastolic cardiac function. The mitral inflow velocity (E) correlates with LV filling pressure, but is influenced by myocardial relaxation time (RT) and filling pressure. The early diastolic septal mitral annular tissue velocity (e') varies with RT alone. The unitless ratio of the E to e' velocities (E/e') is considered a reliable surrogate of LV filling pressure. Prediction of normal diastolic filling pressure is most reliable when E/e' is < 8; and of abnormal filling pressure when E/e' is > 15. The percent change is reported. (NCT01505179)
Timeframe: 6 weeks

Interventionpercent change (Mean)
Ranolazine Group-15
Placebo Group-1

[back to top]

Change in Exercise Capacity at 6 Weeks

Exercise capacity in terms of exercise duration (time in seconds) as described for the baseline value, is repeated at 6 weeks. (NCT01505179)
Timeframe: 6 weeks

Interventionseconds (Mean)
Ranolazine Group659.9
Placebo Group300.5

[back to top]

Change in Oxygen Consumption (VO2) at 6 Weeks

Oxygen consumption (VO2) as described at baseline is remeasured after 6 weeks of drug vs placebo. (NCT01505179)
Timeframe: 6 weeks

Interventionml/kg/min (Mean)
Ranolazine Group17.8
Placebo Group13.5

[back to top]

Change in Quality of Life (QOL) Score

The Minnesota Living with Heart Failure (HF) Questionnaire was re-administered at the 6 week time point. The total quality of life (QOL) scores were compared to the baseline score. The well-validated Minnesota Living with Heart Failure questionnaire is self-administered, has 21 questions and takes 5-10 minutes to complete. The test measures perceived health-related QOL. Each question is scored from 0 to 5 on the Likert scale, where 0 is 'none', and 5 is 'very much'. QOL scores range from 0 to 105; a lower score represents a better quality of life. After an intervention, a decrease in score reflects an improvement in QOL. A minimally important difference in the total score is 5 points. (NCT01505179)
Timeframe: 6 weeks

Interventionunits on a scale (Mean)
Ranolazine Group38.2
Placebo Group50.9

[back to top]

Percentage of Participants Who Had ≥ 30%, ≥ 50%, or ≥ 70% Reduction From Baseline in AFB

AFB was defined as the total time a participant was in AT/AF expressed as a percentage of total recording time. (NCT01522651)
Timeframe: Week 12

,,,,
Interventionpercentage of participants (Number)
≥ 30% Reduction From Baseline AFB≥ 50% Reduction From Baseline AFB≥ 70% Reduction From Baseline AFB
Dronedarone 225 mg21.713.08.7
Placebo22.216.711.1
Ranolazine 750 mg50.022.216.7
Ranolazine 750 mg + Dronedarone 150 mg54.554.527.3
Ranolazine 750 mg + Dronedarone 225 mg45.045.045.0

[back to top]

Absolute Change From Baseline in AFB by Week 12

AFB is defined as the total time a participant is in AT/AF expressed as a percentage of total recording time. Data are presented for baseline-adjusted AFB over 12 weeks of treatment. (NCT01522651)
Timeframe: Baseline; Week 12

,,,,
Interventionpercentage of total recording time (Mean)
BaselineAbsolute Change From Baseline in AFB by Week 12
Dronedarone 225 mg19.15.6
Placebo16.84.6
Ranolazine 750 mg17.3-3.1
Ranolazine 750 mg + Dronedarone 150 mg16.7-3.9
Ranolazine 750 mg + Dronedarone 225 mg16.8-4.7

[back to top]

Percent Change From Baseline in Atrial Fibrillation Burden (AFB) by Week 12

AFB was defined as the total time a participant was in atrial tachycardia (AT)/atrial fibrillation (AF) expressed as a percentage of total recording time. Data are presented for baseline-adjusted AFB over 12 weeks of treatment. Geometric mean is the mean of log-transformed AFB exponentiated. (NCT01522651)
Timeframe: Baseline; Week 12

Interventionpercent change (Geometric Mean)
Placebo-5.9
Ranolazine 750 mg-23.0
Dronedarone 225 mg3.5
Ranolazine 750 mg + Dronedarone 225 mg-59.1
Ranolazine 750 mg + Dronedarone 150 mg-45.5

[back to top]

Atrial Fibrillation Burden (AFB) at Baseline

AFB was defined as the total time a participant was in atrial tachycardia (AT)/atrial fibrillation (AF) expressed as a percentage of total recording time. Geometric mean is the mean of log-transformed AFB exponentiated. (NCT01522651)
Timeframe: Baseline

InterventionPercentage of total recording time (Geometric Mean)
Placebo12.7
Ranolazine 750 mg10.8
Dronedarone 225 mg11.6
Ranolazine 750 mg + Dronedarone 225 mg11.7
Ranolazine 750 mg + Dronedarone 150 mg11.7

[back to top]

Number of Patients With Documented and Confirmed AF Recurrences

(NCT01534962)
Timeframe: 16 weeks (112 days)

Interventionparticipants (Number)
Ranolazine Low Dose31
Ranolazine Intermediate Dose19
Ranolazin High Dose16
Placebo24

[back to top]

Time From Randomization to First Documented AF Recurrence in Patients With Sinus Rhythm 48 Hours After Cardioversion

Excluding patients with early relapses (within 48 hours) while the study drug, started after cardioversion, had not yet reached steady-state. (NCT01534962)
Timeframe: 16 weeks (112 days)

InterventionDays (Median)
Ranolazine Low Dose56.0
Ranolazine Intermediate DoseNA
Ranolazin High Dose117.0
Placebo78.0

[back to top]

Number of Patients in Sinus Rhythm 48 Hours After Cardioversion With Documented AF Recurrence

Documented AF recurrences in those patients who did not experience early relapses (within 48 hours after cardioversion) (NCT01534962)
Timeframe: 16 weeks (112 days)

Interventionparticipants (Number)
Ranolazine Low Dose32
Ranolazine Intermediate Dose19
Ranolazin High Dose21
Placebo27

[back to top]

Number of Patients With Documented AF Recurrences

(NCT01534962)
Timeframe: 16 weeks (112 days)

Interventionparticipants (Number)
Ranolazine Low Dose37
Ranolazine Intermediate Dose25
Ranolazin High Dose23
Placebo31

[back to top]

Time From Randomization to First Documented and Confirmed AF Recurrence

A confirmed AF recurrence was defined as a documented AF recurrence which was confirmed by a consecutive ECG performed at least 1 hour after first AF documentation. (NCT01534962)
Timeframe: 16 weeks (112 days)

InterventionDays (Median)
Ranolazine Low Dose73.0
Ranolazine Intermediate DoseNA
Ranolazin High DoseNA
PlaceboNA

[back to top]

Time From Randomization to First Documented AF Recurrence.

"Time to first AF recurrence reported by patient-reported TT-ECG or 12-Lead ECG at the study site, whichever occurred first.~Patients discontinuing the study without AF were censored at the time of the last available ECG." (NCT01534962)
Timeframe: 16 weeks (112 days)

InterventionDays (Median)
Ranolazine Low Dose51.0
Ranolazine Intermediate DoseNA
Ranolazin High Dose117.0
Placebo58.0

[back to top]

Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24

The average (mean) change from baseline in HbA1c at Week 24 was analyzed. (NCT01555164)
Timeframe: Baseline; Week 24

,
Interventionpercent of HbA1c in blood (Mean)
HbA1c at Week 24Change from baseline in HbA1c at Week 24
Placebo+Metformin7.86-0.20
Ranolazine+Metformin7.72-0.37

[back to top]

Change From Baseline in Fasting Serum Glucose at Week 24

The average (mean) change from baseline in fasting serum glucose at Week 24 was analyzed. (NCT01555164)
Timeframe: Baseline; Week 24

Interventionmg/dL (Mean)
Placebo+Metformin-3
Ranolazine+Metformin3

[back to top]

Change From Baseline in 2-hour Postprandial Serum Glucose at Week 24

"The average (mean) change from baseline in 2-hour postprandial serum glucose at Week 24 was analyzed.~Mixed Meal Tolerance Test (MMTT) Full Analysis Set: randomized participants who received at least one dose of study treatment with a baseline and at least one postbaseline measurement of serum glucose at T=120 minutes during the MMTT, administered under fasting conditions, excluding participants with major eligibility protocol violations; analyzed based on the randomized treatment regardless of actual treatment received." (NCT01555164)
Timeframe: Baseline; Week 24

Interventionmg/dL (Mean)
Placebo+Metformin-4
Ranolazine+Metformin7

[back to top]

Change From Baseline in Maximum ST Segment Change Adjusted for Heart Rate (ST-HR) Index

ST/HR index was measured as the average change in ST segment depression relative to heart rate change over the entire duration of exercise, monitored by ECG during the exercise treadmill tests. Change in maximum ST/HR index between the average of tests 1-3 (pre Ranexa® treatment) performed during baseline period and test 4 (post Ranexa® treatment) during treatment period was reported. (NCT01562041)
Timeframe: Baseline up to Day 15

Interventionmicrovolts/beats per minute (microV/bpm) (Mean)
Test 1Test 2Test 3Test 4Change From Baseline in Maximum ST/Heart Rate Index
Ranolazine 500 mg3.2112.8223.2282.502-0.605

[back to top]

Change From Baseline in X-Axis Intercept of ST-HR Slope

Linear regression was used to determine the slope of the ST/HR relationship in a participant's ECG response monitored during the exercise treadmill test. Change in X- axis intercept of ST-HR slope between the average of tests 1-3 (pre Ranexa® treatment) performed during baseline period and test 4 (post Ranexa® treatment) during treatment period was reported. (NCT01562041)
Timeframe: Baseline up to Day 15

Interventionbeats per minute (bpm) (Mean)
Test 1Test 2Test 3Test 4Change From Baseline in X-axis Intercept of ST/Heart Rate Slope
Ranolazine 500 mg93.488.189.889.22.173

[back to top]

Change From Baseline in Maximum ST Segment Change Adjusted for Heart Rate (ST-HR) Slope

ST-HR slope is an index of exercise induced ischemia. Linear regression was used to determine the slope of the ST/HR relationship in a participant's ECG response monitored during the exercise treadmill test. The highest ST segment/heart rate slope from among all the ECG leads and the X-axis intercept of the associated line were used to generate the maximum slope. Change in maximum ST-HR slope between the average of tests 1-3 (pre Ranexa® treatment) performed during baseline period and test 4 (post Ranexa® treatment) during treatment period was reported. (NCT01562041)
Timeframe: Baseline up to Day 15

Interventionmicrovolts/beat/minute (microV/beat/min) (Mean)
Test 1Test 2Test 3Test 4Change From Baseline in Maximum ST/Heart Rate Slope
Ranolazine 500 mg4.8575.3184.6453.430-1.553

[back to top]

Change From Baseline in Total Exercise Duration

Total exercise duration was defined as the elapsed time between the start of exercise and termination of exercise for severe angina, dyspnea or extreme fatigue assessed during the exercise treadmill test. Change in the duration of exercise between the average of tests 1-3 (pre Ranexa® treatment) performed during baseline period and test 4 (post Ranexa® treatment) during treatment period was reported. (NCT01562041)
Timeframe: Baseline up to Day 15

Interventionminutes (Mean)
Test 1Test 2Test 3Test 4Change From Baseline in Total Exercise Duration
Ranolazine 500 mg11.11811.00811.15011.8920.755

[back to top]

Change From Baseline in Time to Onset of Angina

Time to onset of angina was defined as the elapsed time between the start of exercise and the onset of anginal chest pain as reported by the participant. Change in time to angina between the average of tests 1-3 (pre Ranexa® treatment) performed during baseline period and test 4 (post Ranexa® treatment) during treatment period was reported. (NCT01562041)
Timeframe: Baseline up to Day 15

Interventionminutes (Mean)
Test 1Test 2Test 3Test 4Change From Baseline in Time to Onset of Angina
Ranolazine 500 mg8.6937.5758.1898.0370.473

[back to top]

Change From Baseline in Time to Onset of 1 mm ST Segment Depression (Time to Ischemia)

Exercise-induced ischemia was defined as the new development of horizontal or down sloping ST-segment depression (≥ 1 mm at 60 milliseconds after the J point) vs. baseline tracings. Change in time to onset of 1 mm ST depression between the average of tests 1-3 (pre Ranexa® treatment) performed during baseline period and test 4 (post Ranexa® treatment) during treatment period was reported. (NCT01562041)
Timeframe: Baseline up to Day 15

Interventionminutes (Mean)
Test 1Test 2Test 3Test 4Change From Baseline in Time to Onset of 1 mm ST Depression
Ranolazine 500 mg8.6118.8339.1969.3430.876

[back to top]

Incidence of New Onset Atrial Fibrillation Rate in Post-Operative Cardiac Surgery Patients

(NCT01590979)
Timeframe: 3 weeks after surgery

InterventionParticipants (Count of Participants)
Ranolazine5
Placebo8

[back to top]

Change in QTc Duration at 2 Months

Change in QTc at 2 months on ranolazine vs. at 1 month on placebo. This was prespecified outcome. (NCT01648205)
Timeframe: 1 month to 2 months

Interventionmiliseconds (Mean)
Placebo503
Ranolazine at 2 Months497

[back to top]

Change in QTc at 6 Months

Change in QTc at 6 months on ranolazine vs. at 1 month on placebo. This was prespecified outcome. (NCT01648205)
Timeframe: 1 month to 6 months

Interventionmiliseconds (Mean)
Placebo504
Ranolazine at 6 Months501

[back to top]

QT Interval

(NCT01721967)
Timeframe: 60 Days

Interventionmsec (Mean)
Ranolazine462.8

[back to top] [back to top]

Seattle Angina Questionnaire (SAQ)

The Seattle Angina Questionnaire (SAQ) is a self-administered, 19-item questionnaire, a cardiac disease-related quality-of-life measure. The SAQ is well validated and sensitive to clinical changes. It has five subscales: physical limitation, angina stability, angina frequency, treatment satisfaction, and disease perception. The possible range of scores for each of the five subscales is 0 to 100, with higher scores indicating better quality of life. (NCT01721967)
Timeframe: 60 Days post treatment

Interventionunits on a scale (Mean)
Physical limitationAnginal stabilityAnginal frequencyTreatment satisfactionQuality of life
Ranolazine61.490.086.090.670.8

[back to top]

Drug Tolerability

Total number of patients that tolerated 1,000mg BID dose and 500 mg BID dose (NCT01721967)
Timeframe: 60 days

Interventionparticipants (Number)
1000 mg BID500 mg BID
Ranolazine94

[back to top]

Kansas City Cardiomyopathy Questionnaire (KCCQ)

Kansas City Cardiomyopathy Questionnaire (KCCQ) (scores range from 0 to 100 with higher scores representative of a higher quality of life; clinically important changes are considered > 10 points and >5 points, respectively, as previously established (NCT01721967)
Timeframe: 60 days post treatement

Interventionunits on a scale (Mean)
Physical limitationSymptom stabilitySymptom frequencySymptom burdenTotal symptom scoreSelf-efficacyQuality of lifeSocial limitationOverall summaryClinical summary
Ranolazine7272.772.27573.685.265.266.169.874

[back to top]

Change in LV Diastolic Function

Change (from baseline) in LV diastolic function reflected primarily in mitral annular early diastolic relaxation velocity (E') at 4 weeks post randomization. LV end-diastolic and end-systolic volumes (used to calculate LVEF), left atrial volume, septal and lateral peak early diastolic tissue velocity (e'), septal and lateral peak systolic tissue velocity (s'), and mitral inflow velocity (E) were all measured in accordance with ASE guidelines. (NCT01754259)
Timeframe: 4 weeks

Intervention% change (Number)
Ranolazine1
Placebo-2

[back to top]

Change in Post-exercise Coronary Vasodilator Reserve

Change (from baseline) in post-exercise coronary vasodilator reserve, as measured by PET imaging at 4 weeks post randomization. Per-patient global coronary flow reserve (CFR) was calculated as the ratio of absolute MBF at stress over rest for the entire left ventricle. Quantitation of MBF was performed by two operators blinded to patient, treatment period and treatment order. (NCT01754259)
Timeframe: 4 weeks

Intervention% change (Number)
Ranolazine-4
Placebo2

[back to top]

Left Ventricular End Diastolic Pressure (LVEDP)

(NCT01767987)
Timeframe: During the PCI (Percutaneous Coronary Intervention) procedure - starting at timepoint of guidewire insertion into the access artery until removal of guidewire

InterventionmmHG (Number)
Placebo10

[back to top]

Successful PCI

For the purposes of this study, a successful PCI is considered one where no additional coronary interventions were required within 24 hours after the initial PCI. (NCT01767987)
Timeframe: At discharge or within 1 days, whichever comes first

Interventionparticipants (Number)
Placebo1

[back to top]

TIMI Flow Rate (Grade)

"This TIMI classification was developed by the TIMI (Thrombolysis In Myocardial Infarction) study group to semiquantitatively assess coronary artery perfusion beyond point of occlusion on coronary angiography.* TIMI Grade [Description] TIMI 0 - no perfusion [no antegrade flow beyond the point of occlusion] TIMI 1 - penetration without perfusion [faint antegrade coronary flow beyond the occlusion with incomplete filling of the distal coronary bed] TIMI 2 - partial perfusion [delayed or sluggish antegrade flow with complete filling of the distal territory] TIMI 3 - complete perfusion [normal flow with complete filling of the distal territory]~*(see http://radclass.mudr.org/content/timi-grade-flow-grading-coronary-blood-flow-during-coronary-angiography) TIMI 0 is the least favorable grade. TIMI 3 is the most favorable grade." (NCT01767987)
Timeframe: TIMI Flow Rate (Grade) is assessed immediately after an interventional reperfusion attempt during a PCI (Percutaneous Coronary Intervention) procedure.

Interventionunits on a scale (Number)
Placebo3

[back to top]

Troponin

Troponin labs will be drawn 8-10 hrs after PCI or at discharge whichever comes first (NCT01767987)
Timeframe: 8-10 hrs post PCI

InterventionNG/ML (Number)
Placebo0.023

[back to top]

Death, MI, Revascularization, CHF

(NCT01767987)
Timeframe: 1-4 weeks post PCI

Interventionparticipants (Number)
Placebo0

[back to top]

Death, Myocardial Infarction (Biomarker Greater Than 2x Normal), CHF, Cardiac Arrest

(NCT01767987)
Timeframe: At discharge or within 1 days, whichever comes first

Interventionparticipants (Number)
Placebo0

[back to top]

Incidence of Atrial Fibrillation, Ventricular Tachycardia, or Ventricular Fibrillation in Coronary Cath Lab

Abnormal heart activity (NCT01767987)
Timeframe: During the PCI (Percutaneous Coronary Intervention) procedure - starting at timepoint of guidewire insertion into the access artery until removal of guidewire

Interventionparticipants (Number)
Placebo0

[back to top]

Incidence of Non-sustained Ventricular Tachycardia or Atrial Fibrillation Post PCI

(NCT01767987)
Timeframe: Following completion of PCI through hospital discharge

Interventionparticipants (Number)
Placebo0

[back to top]

Left Ventricular Global Strain Rate

Relativ acceleration or deceleration (1/s) of left ventricular myocardial sections compared to direct opposite section. The more positive the value, the more simultaneously the movements, the more hemodynamically better. (NCT01797484)
Timeframe: 42 days after first dose of Ranolazine

Interventionpercentage of change (Mean)
Ranolazine18
No Additional Medication23

[back to top]

Changes in Right Ventricular Ejection Fraction

right ventricular ejection fraction by cardiac MRI (NCT01839110)
Timeframe: 6 months

Interventionpercentage (Least Squares Mean)
Ranolazine5.8
Placebo-4.7
Observational0.49

[back to top]

Placebo, and Baseline-adjusted Changes in Ventricular Gradient

Compute maximum mean placebo, and baseline-adjusted change for: ventricular gradient (mV*ms). (NCT01873950)
Timeframe: 24 hours

InterventionmV*ms (Least Squares Mean)
Ranolazine 1500mg2.5
Dofetilide 500mcg4.8
Verapamil HCl 120 mg4.2
Quinidine Sulfate 400mg6.0

[back to top]

Change in Relationship (Ratio) Between Heart Rate and QT

Different post-dose time-points employ different techniques for altering heart rate (leg raises and postural maneuvers). Using the measurements from all the time-points of postural maneuvers, the QT/RR relationship was modeled as a linear relationship between the square root of RR in seconds and QT in seconds and computed on a by subject, treatment and time-point basis. The change in the QT and heart rate relationship was assessed as the difference (mean and 95% CI) between the slopes from the models for each drug vs. placebo. (NCT01873950)
Timeframe: 24 hours

Interventionratio (Mean)
Ranolazine 1500mg0.01
Dofetilide 500mcg0.06
Verapamil HCl 120 mg0.02
Quinidine Sulfate 400mg0.11

[back to top]

Change in Spatial QRS-T Angle Using Exposure/Response (Dofetilide and Verapamil Arms)

"The exposure response analysis will be performed for each treatment and will use a linear or nonlinear model (as determined by visual inspection) to quantify the relationship between exposure and Baseline and placebo adjusted change from Baseline for each ECG parameter (same as for primary analysis).~The magnitude of change (mean and 95% CI) in spatial QRS-T angle for the observed mean Cmax for each drug may be calculated." (NCT01873950)
Timeframe: 24 hours

Interventiondegrees per ng/ml (Mean)
Dofetilide 500mcg-3.9
Verapamil HCl 120 mg0.4

[back to top]

Change in Spatial QRS-T Angle Using Exposure/Response (Ranolazine and Quinidine Arms)

"The exposure response analysis will be performed for each treatment and will use a linear or nonlinear model (as determined by visual inspection) to quantify the relationship between exposure and Baseline and placebo adjusted change from Baseline for each ECG parameter (same as for primary analysis).~The magnitude of change (mean and 95% CI) in spatial QRS-T angle for the observed mean Cmax for each drug may be calculated." (NCT01873950)
Timeframe: 24 hours

Interventiondegrees per mcg/ml (Mean)
Ranolazine 1500mg-1.0
Quinidine Sulfate 400mg2.7

[back to top]

Change in Ventricular Gradient Using Exposure/Response (Dofetilide and Verapamil Arms)

"The exposure response analysis will be performed for each treatment and will use a linear or nonlinear model (as determined by visual inspection) to quantify the relationship between exposure and Baseline and placebo adjusted change from Baseline for each ECG parameter (same as for primary analysis).~The magnitude of change (mean and 95% CI) in ventricular gradient for the observed mean Cmax for each drug may be calculated." (NCT01873950)
Timeframe: 24 hours

InterventionmV.ns per ng/ml (Mean)
Dofetilide 500mcg4.0
Verapamil HCl 120 mg1.2

[back to top]

Change in Ventricular Gradient Using Exposure/Response (Ranolazine and Quinidine Arms)

"The exposure response analysis will be performed for each treatment and will use a linear or nonlinear model (as determined by visual inspection) to quantify the relationship between exposure and Baseline and placebo adjusted change from Baseline for each ECG parameter (same as for primary analysis).~The magnitude of change (mean and 95% CI) in ventricular gradient for the observed mean Cmax for each drug may be calculated." (NCT01873950)
Timeframe: 24 hours

InterventionmV.ns per mcg/ml (Mean)
Ranolazine 1500mg-0.7
Quinidine Sulfate 400mg1.6

[back to top]

Placebo, and Baseline-adjusted Changes in Spatial QRS-T Angle

Compute maximum mean placebo, and baseline-adjusted change for: spatial QRS-T angle (degrees) (NCT01873950)
Timeframe: 24 hours

Interventiondegrees (Least Squares Mean)
Ranolazine 1500mg-2.2
Dofetilide 500mcg-4.9
Verapamil HCl 120 mg-2.4
Quinidine Sulfate 400mg3.9

[back to top]

Change in PR, QRS, J-Tpeak, Tpeak-Tend and QTc Using Exposure/Response (Dofetilide and Verapamil Arms)

"The exposure response analysis will be performed for each treatment and will use a linear or nonlinear model (as determined by visual inspection) to quantify the relationship between exposure and Baseline and placebo adjusted change from Baseline for each ECG parameter (same as for primary analysis).~The magnitude of change (mean and 95% CI) in QTc for the observed mean Cmax for each drug may be calculated." (NCT01873950)
Timeframe: 24 hours

,
Interventionms per ng/ml (Mean)
Change in PRChange in QTcChange in QRSChange in J-TpeakcChange in Tpeak-Tend
Dofetilide 500mcg-0.573.60.239.134.4
Verapamil HCl 120 mg28.73.90.3-0.73.6

[back to top]

Change in PR, QRS, J-Tpeak, Tpeak-Tend and QTc Using Exposure/Response (Ranolazine and Quinidine Arms)

"The exposure response analysis will be performed for each treatment and will use a linear or nonlinear model (as determined by visual inspection) to quantify the relationship between exposure and Baseline and placebo adjusted change from Baseline for each ECG parameter (same as for primary analysis).~The magnitude of change (mean and 95% CI) in QTc for the observed mean Cmax for each drug may be calculated." (NCT01873950)
Timeframe: 24 hours

,
Interventionms per mcg/ml (Mean)
Change in PRChange in QTcChange in QRSChange in J-TpeakcChange in Tpeak-Tend
Quinidine Sulfate 400mg3.078.90.426.151.2
Ranolazine 1500mg4.212.00.80.710.0

[back to top]

Placebo, and Baseline-adjusted Changes in PR, QRS, J-Tpeak, Tpeak-Tend and QTc

Compute maximum mean placebo, and baseline-adjusted change for: PR (ms), QRS (ms), J-Tpeak (ms), Tpeak-Tend (ms) and QTc (ms) (NCT01873950)
Timeframe: 24 hours

,,,
Interventionms (Least Squares Mean)
Change in PR intervalChange in QRS durationChange in J-TpeakcChange in Tpeak-TendChange in QTc
Dofetilide 500mcg2.31.139.540.079.3
Quinidine Sulfate 400mg5.12.129.149.878.1
Ranolazine 1500mg6.52.73.38.812.6
Verapamil HCl 120 mg32.12.6-2.44.85.2

[back to top]

Time to First Atrial Fibrillation (AF) Recurrence

There were too few participants for an assessment of time to first recurrence, therefore the numbers of participants with recurrence up to 6 months is reported instead (NCT01887353)
Timeframe: up to 6 months

Interventionparticipants (Number)
Ranolazine0
Placebo2

[back to top]

Change in Treatment Satisfaction as Measured by the Seattle Angina Questionnaire

The Treatment Satisfaction scale is one of five scales of the Seattle Angina Questionnaire. The possible range of scores is 0 to 100, with higher scores indicating better quality of life. (NCT01948310)
Timeframe: Baseline, Week 2 and Week 14

,
Interventionunits on a scale (Mean)
2-0 Weeks14-0 weeks
Placebo Plus Exercise0.83.1
Ranolazine Plus Exercise5.3-1.0

[back to top]

Change in Total Daily Energy Expenditure

Total daily physical activity is measured via Actigraph GT3X accelerometers. Accelerometers will be worn for 7 days pre-drug, post-drug/pre-exercise (week 4) and again in the final month of the exercise intervention (week 13) (NCT01948310)
Timeframe: Week 1, Week 4 and Week 14

,
Interventionkj/hr (Mean)
2-0 weeks14-0 weeks
Placebo Plus Exercise2.022.2
Ranolazine Plus Exercise-7.624.3

[back to top]

Change in Peak Oxygen Consumption (VO2 Max)

This test involves exercising on a treadmill or bike to maximal exertion, during which the subject's breathing and oxygen consumption are measured. Under a set study protocol, treadmill or bike workload will increase every minute until the participant either chooses to end the test or the study personnel choose to end the test for safety purposes. (NCT01948310)
Timeframe: Baseline, Week 2 and Week 14

,
Interventionml/kg/min (Mean)
Change at 2 weeksChange at 14 weeks
Placebo Plus Exercise0.030.9
Ranolazine Plus Exercise0.382.1

[back to top]

Number of Participants With Increase in SUV Uptake

"Number of participants who had increased SUV uptake, as defined by any of the following:~SUVmax increase of 30% with a 2 unit absolute change.~SUVmean increase of 30% with a 0.75 unit absolute change.~SUVmean increase of 20% with a 1 unit absolute change." (NCT01992016)
Timeframe: Within 1 week after completion of ranolazine treatment

InterventionParticipants (Count of Participants)
Arm I (Localized Prostate Cancer)0
Arm II (Metastatic Prostate Cancer)0

[back to top]

Coronary Flow Reserve

Compare changes in coronary flow reserve as measured by cardiac PET(Positron Emission Tomography) in patients receiving Ranolazine versus control. This is the ratio between stress and rest myocardial blood flow in response to stress. (NCT02052011)
Timeframe: 4 weeks

,
Interventionratio (Mean)
Baseline CFRPost-Treatment CFR
Intervention Group1.61.9
Placebo Control1.61.6

[back to top]

Percent Change in mPAP, PAOP and Pulmonary Vascular Resistance (PVR)

"Assess the percent change in mPAP, PAOP and pulmonary vascular resistance (PVR) by RHC.~Additional RHC completed at optional follow up for patients remaining on ranolazine upon completion of 180 day period." (NCT02133352)
Timeframe: 180 days

Interventionpercentage change (Mean)
% Change in mPAP% Change in PAOP% Change in PVR
Ranolazine-21-39-4.0

[back to top]

Change in Cardiac Size and Function

"Assess changes from baseline in measurements of cardiac size and function obtained by MRI after 180 days of twice daily ranolazine.~An additional MRI may be completed at optional follow up visit for patients continuing on ranolazine following completion of the 180 day treatment period." (NCT02133352)
Timeframe: 180 days

Intervention% ejection fraction (Mean)
RVEFLVEF
Ranolazine35.4

[back to top]

Change in Echocardiogram Parameters (LVEF)

"To assess the changes from baseline in echocardiographic parameters (left ventricular geometry and function, LVEF, evidence of diastolic dysfunction, SPAP, right ventricular geometry and function, degree of tricuspid regurgitation) after 180 days of twice daily ranolazine.~An additional echo may be completed at optional follow up visit for patients continuing on ranolazine following completion of the 180 day treatment period." (NCT02133352)
Timeframe: 180 days

InterventionLVEF % (Mean)
Ranolazine.67

[back to top]

Percent Change in Other Hemodynamic Parameters

"Assess % change in other hemodynamic parameters, by RHC, from baseline afeter 180 days of ranolazine.~Right atrial pressure (RAP) Systolic pulmonary artery pressure (SPAP) Diastolic pulmonary artery pressure (DPAP) Cardiac output (CO) Cardiac index (CI)" (NCT02133352)
Timeframe: 180 days

Interventionpercent change (Mean)
RAPSPAPDPAPCOCI
Ranolazine-56-12-332224

[back to top]

6 Minute Walk Test (6MWT)

Assess the change from baseline in 6 minute walk test (6MWT) after 180 days of twice daily ranolazine Optional follow up for some patients also includes 6MWT. (NCT02133352)
Timeframe: 180 days

Interventionmeters (Mean)
Ranolazine33.7

[back to top]

Change in BNP Cardiac Biomarker

"Assess the change from baseline in BNP cardiac biomarkers after 180 days of twice daily ranolazine.~Cardiac biomarkers may be completed at optional follow up visit for patients continuing on ranolazine following completion of the 180 day treatment period." (NCT02133352)
Timeframe: 180 days

Interventionpg/mL (Mean)
Ranolazine32.1

[back to top]

Change in Seattle Angina Questionnaire Score Regarding Treatment Satisfaction

The change in scores of the treatment satisfaction dimension of the Seattle Angina Questionnaire (SAQ) after 12 weeks therapy with ranolazine or placebo are presented. Change at 12 weeks was calculated as (Endpoint Value at 12 weeks - Endpoint Value at Baseline)/Endpoint Value at Baseline. Individual dimensions of the Seattle Angina Questionnaire are transformed to be a score from 0 to 100, where higher scores indicate better health. A positive number for the treatment satisfaction dimension means that the participants are experiencing greater satisfaction with their treatment at week 12 than they were at the baseline visit. (NCT02147067)
Timeframe: Baseline, Week 12

Interventionscore on a scale (Mean)
Ranolazine1.17
Placebo0.28

[back to top]

Change in Seattle Angina Questionnaire Score Regarding Physical Limitation

The change in scores of the physical limitation dimension of the Seattle Angina Questionnaire (SAQ) after 12 weeks therapy with ranolazine or placebo are presented. Change at 12 weeks was calculated as (Endpoint Value at 12 weeks - Endpoint Value at Baseline)/Endpoint Value at Baseline. Individual dimensions of the Seattle Angina Questionnaire are transformed to be a score from 0 to 100, where higher scores indicate better health. A positive number for the physical limitation dimension means that the participants are experiencing less limitation at week 12 than they were at the baseline visit. (NCT02147067)
Timeframe: Baseline, Week 12

Interventionscore on a scale (Mean)
Ranolazine-0.09
Placebo0.27

[back to top]

Change in Seattle Angina Questionnaire Score Regarding Disease Perception

The change in scores of the disease perception dimension of the Seattle Angina Questionnaire (SAQ) after 12 weeks therapy with ranolazine or placebo are presented. Change at 12 weeks was calculated as (Endpoint Value at 12 weeks - Endpoint Value at Baseline)/Endpoint Value at Baseline. Individual dimensions of the Seattle Angina Questionnaire are transformed to be a score from 0 to 100, where higher scores indicate better health. A positive number for the disease perception dimension means that the participants felt that their disease impacted their quality of life less at week 12 than at the baseline visit. (NCT02147067)
Timeframe: Baseline, Week 12

Interventionscore on a scale (Mean)
Ranolazine0.89
Placebo1.00

[back to top]

Change in Seattle Angina Questionnaire Score Regarding Angina Stability

The change in scores of the angina stability dimension of the Seattle Angina Questionnaire (SAQ) after 12 weeks therapy with ranolazine or placebo are presented. Change at 12 weeks was calculated as (Endpoint Value at 12 weeks - Endpoint Value at Baseline)/Endpoint Value at Baseline. Individual dimensions of the Seattle Angina Questionnaire are transformed to be a score from 0 to 100, where higher scores indicate better health. A positive number for the angina stability dimension means that the participants are experiencing fewer changes in their angina at week 12 than they were at the baseline visit. (NCT02147067)
Timeframe: Baseline, Week 12

Interventionscore on a scale (Mean)
Ranolazine0.00
Placebo0.50

[back to top]

Change in Seattle Angina Questionnaire Score Regarding Angina Frequency

The change in scores of the angina frequency dimension of the Seattle Angina Questionnaire (SAQ) after 12 weeks therapy with ranolazine or placebo are presented. Change at 12 weeks was calculated as (Endpoint Value at 12 weeks - Endpoint Value at Baseline)/Endpoint Value at Baseline. Individual dimensions of the Seattle Angina Questionnaire are transformed to be a score from 0 to 100, where higher scores indicate better health. A positive number for the angina frequency dimension means that the participants are experiencing fewer episodes of angina at week 12 than they were at the baseline visit. (NCT02147067)
Timeframe: Baseline, Week 12

Interventionscore on a scale (Mean)
Ranolazine0.70
Placebo0.27

[back to top]

Change in Peak Rate of Oxygen Consumption (VO2 Max)

The change in VO2, as measured by cardiopulmonary exercise testing (CPET), after 12 weeks therapy with ranolazine compared with placebo. VO2 max is the maximum amount of oxygen the participants are utilizing during intense treatment. To standardize exercise stress testing, CPET was performed under the guidance of the MET-TEST CPET network in Atlanta, Georgia. The MET-TEST was created in 2003 and is a high-precision stress test with detailed physiological assessment, allowing accurate and reproducible measurements of peak VO2. Individuals may demonstrate an abnormal CPET response before they develop symptoms or present with cardiac events and abnormal CPET results are strong predictors of future adverse outcomes. Higher VO2 values indicate better oxygen utility and positive value for VO2 change means there was improvement from baseline at the week 12 visit. Change at 12 weeks was calculated as (Endpoint Value at 12 weeks - Endpoint Value at Baseline)/Endpoint Value at Baseline. (NCT02147067)
Timeframe: Baseline, Week 12

InterventionL/min (Mean)
Ranolazine-0.03
Placebo0.06

[back to top]

Change in Metabolic Equivalents of Task (METs) at Peak

Change in exercise was measured as Metabolic Equivalents of Task (METs) at Peak by cardiopulmonary exercise testing (CPET) after 12 weeks therapy with ranolazine compared with placebo. METs are used to describe functional aerobic capacity and harder physical tasks require a higher number of METs. METs at a peak level of exercise was determined for each participant. Change at 12 weeks was calculated as (Endpoint Value at 12 weeks - Endpoint Value at Baseline)/Endpoint Value at Baseline. A positive value for change in METs at Peak of exercise indicates that the participant has improved their aerobic capacity from baseline at the week 12 visit. (NCT02147067)
Timeframe: Baseline, Week 12

Intervention3.5ml of oxygen/kg per min (Mean)
Ranolazine0.00
Placebo4.42

[back to top]

Change in Coronary Flow Reserve (CFR)

The changes in Coronary Flow Reserve (CFR) after 12 weeks therapy with ranolazine compared with placebo are presented here. CFR is a measurement of the maximum increase of blood flow through the coronary arteries during exercise. Average peak velocity (APV) was assessed over a 3- to 5-beats period. CFR was defined as the ratio of hyperemic to basal APV. A low CFR is an indication of coronary artery disease. Change at 12 weeks was calculated as (Endpoint Value at 12 weeks - Endpoint Value at Baseline)/Endpoint Value at Baseline. A positive value for the change in CFR suggests improvement in coronary artery blood flow between the baseline and week 12 visits. (NCT02147067)
Timeframe: Baseline, Week 12

Interventionratio of hyperemic to basal APV (Mean)
Ranolazine0.38
Placebo0.09

[back to top]

Change in Hyperemic Microcirculatory Resistance (HMR)

Change in Hyperemic Microcirculatory Resistance (HMR) after 12 weeks therapy with ranolazine compared with placebo. Average peak velocity (APV) was assessed over a 3- to 5-beats period. HMR was measured as the ratio of distal pressure to APV. Change at 12 weeks was calculated as (Endpoint Value at 12 weeks - Endpoint Value at Baseline)/Endpoint Value at Baseline. Higher HMR is associated with myocardial ischemia and a positive value for change in HMR indicates increased risk for cardiac events at the week 12 visit. (NCT02147067)
Timeframe: Baseline, Week 12

InterventionmmHg/cm/s (Mean)
Ranolazine0.14
Placebo-0.04

[back to top]

Impact of Ranolazine on Hemoglobin A1C

Will evaluate the impact of ranolazine in HgbA1C in women with Metabolic Syndrome (MBS) (NCT02252406)
Timeframe: Change from baseline to 24 weeks

Interventionpercent change (Mean)
Ranolazine Treated-5
Placebo2.6

[back to top]

Impact of Ranolazine on HDL-C Levels in Subjects

Will evaluate the impact of ranolazine in HDL-C levels in women with metabolic syndrome (NCT02252406)
Timeframe: Change from Baseline to 24 weeks

Interventionpercentage of change in HDL (Mean)
Ranolazine Treated6.6
Placebo6.5

[back to top]

Subjective Well Being

overall feeling of well being determined from rating of excellent, good, fair or poor at baseline compared to same at month 4 (NCT02265796)
Timeframe: Compare from baseline to month 4

InterventionParticipants (Count of Participants)
Baseline71904610Baseline7190461116 Weeks7190461116 Weeks71904610
missingexcellent/goodfair/poor
Ranolazine9
Sugar Pill6
Ranolazine12
Sugar Pill16
Ranolazine1
Sugar Pill2
Ranolazine11
Ranolazine10
Sugar Pill10
Sugar Pill4

[back to top]

Seattle Angina Questionnaire Score Change From Baseline to 16 Weeks

"The SAQ quantifies patients' physical limitations caused by angina, the frequency of and recent changes in their symptoms, their satisfaction with treatment, and the degree to which they perceive their disease to affect their quality of life.Each of the 5 dimensions are scored by assigning eachresponse an ordinal value, beginning with 1 for the response that implies the lowest level of functioning, and summing across items within each of the 5 scales. Scale scores then transformed to 0-100 range by subtracting the lowest possible scale score, dividing by the range1 / 3 Seattle Angina Questionnaire (SAQ)of the scale and multiplying by 100. No overall scale score is generated.~Factors and Each scale is transformed to a score of 0 to 100, where higher scores indicate better function (eg, less physical limitation, less angina, and better quality of life).~." (NCT02265796)
Timeframe: Change in baseline to 16 weeks

,
Interventionunits on a scale (Mean)
Physical Limitation baselinePhysical Limitation 16 weeksPhysical Limitation group differenceAngina Stability baselineAngina Stablility 16 weeksAngia Stability group differenceAngina Frequency baselineAngina Frequency 16 weeksAngina Frequency group differenceTreatment Satisfaction baselineTreatment Statisfaction 16 weeksTreatment Satisfaciton group differenceQuality of Life baselineQuality of Life 16 weeksQuality of Life group difference
Ranolazine4840-73958196581168077-4375621
Sugar Pill506063755186480158582-3456318

[back to top]

Ischemia Driven Revascularization or Hospitalization

Number of participants who reported adverse events for ischemia driven revascularization or hospitalization (NCT02265796)
Timeframe: 4 month

InterventionParticipants (Count of Participants)
Ranolazine3
Sugar Pill5

[back to top]

The Effect of Ranolazine on the PVC Burden Over 30 Days

The change in percentage of PVC burden after taking Ranolazine 1000mg twice daily for 30 days (NCT02360397)
Timeframe: Baseline (7 day) Holter compared to day 30 (7 day) Holter

Interventionpercentage of PVC burden (Mean)
percentage of PVC burden at Baselinepercentage of PVC burden at Day 30
Ranolazine5.715.495

[back to top]

Score on Seattle Angina Questionnaire at Baseline and at Day 30

The SAQ quantifies patients' physical limitations caused by angina, the frequency of and recent changes in their symptoms, their satisfaction with treatment, and the degree to which they perceive their disease to affect their quality of life. Each scale is transformed to a score of 0 to 100, where higher scores indicate better function (eg, less physical limitation, less angina, and better quality of life). Angina symptoms may be felt as: chest pain, a heaviness, tightness or squeezing sensation in the chest, aching across the chest, particularly behind the breastbone. The pain may radiate to the neck, jaw, arms, back or teeth. (NCT02360397)
Timeframe: Baseline and day 30

Interventionscore on a scale (Mean)
Baseline SAQ score for Angina FrequencyDay 30 SAQ score for Angina FrequencyBaseline score for Angina StabilityDay 30 SAQ score for Angina StabilityBaseline SAQ score for Physical LimitationDay 30 SAQ score for Physical LimitationBaseline SAQ score for Day 30 SAQ score Quality ofDay 30 SAQ score for Quality of Life
Ranolazine9595505094.44594.44579.16587.5

[back to top]

Number of Non-sustained Ventricular Tachycardia and Sustained Ventricular Arrhythmia Episodes on Holter Monitoring

Number of non-sustained ventricular tachycardia episodes (>8 beats) and sustained ventricular arrhythmia episodes on Holter monitoring at baseline and at 30 days (NCT02360397)
Timeframe: Baseline and Day 30

Interventionnumber of episodes (Number)
Baseline HolterDay 30 Holter
Ranolazine00

[back to top]

The Effect of Ranolazine on Cardiac Ischemia

The effect of ranolazine on cardiac ischemia as measured by change in millimeters of ST segment deviation on ECG monitoring at Baseline and after 30 days of Ranolazine therapy (day 30). (NCT02360397)
Timeframe: Baseline and day 30

Interventionmillimeters (Mean)
Effect of Ranolazine on Cardiac Ischemia0

[back to top]

Absolute Change From Baseline Right Ventricular Ejection Fraction (the Unit is Percentage)

Change in right ventricle ejection fraction as assessed by MRI (NCT02829034)
Timeframe: 26 weeks

Interventionpercentage (Least Squares Mean)
Ranolazine7.56
Placebo-3.99

[back to top]

Change in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP)

NT-proBNP measured at 6-months compared to baseline (NCT02829034)
Timeframe: 6 months

Interventionpg/mL (Least Squares Mean)
Ranolazine-119.72
Placebo-287.75

[back to top]

Percent Change in 6min-walk-test Distance

6-minute walk test (NCT02829034)
Timeframe: 6 months

Interventionpercentage of distance walked (Least Squares Mean)
Ranolazine-0.09
Placebo-0.06

[back to top]

QTc Shortening From Calcium Block (Diltiazem) in the Presence of hERG Block (Dofetilide)

"It will be assessed whether the projected QTc effect of dofetilide alone is significantly greater (i.e., p<0.05) than the projected QTc effect of the combination of dofetilide + diltiazem. This will be assessed at the dofetilide peak plasma level on Day 3 (computed from the combination of dofetilide + diltiazem) on the pooled dofetilide alone, diltiazem alone, and dofetilide + diltiazem data using a linear mixed effects model.~Subsequently, and if the test is significant for QTc, the same test will be performed to assess calcium block (diltiazem) effects on J-Tpeakc." (NCT03070470)
Timeframe: 3 days

Interventionms (Median)
Dofetilide2.2
Diltiazem+Dofetilide-1.7

[back to top]

"Change From Baseline QTc With Predominant hERG Blocking Drug (Chloroquine)"

"The primary outcome measure for the predominant hERG drug (chloroquine) is for the upper bound of the 2-sided 90% CI to be ≥10 msec for the projected placebo-corrected change from baseline QTc effect at the peak plasma level on Day 1 using a linear mixed-effects exposure response model" (NCT03070470)
Timeframe: 3 days

Interventionms (Median)
Chloroquine17.7
Placebo-9.3

[back to top]

"Change From Baseline J-Tpeakc With Balanced Ion Channel Drugs (Ranolazine, Verapamil, Lopinavir / Ritonavir)"

"The primary outcome measure for the balanced ion channel drugs (ranolazine, verapamil, lopinavir / ritonavir) is for the upper bound of the 2-sided 90% confidence interval (CI) to be <10 msec for the projected placebo-corrected change from baseline J-Tpeakc effect at the peak plasma level on Day 3 using a linear mixed-effects exposure response model. Placebo drug concentration was set to 0 (see SAP)." (NCT03070470)
Timeframe: 3 days

Interventionms (Median)
Ranolazine-8.3
Verapamil-7.8
Lopinavir / Ritonavir-11.5
Placebo-10.9

[back to top]